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Spatiotemporal control of Mycobacterium tuberculosis cell wall biogenesis by the 
peptidoglycan synthase PonA1 
 
 
Abstract 
 
Mycobacterium tuberculosis causes one of the most pernicious infectious diseases of humankind 
– tuberculosis, which is still a global problem in the 21st century. Drug-resistant M. tuberculosis infections 
are on the rise, necessitating novel drug development. A particularly fruitful avenue for drug development 
is the bacterial cell wall, as it is a structure required for bacterial survival and is accessible to small 
molecules. This complex structure must be dynamically remodeled every cell cycle to promote bacterial 
growth, and our understanding of how M. tuberculosis governs this process and the enzymes involved is 
rudimentary.  
My work investigates how M. tuberculosis governs the synthesis and remodeling of an essential 
component of its cell wall – peptidoglycan. For cells to grow and divide, the peptidoglycan layer must be 
actively metabolized. Failures in the peptidoglycan structure result in cell lysis and death, which is why 
peptidoglycan synthesis is often targeted by antibiotics, such as penicillin. Hence, peptidoglycan must be 
static enough to resist interior turgor pressure and exterior insults (like antibiotics) and yet it must also be 
plastic enough to allow local restructuring to promote cell growth. How does the cell govern these 
paradoxical processes in both space and time to ensure survival?  
I used a key peptidoglycan synthase, PonA1, to understand how M. tuberculosis engineers its cell 
wall during growth and division. PonA1 localizes to the cell septum during division, where it interacts with 
the essential peptidoglycan hydrolase RipA and modulates RipA activity during cell separation. PonA1 
also localizes to the cell pole where it promotes expansion of the peptidoglycan layer of the cell envelope. 
I found that PonA1 is critical for the proper spatial organization of new pole growth and that 
phosphorylation of PonA1 modulates the rate of cell elongation at the pole.  
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In an effort to expand our understanding of how M. tuberculosis remodels its cell wall, I performed 
a whole genome mutagenesis screen to identify genetic partners of PonA1. I found factors critical for 
peptidoglycan synthesis, namely PonA2 and LdtB, a nonclassical transpeptidase that synthesizes the 
predominant crosslink in mycobacterial peptidoglycan. Further genetic and biochemical studies showed 
that simultaneous loss of PonA2 and LdtB is lethal to M. tuberculosis, suggesting an opportunity to 
develop chemotherapeutics targeting 3-3 transpeptidases like LdtB. These studies also suggested that 
enzymatic pathways that govern M. tuberculosis cell wall synthesis are spatially resolved.  
My work identified genetic networks that govern cell wall construction in M. tuberculosis and 
showed the critical role of the peptidoglycan synthase PonA1 in controlling growth at the cell pole. 
Defining the spatiotemporal dynamics of key cell wall synthase proteins is important for understanding M. 
tuberculosis’ physiology. My work expands our understanding of how a prevalent human pathogen 
governs the synthesis of its cell wall, a critical source for novel drug development. 
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Section 1.1 Overview and Attributions 
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as a list of known factors involved in cell wall biogenesis in M. tuberculosis. 
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Abstract 
Mycobacterium tuberculosis, the aetiologic agent of tuberculosis, owes much of its success as a 
pathogen to its unique cell wall and unusual mechanism of growth, which facilitate its adaptation to the 
human host and could play a role in clinical latency. Asymmetric growth and division increases population 
heterogeneity, which may increase antibiotic tolerance and the fitness of single cells. Here we review the 
unusual mechanisms of mycobacterial growth and cell wall biogenesis and discuss how these processes 
might affect M. tuberculosis survival in vivo and contribute to the persistence of infection.  
 
Introduction 
Mycobacterium tuberculosis is an extraordinarily successful human pathogen that infects up to one third 
of the global population [1] and causes one of the most recalcitrant bacterial infections of the modern era. 
Infection begins with the inhalation of aerosols containing M. tuberculosis, which are primarily taken up by 
alveolar macrophages, although other host cells can phagocytose the bacterium, including dendritic cells, 
monocytes and neutrophils [2,3]. A local proinflammatory response occurs in the lung, which results in the 
recruitment of additional monocytes and lymphocytes [3,4]. Assembly of these cells around infected 
macrophages generates a cellular mass, known as a granuloma, which is a pathological hallmark of 
tuberculosis (TB).  
 
Granuloma histology is heterogeneous, even within a single individual, and ranges from cellular to 
caseous to fibrotic lesions [5]. Granulomas are traditionally considered an attempt by the host to control 
the infection, but the ability to restrict mycobacterial proliferation varies [6,7]. For example, caseating 
granulomas, which contain hypoxic centres [8], often rupture and release bacteria, which are then free to 
invade the surrounding host cells [4]. Furthermore, M. tuberculosis localizes to distinct regions within the 
granuloma [5], which also contain different subsets of immune cells. Thus, depending on the bacterial 
location and the immune cells present, the inflammatory response is likely to differ between distinct sites 
of the granuloma [9], which probably affects clearance of the infection. Inside macrophages, M. 
tuberculosis is usually found within a phagosome of variable maturation states [3] and encounters an 
arsenal of host defences, including phagosome acidification, antimicrobial peptides and reactive oxygen 
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species [4]. This range of distinct microenvironments exerts discrete selective pressures on individual 
bacterial cells, which suggests that mycobacteria need to adapt to ensure survival. How is such 
adaptation achieved? Recent work has revealed that mycobacterial cell growth and division produces 
heterogeneous daughter cells [10-13], which also undergo substantial cell wall remodelling during 
infection [14-17].  
 
Proliferation of bacterial cells can be divided into two stages: elongation of the mother cell and division of 
the elongated mother cell into two daughter cells. In most bacteria, cell division is a symmetric process 
and produces daughter cells of the same size [18]. However, mycobacteria do not adhere to the “one-
size-fits-all” rule and grow and divide in an asymmetric manner, which produces daughter cells of unequal 
sizes [10-13]. This trait might have been selected for, as cells of different sizes might have distinct 
survival advantages in the highly variable host environment.  
 
As discussed below, the unique mode of mycobacterial elongation and division produces a population of 
daughter cells that vary in size, growth rate and cell wall composition [10-13], which functionally diversify 
the population. This phenotypic heterogeneity is further enhanced by cell wall remodelling processes that 
occur within the host [141-17]. Mycobacteria have an elaborate cell envelope comprised of several layers 
(Figure 1.1). Each of these layers displays different chemical modifications and the architecture of the cell 
wall is also molded through complex regulation. In the host, further remodelling occurs [14-17], which 
generates a population of cells that not only differ in size and growth properties, but also in the 
composition of their cell wall. This diversity is predicted to increase survival in vivo and has the potential 
to influence disease progression and clinical latency.  
 
In this Review, we discuss the mechanisms and regulation of mycobacterial cell wall biogenesis, cell 
elongation and division. We also describe how these processes produce heterogeneity at the population 
level and consider the implications of single cell diversity for survival in the host.  
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Figure 1.1. The mycobacterial cell wall.  A thick layer of peptidoglycan (PG) covers the cell’s plasma 
membrane (not shown). Mycobacterial PG contains unique chemistry, including glycolylation and 
amidation. The peptide crosslinks exist in two forms: as either 3-3 or 4-3 peptide crosslinks. 
Arabinogalactan (AG) is covalently crosslinked to the PG layer. The AG can be modified with succinyl 
moieties or non-N-acetylated galactosamines. A thick layer of mycolic acids (MA) are attached to the 
arabinogalactan layer and are thought to form an outermembrane like structure. During growth in more 
host-like conditions or during infection, the cell wall is surrounded with a capsule, which is composed of 
sugars and proteins. 
 
 
The cell envelope of mycobacteria 
The mycobacterial cell wall is a complex structure required for cell growth, resistance to antibiotics and 
virulence [76,105,106]. It is composed of three distinct macromolecules – peptidoglycan (PG), 
arabinogalactan (AG), and mycolic acids (MA) – surrounded by a non-covalently linked outer capsule of 
proteins and polysaccharides [23,76,105,107] (Figure 1.1; see Appendix 1 for more details). The high 
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density of lipids in the cell wall prevents accurate Gram staining and mycobacteria are referred to as acid-
fast as they can be stained by acid-fast dyes, such as Ziehl-Neelson [23]. The cell wall is the most 
common target of antituberculosis drugs and many compounds that are in clinical use or are under 
development target enzymes that synthesize each layer of the cell wall [108].  
 
The PG layer surrounds the plasma membrane and comprises long polymers of the repeating 
disaccharide N-acetyl glucosamine–N-acetyl muramic acid (NAG-NAM) that are linked via peptide 
bridges. The PG precursor Lipid II is generated in the cytoplasm [18,23] and is likely transported across 
the periplasm by the transmembrane protein MviN [21]. Unidentified hydrolases are required to open the 
PG mesh for the insertion of new precursors [18], which are added in an “inside to outside” manner [109]. 
The penicillin binding proteins (PBPs) PonA1 and PonA2 incorporate new subunits into the existing 
structure. Transpeptidases, such as PBPA, PBPB, LdtA and LdtB crosslink the newly inserted material 
[23]. Compared to other model bacteria, such as Escherichia coli and Bacillus subtilis, mycobacterial PG 
is heavily crosslinked. Up to 80% of the PG contains ‘nontraditional’ 3→3 peptide crosslinks instead of the 
‘traditional’ 4→3 crosslink [72,75]. The PG polymer is also modified, such as glycolylation of NAM 
residues [73,110] and amidation of the D-Glu and meso-diaminopimelic acid (DAP) residues of the 
peptide side chain [72,111]. Amidation may mask recognition by the innate immune receptor Nod1, which 
has been observed in B. subtilis [112]. However, glycolylated NAM is efficiently recognized by Nod2 and 
induces the production of inflammatory cytokines in M. tuberculosis-infected macrophages [113,114].  
 
A layer of AG surrounds the PG layer (Figure 1.1). Galactan comprises a repeating disaccharide unit of 6-
D-Galfβ1→5-D-Galfβ and is synthesized by the galactofuranosyl transferases Glf, GlfT1 and GlfT2. 
Galactan is decorated with long arabinan polymers that are synthesized by the successive actions of 
DprE1, DprE2 [115], AftA, EmbA, EmbB and AftB [105]. Variability in arabinosylation exists, with some 
galactan chains remaining free of arabinan [116]. Arabinan chain termini are branched, a motif that is 
generated by the actions of AftD [117] and Rv1459 [105]. Arabinan can also be further modified by the 
addition of succinyl or unusual non-N-acetylated galactosamine (GalN) moieties [105]. The GalN 
 ! 7 
modifications are mainly present in pathogenic mycobacteria and may promote efficient infection, which 
has been observed in Francisella tularensis [74].  
 
The majority of arabinan is ligated with long carbon chain mycolic acids (MA) [76,77,105], which form the 
characteristic thick waxy lipid coat of mycobacteria [23,118] and are major contributors to the 
impermeability of the cell wall [23,76,77] and virulence [76,100]. MA are formed from two fatty acids, a 
saturated shorter C20-C26 α-branch that is connected to a C60-C90 meromycolate branch. These branches 
are generated by the FASI and FASII [76,77,119]. FASI products are transferred to FASII for extension by 
the combined action of FabH, AcpM and FabD [76,77]. MA are then processed and matured by a 
cascade of enzymes [76,77,120,121] resulting in three distinct meromycolate variants: α-meroacids, 
methoxy-meroacids and keto-meroacids [76,77]. All three variants are required for full virulence during 
infection and have varying levels of saturation, cyclopropanation and oxygenation [76,77]. The inner 
membrane transporter MmpL shuttles MA to the cell surface [122-124] where the FbpABCD (Antigen85) 
complex ligates the MA monomer to AG [76,77,105]. While the coordination of MA and AG synthesis and 
insertion in the cell wall remains unknown, recent data suggest these macromolecules are produced and 
exported at the cell pole [19,125], where mycobacteria generate new cell growth. 
 
Canonical cell growth in model organisms 
The traditional model bacteria Escherichia coli and Bacillus subtilis have a vastly different cell wall 
architecture compared to mycobacteria and as such, cell wall synthesis and cell division rely on a 
different set of proteins. In E. coli and B. subtilis elongation occurs along the lateral cell wall and the 
elongation complex is comprised of PG synthases, lipoprotein modulators of PBP activity, cytoskeletal-
like proteins and PG hydrolases [18,126-128]. PG synthesis is coordinated by bifunctional (E. coli PBP1a 
and perhaps PBP1b [18]; B. subtilis PBP1 [129]) and monofunctional (E. coli PBP2 [18]; B. subtilis PBP2a 
and PbpH [126]) PBPs  (Table 1.1). The actin homologue MreB forms filaments underlying the elongation 
complex and facilitates elongation in E. coli and B. subtilis, which has two additional MreB homologues 
MreBH and Mbl [130], by guiding elongation complexes along the lateral wall [18,130] (Table 1.2). It has  
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Table 1.1. Major cell growth and division factors in E. coli, B. subtilis, and mycobacteria 
 
 
 E. coli B. subtilis mycobacteria function 
elongation PBP1a18 PBP1126 PonA128 PG synthase 
 PBP1b?18   PonA2? PG synthase 
 PBP218 PBP2a123 LdtAB?31 PG synthase 
   PbpH123   PG synthase 
 Spr124    PG hydrolase 
 YdhO124    PG hydrolase 
 YebA124    PG hydrolase 
   CwlO125  PG hydrolase 
   LytE125  PG hydrolase 
 MreBCD18 MreBCD127   structural protein 
   MreBH127   structural protein 
   Mbl127   structural protein 
    Wag3123 structural protein 
     CwsA25 structural protein 
     
division PBP1b18 PBP1123 PonA128 PG synthase 
 PBP1a?18   PonA2? PG synthase 
 PBP318 PBP2b123 PBPA30 PG synthase 
     PBPB41 PG synthase 
 AmiABC18 LytC135   PG hydrolase 
   LytD135   PG hydrolase 
   LytF135 RipA46 PG hydrolase 
     RpfB47 PG hydrolase 
 ZipA18     structural protein 
 ZapABCD18,133 ZapA34   structural protein 
 FtsA18 FtsA34 FhaB40 structural protein 
   SepF34   structural protein 
 FtsQLB18 DivIBC130 FtsQ22 structural protein 
 FtsW18 FtsW34 FtsW22 structural protein 
 FtsZ18 FtsZ34 FtsZ22 structural protein 
 FtsN18   structural protein 
 FtsP134   structural protein 
   CrgA42 structural protein 
   CwsA25 structural protein 
 
 
also been reported that interactions between FtsZ and MreB are necessary for appropriate cell division in 
E. coli [131], suggesting a potential mechanism for coordinating elongation and division.  
 
Similarly to mycobacteria, polymerization of FtsZ initiates cell division in E. coli and B. subtilis. The 
divisome is mainly composed of PG synthases that construct the septum (E. coli PBP1b, perhaps PBP1a, 
and PBP3 [18]; B. subtilis PBP1 and PBP2b [35]), structural proteins (E. coli FtsW, FtsN, FtsQLB [18]; B. 
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subtilis FtsW, DivIBC [132]) and hydrolases that physically separate daughter cells (E. coli AmiABC [18]; 
B. subtilis LytCDF [133]). Other factors that regulate divisome formation are also involved [18,35,134]. 
Placement of the Z-ring is carefully controlled, and in E. coli, this is regulated by the MinCDE system 
during normal growth and by SulA when the SOS response is induced [134] (Table 1.2). In B. subtilis, the 
functional homologues of MinCDE (MinCD and DivIVA), together with EzrA, are responsible for 
determining the site of Z ring formation [35]. EzrA interacts with FtsZ and PBP1, suggesting that it may 
synchronize elongation and cell division in B. subtilis. The B. subtilis ClpXP protease also regulates Z-ring 
formation by inhibiting FtsZ polymerization [35]. The UDP-glucose transporter UgtP inhibits FtsZ 
polymerization during nutrient-limiting conditions, thereby coupling growth rate to cell division in B. subtilis 
[35]. The DNA-binding nucleoid occlusion factors (such as SlmA in E. coli [134] and Noc in B. subtilis 
[35]) also function in FtsZ placement and regulate Z-ring formation through direct interactions with FtsZ 
and coordination with the replication machinery, respectively [134] (Table 1.2). 
 
Table 1.2 Cell morphogenesis systems in E. coli, B. subtilis, and mycobacteria 
 E. coli B. subtilis mycobacteria 
negative regulators of 
the Z-ring 
minCDE, SulA minCD and DivIVA, 
ClpX, UgtP, MciZ 
(sporulation) 
FtsZ 
phosphorylation?, 
ClpX?, ChiZ?, 
Rv3660c? 
positive regulators of 
the Z-ring 
FtsA, ZipA, ZapABCD FtsA, SepF, ZapA FtsW?, FhaB (FipA) 
nucleoid occlusion SlmA Noc ? 
subcellular guidance 
of PG synthesis 
MreBCD, RodZ, 
RodA, PBP2 
MreBCD, RodZ, RodA Wag31 (DivIVA)?, 
RodA? 
 
 
 
Peptidoglycan synthesis & polar growth  
Traditional model organisms, such as E. coli and B. subtilis, are rod-shaped bacilli in which elongation of 
a mother cell occurs along the cell body, followed by division at mid-cell to generate two equally-sized 
daughter cells.  By contrast, elongation occurs at the cell poles in mycobacteria and results in the 
production of unequally-sized daughter cells (Figure 1.1). 
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Is polar growth symmetric or asymmetric?  
All rod-shaped bacteria contain two poles: an old pole, which is inherited from the mother cell and a new 
pole that is synthesized during division. In mycobacteria, polar growth results in daughter cells of different 
sizes and two hypotheses were recently proposed to explain how this occurs [10,13] (Figure 1.2). One 
model reported that growth is unipolar owing to the extremely slow growth of the new pole relative to the 
old pole [10] and it is now recognized that both poles elongate but at different rates [10,13], thus giving 
rise to daughter cells of different sizes. The second model suggests that the growth rate of the old and 
new poles is symmetric for the majority of the cell cycle, but that growth predominantly occurs at the old 
pole after cytokinesis [13], thereby resulting in unequally-sized daughter cells. The use of different 
experimental conditions and methods for determining the timing of cell division could account for the 
deviating observations. 
 
The evidence for the symmetric model was derived from the study of Mycobacterium smegmatis, in which 
polar elongation was measured between successive cytokinesis events [13] (Figure 1.2A). Because 
cytokinesis partitions the mother cell by separating the cytosolic contents, the authors reason that it is 
during this process that the two daughter cells are generated. To visualize cell growth, cells were pulse 
labelled with a fluorescent amine-reactive dye that stains the cell surface. The dye does not diffuse during 
cell growth and enables visualization of newly incorporated, unlabelled cell wall material over time [10,13]. 
Using this cell surface dye and a fluorescently tagged Wag31 (a protein that localizes to the division 
septum) the authors assessed polar growth in single cells over time using a microfluidics approach [13]. 
After cytokinesis (which is detected by Wag31 localization to the septum) but before the physical 
separation of the cells, growth occurs predominantly at the old pole (Figure 1.2A). After physical cell 
separation, both the new and old poles of the daughter cells elongate at the same rate until the following 
cytokinesis event [13].  
 
In the second model, M. smegmatis polar elongation was measured between successive cell separation 
events (Figure 1.2B). Similarly to the previous study, a microfluidics device was used to monitor single 
cells stained with the fluorescent amine-reactive dye [10]. The marker does not obscure the initiation of 
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Figure 1.2. Elongation and division of mycobacteria generates asymmetric daughter cells. 
Mycobacterial cells elongate by incorporating cell wall material (dark orange or grey) at their cell poles 
and all mother cells contain an old pole (which was inherited from the previous cell division) and a new 
pole (which was synthesized during the previous cell division). The process of cell division can be 
subdivided into several stages, including synthesis of the plasma membrane (thin grey line) roughly at 
mid-cell during cytokinesis, synthesis of a peptidoglycan septum at mid-cell (which is known as 
septation), constriction of the cell wall and hydrolysis of the septum as the two cells physically separate. 
Two models have been described to explain how daughter cells of different sizes are generated and the 
models differ in terms of their definitions of cell division. (A) In the first model [13], in which cytokinesis is 
used to define cell division, growth at both cell poles is symmetric until cytokinesis. From cytokinesis until 
the cells physically separate, growth occurs predominantly at the old pole, which generates two daughter 
cells of unequal sizes. In this model, septation and the initiation of constriction were not specifically 
measured (cells shown in grey). (B) In the second model [10], in which the initiation of constriction is used 
to define cell division, the poles elongate at different rates throughout the cell cycle, with the old pole 
elongating faster than the new pole at all stages of the process. This model did not specifically measure 
cytokinesis or septation (cells shown in grey). Despite discrepancies in the timing of asymmetric growth, 
both models demonstrate that mycobacterial growth generates daughter cells of unequal sizes. 
 
 
cell constriction [10], which indicates the beginning of physical separation. Using physical separation as 
the read-out for cell division, the authors found that cells elongate preferentially at the old pole throughout 
the entire cell cycle (which the authors term unipolar growth) and this was also observed in M. 
BA
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e
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septation
cell elongation
initiation of constriction
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tuberculosis [10]. Subsequent studies, which have also used the physical separation of daughter cells to 
define cell division, have also shown that polar growth occurs predominantly at the old pole throughout 
the cell cycle [11,12]. Whether polar elongation is symmetric or asymmetric depends, in part, on whether 
cell division is defined as cytokinesis [13] or the physical separation of cells [10]. The use of a fluorescent 
tagged allele of Wag31 may also mask fully wildtype elongation, as recently reported [19]. However, 
irrespective of the methods used, both models are in agreement that the cell cycle produces daughter 
cells of different sizes, which elongate at different rates.  
 
Daughter cells that inherit the old pole are larger than their siblings that inherit the new pole and they also 
elongate faster after the cells separate [10,13]. Hence, cell size, cell age and the nature of the cell poles 
(old versus new, which correlates with cell size) determine the elongation rate (referred to as velocity in 
Ref. 13) of newly divided cells. Thus, although daughter cells are genetically identical cells, they are 
phenotypically different. This is in marked contrast to E. coli [10,12], and even Corynebacterium 
glutamicum, which also displays polar growth but produces daughter cells of a similar size and with 
similar elongation rates [11]. Asymmetric growth of mycobacteria leads to intrinsic heterogeneity in the 
population, which can have important consequences. For example, large and small daughter cells within 
microcolonies have been reported to differ in their susceptibility to antibiotics, such that large cells (that 
have inherited the old pole) are more sensitive to cell wall synthesis inhibitors than their smaller sibling 
cells [10]. However, this has been challenged by studies in which antibiotic sensitivity was tested across 
populations instead of within microcolonies [13,20]. Furthermore, asymmetric growth disturbs the 
distribution of cell wall components, with one daughter cell inheriting mostly newly synthesized cell wall 
(Figure 1.2). The production of phenotypically distinct daughter cells may confer an advantage when the 
population is challenged with the variable environments encountered in the host and it could also 
contribute to the heterogeneous bacterial population that is observed in patients with TB, including cells 
that are recalcitrant to antibiotics. 
 
Peptidoglycan synthesis 
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Polar growth requires the synthesis of new cell wall material, which is particularly complicated for 
mycobacteria as they must simultaneously synthesize PG, arabinogalactan (AG), and mycolic acids (MA) 
(Figure 1.3). Although the arabinogalactan and mycolic acid biosynthetic machineries have been 
characterized, here we focus on peptidoglycan synthesis as more is known about how PG synthesis and 
remodelling contribute to cell proliferation. For both elongation and division, PG precursor subunits (which 
are known as Lipid II) [18] are shuttled from the cytosol to the periplasm by MviN, a transmembrane 
protein that links precursor synthesis to cell wall incorporation. MviN activity is promoted by FhaA (which 
contains a forkhead associated (FHA) domain) that recognizes phosphorylated threonines and binds to a 
phosphorylated domain of MviN [21]. FhaA localizes to the poles and septa [21], the sites where active 
cell wall synthesis occurs, so it may be involved in localizing MviN. After transport to the cell exterior, 
Lipid II is covalently inserted into the expanding cell wall (Figure 1.3). 
 
The elongation complex 
Penicillin binding proteins (PBPs) and PG hydrolases coordinate PG synthesis and hydrolysis, 
respectively, and are therefore key players in PG remodelling that require stringent regulation.  A 
macromolecular machine, known as the elongation complex, regulates peptidoglycan remodelling during 
cell elongation, and comprises proteins with scaffolding, hydrolytic and synthetic roles [18] (Figure 2.2A). 
To ensure that elongation is directed to the cell poles, cytoplasmic proteins anchor the elongation 
complex at these sites. In actinobacteria, the coiled-coil protein DivIVA is used as an anchor [22,23], 
rather than cytoskeletal-like proteins, which are used to guide cell wall synthesis in other bacteria [18]. In 
B. subtilis DivIVA recognizes membrane curvature [22], which ensures its localization to the poles; recent 
data indicates the recognition of membrane curvature also targets Wag31, the mycobacterial DivIVA 
homologue, to the pole [19].  
 
It is likely that Wag31 anchors the nascent elongation complex at the pole and functions as a base for the 
recruitment of the remaining components of the complex [19]. As proper Wag31 localization at the 
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Figure 1.3. Protein machineries direct cell growth and division. 
Large macromolecular complexes comprised of PG synthases (pink), PG hydrolases (green), structural 
proteins (yellow) and regulatory factors (blue) coordinate cell elongation and cell division. (A) The multi-
protein elongation complex drives polar elongation and is anchored at the poles by Wag31, which is 
stabilized by CwsA. The PG synthase PonA1 incorporates new PG subunits into the spaces created by 
the hydrolases. PonA2 and the nonclassical transpeptidases LdtA and/or LdtB might coordinate PG 
synthesis with PonA1, which would generate the two different types of crosslinks (4→3 and 3→3) that are 
observed in mycobacterial PG. Protein cofactors may coordinate this different activity or activate the PG 
synthases (B) Another large macromolecular machine, the divisome, is responsible for cell division. 
Septation is initiated by polymerization of FtsZ and subcellular placement of the Z-ring is regulated by 
several factors (purple), including ClpX, ChiZ and Rv3660c, as well as phosphorylation of FtsZ by PknA. 
FhaB stabilizes the Z-ring and then the structural proteins FtsW, FtsQ, CrgA and CwsA assemble to form 
the divisome. The PG synthases PBPB, PBPA, and PonA1 synthesize the septum and the hydrolases 
RipA and RpfB (and possibly other hydrolases) cleave the septum to separate the daughter cells. Septal 
hydrolysis might also be facilitated by FtsEX, but this remains to be confirmed.  
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Figure 1.3 (Continued) 
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pole [24,25] requires interaction with cell wall synthesis protein A (CwsA) [26], CwsA may recruit or 
stabilize Wag31 at the pole (Figure 1.3A). Indeed, overexpression of CwsA increases polar localization of 
Wag31 in M. smegmatis [27] whereas deletion of cwsA decreases Wag31 polar localization [26]. 
Expression of a phosphomimetic version of Wag31 stimulates the enzymatic activity of MurG and MraY 
[25] (which are involved in Lipid II synthesis), suggesting that Wag31 may interact with Lipid II synthases 
and link Lipid II biosynthesis to cell wall incorporation. This hypothesis is supported by the close proximity 
of wag31 to the Lipid II biosynthetic cluster (a 6kb distance) in the mycobacterial genome. After the 
establishment of the Wag31 anchor, it is likely that peptidoglycan remodelling enzymes are then 
recruited. Wag31 might interact directly with transmembrane PG synthases, such as PonA1, which would 
ensure that cell wall synthesis is connected to cytoplasmic cues, and genetic evidence indicates that such 
interactions exist. For example, Wag31 is required for shape maintenance and peptidoglycan 
incorporation at the pole [19,24,25,28] and its depletion produces round cells that have growth defects 
[24], and Wag31 overexpression produces branching [28]. These phenotypes are consistent with PonA1 
depletion [29] and overexpression (Kieser, KJ and Rubin, EJ, unpublished data), respectively.  
 
M. tuberculosis PonA1 and PonA2 are predicted to be essential for growth during infection [30]. PonA1 
localizes to the poles and division septum in M. smegmatis [29], which suggests that it may synchronize 
the elongation and division complexes. Indeed, PonA1 interacts with the hydrolase RipA, which localizes 
to the septum and is required for cell division [29]. Mycobacterial elongation does not seem to require 
monofunctional PBPA [31], the putative homologue of PBP2, which is required for cell elongation in E. 
coli [18]. Deletion of pbpA in M. smegmatis produces cells that are viable but form filaments [31], 
suggesting that PBPA has a role in division instead of elongation in mycobacteria. Because mycobacterial 
PG is heavily 3→3 crosslinked (Figure 1.1), noncanonical transpeptidases (such as LdtA and/or LdtB) 
might be recruited to the elongation complex to substitute for PBPA. Recent evidence has shown that the 
absence of LdtA and LdtB leads to the production of bulging, short cells, which suggests a defect in cell 
elongation [32]. The coordination of 4→3 and 3→3 crosslinking during elongation may be facilitated by 
cofactors that modulate the activity of PG synthases [18] (Figure 1.3A).  
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Mycobacterial cell division  
Following elongation, mycobacteria divide at roughly mid-cell to form two daughter cells and a large multi-
protein complex, known as the divisome, coordinates this step. Crosstalk between components of the 
elongation complex and the divisome probably triggers peptidoglycan synthesis to move from the poles to 
mid-cell [33]. The divisome contains cytoskeletal-like proteins, structural factors, and PG synthases and 
hydrolases [18,23] (Figure 1.3B) that coordinate both the synthesis and then the splitting of the septum 
during cell division.  
 
Asymmetric septation 
Septal site selection contributes to the inherent phenotypic heterogeneity of mycobacterial cells. Unlike 
other species, such as E. coli or C. glutamicum, several studies have revealed that septa are placed over 
a surprisingly wide zone within the cell body of Mycobacterium bovis BCG, Mycobacterium marinum and 
M. smegmatis [11,12]. What are the functional consequences of promiscuous septal placement? Irregular 
septation enhances the asymmetric size of daughter cells and results in the differential distribution of 
proteins and small molecules to daughter cells, which further increases population heterogeneity [34].  
 
Formation of the Z-ring  
In almost all bacteria, septation is initiated by polymerization of the self-activating GTPase FtsZ into a 
ring-like structure, known as the Z-ring [35]. The Z-ring determines the site of septation and provides the 
energy for membrane constriction [36], in addition to serving as the scaffold for downstream 
peptidoglycan remodelling enzymes [18]. As the Z-ring determines the site of eventual cell division, its 
proper placement is paramount. Mycobacteria regulate Z-ring formation at multiple levels by modulating 
FtsZ polymerization and guiding Z-ring localization. The MinD homologue Rv3660c is a putative regulator 
of Z-ring formation and its overexpression reduces ftsZ expression and inhibits septum formation, 
resulting in highly elongated cells [37]. Unlike other bacteria, mycobacterial FtsZ is phosphorylated 
through the action of PknA, a serine-threonine protein kinase (STPK), which reduces GTP hydrolysis by 
FtsZ and hence its polymerization in vitro is inhibited [38]; both activities are required for constriction of 
the Z-ring to promote division [36]. Expression of mycobacterial PknA in E. coli, results in phosphorylation 
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of E. coli FtsZ and the production of elongated cells [38], which suggests that FtsZ phosphorylation 
perturbs polymerization and dysregulates septum formation in the cell. ClpX, an integral member of the 
ClpXP protease, regulates FtsZ polymerization through a direct interaction with FtsZ and overexpression 
of ClpX decreases the production of Z-rings, resulting in elongated cells [39]. A similar phenotype has 
been observed on overexpression of ChiZ, a lysin motif (LysM) domain containing protein [40]. As 
overexpression of any of these factors individually does not abolish Z-ring formation, this suggests that 
these systems function in parallel to coordinate Z-ring formation. 
 
The divisome  
After the Z-ring forms at approximately mid-cell, other proteins assemble to form the divisome. In addition 
to FtsZ, the structural elements of the divisome are FhaB, FtsW, FtsQ, CrgA and CwsA (Figure 1.3B). 
The small FtsZ-interacting protein FhaB (also known as FipA) forms a bridge between FtsZ and FtsQ and 
its deletion increases cell length [41], which suggests that FhaB is crucial for mediating interactions 
between FtsZ and FtsQ to ensure proper Z-ring formation. The FtsZ-FhaB-FtsQ ternary complex has 
been shown to be required for Z-ring formation under oxidative stress, and consequently loss of FhaB 
inhibits bacterial replication in macrophages [41]. FtsZ also interacts with the cytoplasmic tail of FtsW, 
which is unique to mycobacteria [42]. PBPB (a homologue of E. coli PBP3) joins the complex by 
interacting with the extracytoplasmic loops of FtsW [42] and the FtsZ-FtsW-PBPB complex links 
cytoplasmic structural cues (polymerization of the Z-ring) to septum synthesis [42]. FtsQ associates with 
the actinomycete-specific cell division protein, CrgA [43], which in turn interacts with FtsZ, PBPA and 
PBPB, thereby stabilizing the whole complex. CrgA localizes to the divisome after FtsZ and has a role in 
recruiting PBPB. Depletion of CrgA results in elongated cells, which is probably due to the inability to 
recruit PBPB to the divisome [43]. Furthermore, CrgA interacts with the elongation complex protein CwsA 
[26], and this interaction might coordinate elongation and division during the cell cycle to ensure that 
septum formation occurs post-elongation.  
 
These structural components stabilize the divisome and promote the synthesis of a septum. Three PG 
synthases, PBPA, PBPB, and PonA1, synthesize the septal peptidoglycan. PonA1 is the sole bifunctional 
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PG synthase known to localize to the septum [29]. As described above, PBPA functions predominantly in 
septation [31] and the other monofunctional transpeptidase, PBPB, is required for septal synthesis and 
growth in vitro [44]. Chemical inhibition of PBPB produces branched cells [45]. Continued cell elongation 
can occur even with abnormal septation, which suggests that elongation and division are discrete, but 
interconnected, processes. PBPB also interacts with the polar anchor protein Wag31 [46], likely when the 
division septum is transitioning to a pole. This physical crosstalk with the elongation complex may allow 
elongation to occur even when PBPB’s synthesis of septal PG is chemically dysregulated. The Wag31-
PBPB interaction is particularly important for survival during oxidative stress [46], and similarly to the 
CrgA-CwsA interaction, it might have a role in relaying information between the elongation and division 
machineries. Recent evidence suggests that Wag31 localizes to the division site after formation of the 
septum, and its concentration increases as division commences [13]. This would enable Wag31 to form 
an anchor at the nascent cell pole immediately after cell division to facilitate recruitment of the elongation 
complex for the next division cycle. 
 
Cell division 
After completion of septum synthesis, it is then cleaved to physically separate daughter cells. 
Peptidoglycan contains a variety of chemical bonds that require cleavage by distinct enzymes [18]. In 
other bacterial systems, multiple PG hydrolases, which display functional redundancy, participate in cell 
division [18]. By contrast, mycobacteria have at least one essential PG hydrolase, RipA [47], and its 
depletion results in the generation of cell chains that fail to grow [47]. RipA interacts with another PG 
hydrolase known as resuscitation promoting factor (Rpf) B [48], and in vitro analysis has demonstrated 
that these two PG hydrolases synergistically cleave peptidoglycan [47]. This synergy is counteracted by 
the PG synthase PonA1, probably owing to competition with RpfB for binding to RipA [29]. The balance 
between PonA1-RipA and RipA-RpfB interactions may be used as a mechanism to ensure that synthesis 
of the septum precedes its hydrolysis. Septal hydrolysis in other species, such as E. coli, requires 
amidases and FtsE and FtsX [18] but the activity of mycobacterial amidases and other hydrolases in 
septation is poorly understood [49,50]. Recent evidence suggests that FtsX regulates the hydrolytic 
activity of RipC [51], although the role of RipC in mycobacterial cell division remains unclear. At the 
 ! 20 
completion of cytokinesis, mycobacteria exhibit a “v-snapping” phenotype [23] (Figure 1.2). This may 
result from asymmetric splitting of the septum or from uneven shearing of the arabinogalactan and 
mycolic acid layers on the cell surface [23].  
 
Does dissolution of the septum affect cell shape? Although cell length is heterogeneous in mycobacteria, 
cell width seems to be uniform. This may be due to the retention of unsalvageable peptidoglycan in the 
polar cap. RipA, homologues of which are not essential in other bacterial species, generates peptide 
fragments [47] that cannot be used in future crosslinking reactions, which inhibits the incorporation of new 
PG monomers. Thus, insertion of nascent material might be restricted to the sub-polar region [19] 
because of the static polar cap, resulting in cells of uniform width.  
 
Regulation of growth and division   
Mycobacteria encode a plethora of regulatory pathways to control cell wall synthesis, cell growth and 
division, and the enzymes and processes involved represent another source of heterogeneity [52].  
  
Transcriptional regulation 
Cell wall biosynthesis can be modulated at the level of gene expression. The three transcription factors, 
EmbR, MabR, and FasR regulate expression of the cell wall synthases EmbA, EmbB, and the FASI and 
FASII complexes [53-55]. The transcriptional activator EmbR binds to the promoter of the embCAB 
operon, which encodes arabinosyltransferases in M. tuberculosis, to increase arabinogalactan synthesis 
[53] (Figure 1.4A). The FHA domain of EmbR is phosphorylated by the serine/threonine kinase PknH, 
which promotes EmbR binding to the embCAB promoter, and this is further enhanced in macrophages as 
PknH expression is known to increase [53]. This increase in arabinogalactan synthesis may facilitate 
adaptation to the stresses encountered inside macrophages.  
 
Large and complex lipids such as the immunomodulatory mycolic acids are energetically expensive to 
produce, and the cell has evolved to tightly regulate their synthesis. The transcription factors MabR and 
FasR, both of which are required for cell proliferation, regulate mycolic acid synthesis [54,55]. MabR 
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binds to the promoter of the FASII locus and negatively regulates expression of fabD, acpM, kasA and 
kasB, thereby decreasing MA production [54]. MabR overexpression also decreases fas expression, 
suggesting that feedback between the FASI and FASII complexes (Figure 1.1) regulates transcript levels 
[54]. Mycolic acid production is also positively regulated through the activity of FasR, which binds to 
conserved sites in the fas promoter [55]. Depletion of FasR results in decreased expression of fas and 
reduction in mycolic acid synthesis in M. smegmatis [55]. The opposing regulation carried out by MabR 
and FasR enables fine-tuning of mycolic acid production. 
 
Two component systems (TCSs) are also involved in regulating gene expression. Mycobacteria encode 
twelve TCSs that function analogously to the STPK system. The TCS response regulator MtrA is required 
for growth of M. tuberculosis [56], and deletion of its cognate sensor kinase MtrB in M. smegmatis causes 
cells to swell and form chains [57], indicating that this TCS is essential for the maintenance of cell shape 
and division. MtrA binds to the promoters of several cell division factors, including the mycolic acid 
transferases FbpA, FbpB, and FbpC[56], and the divisome-specific PG hydrolase RipA [57]. 
Phosphorylation of MtrA negatively regulates fbpB expression [56]. By contrast, MtrA positively regulates 
fbpA expression irrespective of its phosphorylation status [56]. mtrA is upregulated by low pH [58], which 
suggests that MtrA can regulate cell cycle progression and production of mycolic acids in response to pH 
changes in the macrophage.  
 
Post-translational modifications 
Mycobacteria have a surprisingly large complement of eukaryotic-like STPKs that regulate important 
steps in cell morphogenesis [59,60]. As mycobacteria lack canonical regulatory systems for the 
coordination of cell division, the large complement of STPKs and TCSs may substitute for such systems. 
Phosphorylation modulates growth through two main mechanisms: by directly controlling protein activity 
or by stimulating and balancing protein-protein interactions between cell envelope biogenesis [61-63], 
elongation [21] and divisome proteins [41,60]. The two kinases, PknA and PknB, are essential for growth 
in vitro [59]; overexpression of either PknA or PknB produces bulging cells that have reduced growth 
rates, whereas depletion of either kinase generates elongated, narrow cells [59]. 
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Figure 1.4. Regulatory mechanisms controlling synthesis of the mycobacterial cell wall. 
Mycobacteria use several mechanisms to regulate cell wall synthesis and cell division. (A) At the 
transcriptional level, the transcription factor EmbR activates expression of embCAB, which encodes 
EmbA and EmbB, arabinosyltransferases involved in AG synthesis, and increase AG production by 
binding to the embCAB promoter. Phosphorylation of EmbR by the kinase PknH stimulates promoter 
binding, leading to an increase in AG synthesis. (B) Post-translational modifications of cell wall precursor 
synthases, such as phosphorylation of FabH, also occurs. FabH shuttles mycolic acids from FASI to 
FASII for acyl chain extension, but its activity is inhibited by PknF-mediated phosphorylation, thereby 
decreasing mycolic acid production. (C) Mycobacteria encode a unique pupylation system that targets 
proteins for proteasomal degradation, including those involved in cell wall synthesis. For example, the 
response regulator MtrA is pupylated by PafA, which promotes its proteasomal degradation. This relieves 
MtrA repression of fbpB, which encodes mycolic acid transferase complex member FbpB, expression, 
increasing mycolic acid cell wall incorporation. 
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Figure 1.4 (Continued) 
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Assembly and disassembly of the divisome is regulated, in part, by phosphorylation. Phosphorylation of 
FtsZ by PknA reduces its polymerization in vitro and probably promotes its interaction with FhaB, which 
contains an FHA domain, that is required for FtsZ interaction [41]. Because FhaB interacts with other 
divisome components, its interaction with FtsZ might stabilize the interactions between the Z-ring and the 
rest of the divisome complex. FhaB is also phosphorylated by PknA, which is necessary for FtsZ-FhaB-
FtsQ ternary complex formation [41]. In addition, FtsQ is phosphorylated [60] but whether this is required 
for interactions with FhaB or CrgA remains unexplored. FtsZ, FhaB, and FtsQ are key structural 
components of the divisome, and the high degree of phosphorylation may regulate formation of the 
divisome in response to environmental cues. 
 
Synthesis of all components of the cell wall is affected by phosphorylation. The transmembrane protein 
MviN, which likely shuttles Lipid II precursors across the periplasm, is phosphorylated by PknB and this 
recruits its essential interacting partner, FhaA [21]. Phosphorylation of Wag31 by PknA is required for 
correct polar localization and PG biosynthesis [25]. Hyper-phosphorylation of Wag31 can stimulate Lipid II 
synthesis [25] and probably PG incorporation. The PG synthase PonA1 is also phosphorylated [60]. As 
PonA1 functions as part of both the elongation complex and the divisome [29], its phosphorylation status 
may direct PonA1 to the distinct complexes.  
 
Arabinogalactan and mycolic acid synthesis are also subject to phosphorylative control. As described 
above, EmbR is phosphorylated by PknH [53] which results in the stimulation of arabinogalactan 
synthesis. Several factors involved in MA precursor synthesis are phosphorylated, including FabD, FabH, 
MabA, KasAB, InhA, Pks13, and PcaA [61,63,64]. Phosphorylation of KasB [64] and MabA [62] leads to 
an increase in their activity and increased production of mycolic acids. Phosphorylation of FabH, which 
shuttles mycolic acid precursors from FASI to FASII synthase, decreases its catalytic activity [64], which 
probably decreases mycolic acid production (Figure 1.4B).  
 
Protein processing and degradation 
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Several studies have shown that proteolytic processing of cell division proteins is required for normal 
mycobacterial growth [46,65-67]. The essential hydrolase RipA requires cleavage for full catalytic activity 
to separate daughter cells [65,66]. The essential septal synthase PBPB also undergoes cleavage by the 
metalloprotease Rv2869 during oxidative stress [46], which may decrease cell division during unfavorable 
conditions.  
 
In addition to processing, cell division proteins are subject to degradative control. Mycobacteria encode a 
system analogous to eukaryotic ubiquitylation, which is termed pupylation [67,68]. Conjugation of the 
prokaryotic ubiquitin-like protein (Pup) by PafA to target proteins results in their proteasomal degradation, 
and in addition, Pup can also be removed by the depupylase Dop (which is functionally analogous to de-
ubiquitylases) [69], providing another layer of regulation. Several factors that are involved in cell wall 
assembly are pupylation targets, including MurA, KasB, and MtrA [68]. MtrA is targeted for proteasomal 
degradation [68], and its directed turnover may regulate cell wall assembly and cell division. For example, 
MtrA’s degradation could relieve repression of fbpB, a member of the mycolic acid transferase complex 
(Figure 1.4C). However, not all pupylated proteins are targeted to the proteasome [68] and it remains to 
be determined what effect, if any, this modification has on the function of MurA and KasB, for example, 
and the processes they control.  
  
Cell wall remodelling and asymmetric growth in vivo 
 
Cell wall plasticity facilitates bacterial survival 
Cell envelope biogenesis and cell division are tightly regulated, and the many levels of regulation provide 
ample opportunity for stochastic phenotypic differences to arise between individual cells. Such differences 
are likely to amplify the heterogeneity that is produced by asymmetric cell elongation and division. 
Moreover, re-structuring of the cell wall is a major mechanism that M. tuberculosis uses to adapt to the 
changing host environment [14-17] and to subvert host defences during infection [70]. In addition, the cell 
wall is a major target for antibiotics and mutations in components of the cell wall synthesis machinery lead 
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to clinical drug resistance [71], which highlights the importance of this structure as an interface with the 
host and as a clinical drug target. 
 
The three major cell wall components exist as irregular structures. Peptidoglycan and arabinogalactan are 
extensively modified with glycolyl, amide, succinyl, and galactosamine residues [72-74] and PG contains 
unusual linkages between monomers [72,75] (Figure 1.1). The three forms of mycolic acids (α-meroacids, 
methoxy-meroacids, and keto-meroacids) are synthesized with different acyl chain lengths and saturation 
and are also modified by cyclopropanation, all of which vary from molecule to molecule [76,77] (Figure 
1.1). The combination of these alterations induces physicochemical changes in the cell wall, which have 
been found in bacteria that are grown in vivo, suggesting that they are part of an adaptive response for 
the generation of a heterogeneous bacterial population. A potential consequence of this population 
diversity is that a subpopulation of bacteria are equipped to survive when faced with the dynamic stresses 
encountered in vivo, such as the immune response and antibiotics. 
 
Several studies have shown that the composition of the cell wall changes during infection (Figure 1.5). 
Bacilli isolated from chronically infected patients are no longer acid-fast, which suggests that gross 
structural and/or compositional changes occur during extended periods of in vivo growth [14]. Cells 
isolated from infected guinea pigs display differences in mycolate composition compared to cells grown in 
vitro [15]. Transcriptional analysis of bacteria isolated from diverse regions of the lung has revealed 
substantial changes in the expression of cell wall biosynthetic genes and membrane proteins compared 
to in vitro cultures [16], including the upregulation of lipid synthesis genes. For example, pcaA, desA1 and 
desA3, which are involved in mycolic acid processing, are upregulated and are required for virulence in 
vivo [78]. Furthermore, the length and abundance of the cell wall lipids phthiocerol dimycocerosate 
(PDIM) and sulfolipid-1 (SL-1) increase during growth of M. tuberculosis in vivo [17]. Upregulation of lipid 
biosynthesis could confer multiple benefits to the bacterium: a thicker cell wall restricts the transit of toxic 
molecules (such as antibiotics) across the cell membrane, mycolic acids can manipulate the immune 
system [79] and absorb oxidative radicals [80] and lipids function as a sink for toxic byproducts from 
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cholesterol catabolism during growth in macrophages [81,82], which is required for bacterial survival in a 
murine model of TB [83].  
 
Mycobacterial peptidoglycan is also extensively modified to interact with and adapt to host conditions 
(Figure 1.5). The noncanonical transpeptidases LdtA and LdtB catalyze the predominant 3→3 peptide 
crosslink in PG. LdtB expression peaks during late log phase and late stationary phase, whereas LdtA 
expression increases during late stationary phase only [84]. LdtB mutants are unable to persist and 
decline in number over the course of infection [84]. These data indicate that heavily 3→3 crosslinked 
peptidoglycan is necessary for maintenance of the infection and resisting immune clearance. LdtB 
mutants are also more susceptible to amoxicillin [84], suggesting that these unique crosslinks may have a 
clinically relevant role in resisting antibiotic stress. 
 
In addition to unconventional crosslinks, transcriptomic analysis of M. tuberculosis isolated from 
granulomas has shown that several steps of peptidoglycan biosynthesis are upregulated in vivo, including 
genes responsible for precursor production (such as murE and ddl) and remodelling (such as Rv1730c 
and rpfA) [16]. In addition, PonA1 is required for M. tuberculosis survival during hypoxia [85] and PonA2 
is required during infection [86] and to support growth of M. smegmatis in reduced replication states 
[87,88]. Furthermore, PG editing by low molecular weight PBPs, such as DacB1 and DacB2, which 
hydrolyze the terminal D-alanine residues from N-acetyl muramic acid (NAM) subunits, is required for 
survival in the host as DacB1 is predicted to be essential for infection of nonhuman primates [89]. DacB1 
remodelling of PG may maintain the 3→3 crosslinks critical for persisting in vivo, as removal of the 
terminal D-alanines inhibits 4→3 crosslinking. These data correlate with genetic evidence that 
demonstrates additional cell wall assembly enzymes become essential in host-like conditions [30,44,90-
92]. Taken together, these data suggest that cells must undergo peptidoglycan remodelling to adapt to a 
variety of stresses, many of which mirror conditions that might be encountered in the host during latent or 
active infection. 
 
The wide range of microenvironments imposed by the host induce a variety of metabolic 
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Figure 1.5. Cell wall remodelling may promote survival during infection. 
During growth in vivo, substantial changes occur in the cell wall of M. tuberculosis. Active proliferation 
during infection and the utilization of host carbon sources during growth in macrophages leads to an 
increase in the production of mycolic acids and cell wall lipids such as PDIM, which may promote survival 
in the host environment. In addition, during growth in vivo, peptidoglycan is remodelled and the crucial 
3→3 crosslinks that promote chronic infection and antibiotic resistance are maintained. During slow 
growth and in nonreplicative states, the cell wall becomes thicker, probably due to an increase in the 
synthesis of multiple cell wall layers. During slow growth and nonreplicative states, as well as in hypoxic 
environments, M. tuberculosis downregulates the abundance of immunostimulatory mycolic acids to 
potentially avoid immune recognition and crosslinking of PG may increase to promote cell wall rigidity and 
bacterial survival under stress. These cell wall changes, combined with the inherent plasticity of cell wall 
synthesis, generate a population of unique single cells that may have variable fitness during infection.  
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Figure 1.5 (Continued) 
 
variable MA synthesis
capsule production
PG remodeling
increased PG crosslinking
ac
tive
 pro
life
rati
on
in v
ivo
hos
t ca
rbo
n s
ou
rce
s
human or animal infection
mammalian cell infection
in vitro bacterial culture
slow or nonproliferation
in vivohypoxia
1
2
1
2
M
M G
M
M G
M
M G
M
M
M
M G G
M
M G
M
MG M
M
M G
M
M G
M
M G M
M
M G
M
M G G
M
M
G
1
2
1
M
M G
M
M G
M
M G
M
M
M
M G G
M
M G
M
MG M
M
M G
M
M G
M
M G M
M
M G
M
M G G
M
M
G
2
 ! 30 
changes [81,82,93] that, combined with stochastic variation in cell wall composition, such as variable 
peptidoglycan modifications, and asymmetric cell division, could result in a substantially heterogeneous 
bacterial population. Changes in metabolism and growth rate [93,96] have consequences for the cell wall. 
For example, mutation of cell wall genes generate low fitness mutants under slow growth rates in a 
carbon-limited chemostat, which suggests that PG synthesis, mycolic acid synthesis and synthesis of the 
cell surface lipid PDIM [97] are all required under these conditions. These cell wall synthetic requirements 
probably result in gross changes in the cell wall, such as the thickening observed by electron microscopy 
in low oxygen environments [98]. Many of these changes might be closely linked to overall lipid 
metabolism, as the lipid-rich cell wall obtains its precursors from normal metabolism [17,81,82]. If lipid 
production decreases, which occurs during hypoxia [99], the lipid composition of the cell wall changes 
(Figure 1.5). As many of these lipids are pro-inflammatory molecules [78,79], changes in their abundance 
will also affect interactions between the pathogen and the host. Indeed, deletion of kasB, a component of 
the mycolic acid synthase complex FASII, in a clinical strain of M. tuberculosis attenuates virulence [100]. 
Immunocompetent mice infected with a ΔkasB mutant seem to remain healthy for up to 600 days post-
infection, whereas mice infected with wild-type or a kasB complemented strain succumb to infection 
within 356 days. The persistence of ΔkasB bacteria is probably due to their shortened and altered mycolic 
acid chains [100], which are predicted to reduce immunogenicity. 
 
Asymmetric growth may enhance population heterogeneity 
Asymmetric growth and the resulting heterogeneity in cell size may have a role in the lifecycle of M. 
tuberculosis within the human host, including its ability to actively grow in the range of host 
microenvironments as well as to persist in a quiescent state [5].  
 
Several studies have modelled how asymmetric growth and division influence cell fate during antibiotic 
therapy in vitro [10,20]. For instance, as mentioned above, analysis of microcolonies suggests that cells, 
which have inherited the old pole, are more recalcitrant to cell wall inhibitors than sibling cells that have 
inherited the new pole [10]. In addition to the heterogeneity that accompanies cell growth and division, 
recent work suggests that stochastic changes in katG, which produces the catalase-peroxidase KatG that 
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is required to activate isoniazid, gene expression are responsible for mycobacterial survival during 
isoniazid treatment [20]. It has been shown that individual M. smegmatis cells vary in their susceptibility to 
isoniazid, which is independent of the genetic background and cell age [20]. Unlike E. coli, these 
stochastic processes are also independent of growth rate and cell size [101]. Variation in gene expression 
is also likely to influence cellular responses other than antibiotic resistance, which would also contribute 
to the ability to adapt to different conditions – an essential requirement for persisting in hypoxic conditions 
in vivo [93] as well as for antibiotic tolerance [102-104]. Deterministic and stochastic means of tolerance 
to antibiotics, combined with the diversity in cell size and cell wall composition, could contribute to the 
notoriously long course of antibiotic therapy that is required to treat M. tuberculosis infections. 
 
Outlook  
The mycobacterial cell wall is a complex structure and the mechanisms required for its biogenesis, 
including regulation, reflect this complexity. Regulation of cell wall synthesis occurs at the level of 
transcription and post-translational mechanisms, including proteolytic processing, pupylation and 
widespread phosphorylation. This enables mycobacteria to manipulate the composition of the cell wall in 
response to changing environmental conditions in the host. Thus, it seems reasonable to propose that 
dynamic remodelling of the cell wall [14-17] and the unusual mechanism of asymmetric elongation and 
division [10-13], are major contributors to the ability of the bacterium to evade immunity and persist within 
the host.  
 
The findings presented in this Review offer insight into how cell-to-cell heterogeneity can arise in the 
population. The mechanisms controlling asymmetric growth and its regulation remain to be elucidated, 
but it is likely that interplay between the elongation and division machineries is important. Finally, 
population diversity is further enhanced by stochastic changes in gene expression, which lead to variation 
in growth, particularly on exposure to antibiotics [20].  
 
Biochemical and genetic techniques have made substantial headway in elucidating the details of cell wall 
synthesis during growth in vitro. However, several hurdles remain. Studying the mechanistic basis and 
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the importance of heterogeneity in individual bacteria will require more advanced single cell techniques, 
such as microfluidics, an area that is just emerging. Similarly, progress in our understanding of bacterial 
adaptation during infection is required; although in vitro models and animal models can replicate some 
aspects of infection, their correlation with in vivo infection of the human host remains largely unknown. 
Thus, we still require technical breakthroughs to gain a more complete picture of the mycobacterial cell 
wall, as well as cell growth and division in the most important environment – us. 
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Section 2.1: Overview and Attributions 
 
Overview  
This chapter is comprised of a manuscript that was published in PLoS Pathogens in February 2013 as 
well as additional unpublished work (Figures 2.9 and 2.10). 
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2.7D,E. Michael Chao performed the remaining experiments except for those in Figure 2.7B,C which 
were performed by Shoko Minami. Michael Chao and I composed and edited the manuscript. I also 
generated the strains and performed the experiments in the unpublished data section (Figures 2.9 and 
2.10). 
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Abstract 
Peptidoglycan hydrolases are a double-edged sword. They are required for normal cell division, but when 
dysregulated can become autolysins lethal to bacteria. How bacteria ensure that peptidoglycan 
hydrolases function only in the correct spatial and temporal context remains largely unknown. Here, we 
demonstrate that dysregulation converts the essential mycobacterial peptidoglycan hydrolase RipA to an 
autolysin that compromises cellular structural integrity. We find that mycobacteria control RipA activity 
through two interconnected levels of regulation in vivo—protein interactions coordinate PG hydrolysis, 
while proteolysis is necessary for RipA enzymatic activity. Dysregulation of RipA protein complexes by 
treatment with a peptidoglycan synthase inhibitor leads to excessive RipA activity and impairment of 
correct morphology. Furthermore, expression of a RipA dominant negative mutant or of differentially 
processed RipA homologues reveals that RipA is produced as a zymogen, requiring proteolytic 
processing for activity. The amount of RipA processing differs between fast-growing and slow-growing 
mycobacteria and correlates with the requirement for peptidoglycan hydrolase activity in these species. 
Together, the complex picture of RipA regulation is a part of a growing paradigm for careful control of cell 
wall hydrolysis by bacteria during growth, and may represent a novel target for chemotherapy 
development. 
 
Introduction 
Mycobacterium tuberculosis is the causative agent of tuberculosis and accounts for up to 10 million 
symptomatic infections a year [1]. The spread of multi-, extensively- and now totally- drug resistant strains 
[2] has created a pressing need to understand essential mycobacterial processes in an effort to define 
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novel targets for chemotherapy.  One highly essential bacterial process is peptidoglycan (PG) synthesis 
and remodeling, which is critical for providing structural integrity in nearly all bacteria. PG forms a 
continuous macromolecular mesh that is part of the bacterial cell wall and is required for correct cellular 
morphology and opposition to osmotic forces. Despite extensive biochemical and genetic characterization 
of the enzymes responsible for the synthesis and degradation of PG (reviewed in [3,4]), the mechanism 
by which these enzymes coordinate their activities remains poorly defined. It is clear, however, that 
dysregulation of this homeostatic balance frequently has lethal effects on the bacterium—inactivation of 
peptidoglycan synthases, either through the use of penicillin derivatives or overexpression of dominant 
negative forms of PG synthetic enzymes, induces lysis of cells [5,6]. In many cases, this lethality can be 
suppressed by inactivation of several peptidoglycan hydrolases [5,7], suggesting that PG hydrolase 
autolysin activity is restrained by functional interactions with PG synthases. This idea is consistent with a 
‘make-then-break’ approach to cell wall synthesis where new PG subunits are first incorporated before 
the existing sacculus is cleaved to allow expansion [8]. One example of this is the formation of the septal 
PG—cells ensure that the septal PG is formed before PG hydrolases cleave apart the daughter cells. 
 
Recent work suggests that the activity of PG synthetic and hydrolytic enzymes is regulated by the 
formation of protein complexes. In E. coli, the PG amidases AmiA, AmiB and AmiC can interact with non-
enzymatic partners that upregulate septal peptidoglycan hydrolysis [9]. Conversely, the major bifunctional 
PG synthases, PBP1A and PBP1B in E. coli interact with and rely on essential lipoprotein partners for 
function [10]. In addition to interactions with non-enzymatic partners, several affinity chromatography and 
genetic studies have identified interactions between PG modulating enzymes themselves [11]. While the 
exact interactions may be species-specific, in general, PG synthases can associate with both other PG 
synthases and with PG hydrolases. Likewise, PG hydrolases can form predicted hydrolytic complexes 
with other autolysins [11,12,13]. These results suggest a general paradigm where PG modulating 
enzymes of both similar and opposing functions assemble as multi-protein complexes that spatially and 
temporally coordinate PG synthesis and hydrolysis during bacterial growth and division. An immediate 
challenge is to translate the many identified interactions into functional in vivo effects on the growth and 
division of bacteria. 
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Previously, we have studied regulation of the essential M. tuberculosis PG hydrolase, RipA (Rv1477).  
RipA belongs to the NLPC/p60 family, and has been characterized as a D,L D-glutamate-diaminopimelic 
acid (DAP) endopeptidase that cleaves within the pentapeptide bridges of the PG sacculus, thereby 
removing cell wall crosslinks [14].  The RipA homologue in Listeria (P60) and in Mycobacterium marinum 
(IipA) can be deleted, but this causes septal resolution defects [15,16].  In contrast, RipA is essential in M. 
tuberculosis [17], and depletion of RipA produces a chaining phenotype in M. smegmatis, which causes 
severe growth inhibition [18]. This is unlike the case in E. coli, where extensive chaining and growth 
inhibition requires inactivation of several PG hydrolases [19]. 
 
In this work, we interrogate the mechanism by which RipA activity is regulated in vivo during vegetative 
growth. We report that RipA requires careful control to support growth and division without compromising 
the cell’s structural integrity—RipA becomes a lethal autolysin when its activity is dysregulated. Under 
physiological conditions, RipA relies on protein interactions to correctly control its degradative capacity.  
These interactions are also necessary for proteolytic cleavage of RipA to produce active enzyme. RipA 
cleavage and activation is more robust in M. smegmatis than in the pathogenic M. tuberculosis or M. 
bovis BCG, which may be a reflection of the different PG hydrolysis requirements between fast and slow 
growing mycobacteria. However, bypassing RipA cleavage by overexpressing fully active truncated 
enzyme compromises the structural integrity of both M. smegmatis and M. tuberculosis, suggesting that 
RipA cleavage may be rate-limited in order to synchronize PG hydrolysis with the growth rate of the 
bacterium. These results suggest a model in which RipA is regulated by several interconnected post-
transcriptional mechanisms—proteolytic processing produces active enzyme, while protein-protein 
interactions upstream and downstream of cleavage ensure RipA functions correctly at the septum.   
 
Results 
Dysregulated RipA functions as a lethal autolysin 
When RipA is depleted, daughter cells are unable to separate and instead, grow as chains (Figure 2.1A). 
While cells require peptidoglycan hydrolysis to accomplish cell separation, excessive cell wall degradation 
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can compromise structural integrity and lead to lysis. We hypothesized that RipA sits in this precarious 
situation, where the cell cannot tolerate either too little or too much RipA activity. 
 
We investigated whether excessive RipA activity is toxic to mycobacteria by inducing M. smegmatis RipA 
(RipASm) from a tetracycline-inducible episomal plasmid in M. smegmatis. Unlike the chaining phenotype 
we have previously observed with RipA depletion, RipA overexpression caused the rod-shaped cells to 
become spherical and lyse, (Figure 2.1A,D). This is dependent on catalytic activity, as overexpression of 
a catalytic mutant, RipASm C408A, does not display this phenotype (Figure 2.1A,D). The spherical 
phenotype of RipASm overexpression led to a severe growth defect by optical density (Figure 2.1B) and 
over one hundred fold killing, as determined by CFU enumeration (Figure 2.1C). Thus, excessive RipA 
activity in the cell is highly lethal. 
 
 
RipA depletion protects against PBP inhibition 
To determine whether a more physiological level of RipA could be converted to a lethal autolysin, we 
dysregulated RipA activity through the use of the beta-lactam antibiotic meropenem. Beta-lactam 
antibiotics block PG precursor incorporation, which causes excessive PG hydrolase activity and cell lysis 
[7]. While M. tuberculosis is relatively resistant to most beta-lactams, recent work has shown that 
meropenem is more resistant to the endogenous mycobaterial beta-lactamase, and is highly effective at 
killing M. tuberculosis, especially in combination with the beta-lactamase inhibitor clavulanate [20]. 
Meropenem targets PBP2 and PBP3 in E. coli, as well as L,D transpeptidases in M. tuberculosis [21,22]. 
Since RipA is known to interact with the PG synthase PBP1, which is required for normal vegetative 
growth [23] and morphology in mycobacteria [24] (depletion of the protein leads to rounded cells), we 
asked whether meropenem treatment can dysregulate RipA and convert the enzyme into a lethal 
autolysin. 
 
 
We first treated M. smegmatis with 10 µg/mL meropenem and assessed morphological changes over 
time by microscopy. Treated cells filament and swell at the poles and septa, which are the sites of 
mycobacterial PG incorporation (Figure 2.2A, arrows). This morphological toxicity correlated with a 
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Figure 2.1.  Dysregulation of RipA in M. smegmatis causes growth attenuation.   
(A) Micrographs of RipA dysregulated strains after 24 hours of depletion or induction.  RipA depletion was 
achieved by placing ripA under the control of an anhydrotetracycline (aTc) inducible promoter [18].  
Depletion occurred over 24 hours by growing this strain in the absence of aTc.  Alternately, wildtype RipA 
(RipASm) or catalytically inactive (RipASm C408A) M. smegmatis RipA was overexpressed in wildtype 
cells.  In the C408A overexpression strain, both chaining (white arrows) and bulging (red arrows) cells 
were observed.  Membranes were stained with TMA-DPH. Scale bar represents 2 µm. (B) M. smegmatis 
strains overexpressing wildtype (RipASm) and catalytically inactive (C408A) RipA were induced with aTc 
and growth assessed by OD600 over time. (C) M. smegmatis was induced with aTc to overexpress either 
wildtype RipASm or inactive RipASm C408A.  Colony forming units (CFUs) were enumerated at the 
indicated time course by serial dilution and plating onto inducer-free agar. (D) Time-lapse microscopy was 
used to visualize M. smegmatis grown on an agar pad with aTc to overexpress wildtype RipASm (left 
panels) or catalytically inactive RipASm C408A (right panels).  A transcriptional cytosolic GFP reporter was 
used to visualize RipA induction as well as determine cytokinesis and cell lysis.  Presented here are 
frames from agar pads at four time points post-induction, showing individual cells before and after cell 
lysis, as detected by loss of GFP signal (arrows).  Scale bar represents 2 µm. 
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Figure 2.1 (Continued) 
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Figure 2.2.  RipA depletion protects cells from meropenem-induced lysis. 
(A) A RipA conditional depletion strain of M. smegmatis was grown in the presence of inducer (RipA 
replete conditions) and 10 µg/mL of meropenem.  Cells were imaged for morphological changes at 
various time points after meropenem addition.  During meropenem treatment, septal and polar bulging 
were observed (arrows). Cell membranes were stained with FM4-64. Scale bar represents 2 µm. (B) 
Lysis of M. smegmatis cells from (A) was also characterized by OD600 at various times post meropenem 
treatment.  (C) The RipA conditional depletion strain of M. smegmatis was grown with anhydrotetracylcine 
(aTc) inducer (RipA replete) or pre-depleted (RipA deplete) in the absence of aTc for 6 hours.  These 
cells were then treated with 10µg/mL of meropenem for 6 hours, washed, serially diluted and plated for 
CFU enumeration. (**, the difference between survival in RipA replete cells and RipA depleted cells in the 
presence of meropenem was significant with a p-value = 0.0006). (D) Cells post meropenem treatment in 
(C) were imaged by fluorescence microscopy to determine morphological changes.  The plasma 
membrane was visualized with FM4-64.  Scale bar represents 2 µm. 
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Figure 2.2 (Continued) 
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decrease in optical density over time, which suggested lysis (Figure 2.2B). This was borne out by CFU 
analysis, which showed that 80% of treated cells were killed within 6 hours of meropenem treatment 
(Figure 2.2C, bar 2). 
 
The bulging at sites of PG incorporation after meropenem treatment suggested an excess of PG 
hydrolase activity. Since RipA localizes both to poles and septa, we hypothesized that RipA may play a 
role in killing meropenem treated cells. To test this idea, we depleted M. smegmatis of RipA before 
meropenem treatment and then assessed survival with meropenem treatment by CFU enumeration. We 
found that unlike RipA replete cells (Figure 2.2C, bar 2), meropenem did not kill RipA depleted cells 
(Figure 2.2C, bar 4). Furthermore, while RipA replete cells bulged under meropenem treatment as 
expected (Figure 2.2D, arrows), the RipA depleted cells appeared refractory to swelling (Figure 2.2D). As 
a control, cells were treated with SDS (which causes non-specific cell wall and membrane stress), as well 
as streptomycin, which targets protein synthesis. These control cells showed no survival or morphological 
differences between RipA replete and depleted cells (data not shown), demonstrating RipA specifically 
interacts with meropenem-affected pathways. Given that RipA enzymatic activity is modulated through 
protein-protein interactions with different PG synthetic and hydrolytic partners [18,24], the meropenem 
data suggest that RipA is held in check in complexes by an interacting protein, such as PBP1. 
Furthermore, although there are many hydrolases that could contribute to cell death when PG synthesis 
is blocked, we found that at least for the synthases blocked by the clinically relevant beta-lactam antibiotic 
meropenem, RipA is quantitatively the single most important hydrolase. 
 
RipA post-transcriptional processes are required for septal resolution 
Our results demonstrate that RipA dysregulation is highly detrimental to the cell. Thus, mycobacteria must 
control the activity of RipA during growth—there must be enough PG hydrolase activity around to support 
growth and division, but not an excessive amount so as to compromise structural integrity. One way this 
control may be regulated is at the transcriptional level. 
 
 ! 52 
We assessed whether the cell downregulates RipA expression using quantitative PCR.  Since RipA is 
required for septation, which does not occur in non-replicative conditions, we compared RipA expression 
between exponential and stationary phases. We found that RipA remained expressed from exponential 
phase through the transition into stationary phase (data not shown), suggesting there may be post-
transcriptional mechanisms responsible for restraining RipA activity when it is not needed. Thus, we 
investigated whether achieving tight control of RipA activity may rely on post-transcriptional processes.   
 
We hypothesized that removal of wildtype RipA from its endogenous niche in vivo would inhibit correct 
septal resolution and therefore phenocopy RipA depletion. If RipA requires downstream interactions for 
activity, e.g. with members of septal complexes or with post-translational enzymatic regulatory proteins, 
then we should be able to create a dominant negative RipA mutant, where the critical catalytic cysteine 
[25] is mutated to a nonfunctional alanine. Overexpression of the RipASm C408A catalytic mutant should 
result in competition between nonfunctional RipA and endogenous RipA for required post-translational 
activation processes. If RipA requires these interactions to function, then we would observe chaining.  
Indeed, when we induced RipASm C408A, cells grew as short chains (Figure 2.1A, white arrows), 
suggesting that RipA interactions are necessary for correct septal PG hydrolysis. 
 
While overexpression of the RipASm C408A mutant produced a severe growth defect (Figure 2.1B,C), it 
was not accompanied by the widespread lysis that was observed upon wildtype RipASm overexpression 
(Figure 2.1C). The apparent drop in optical density upon longer induction of the RipASm C408A strain 
(Figure 1B) was due to clumping of the culture, which though affecting optical density, did not lead to a 
drop in CFU, indicating growth inhibition rather than lysis (Figure 2.1C). However, we did observe 
occasional lysis of the RipASm C408A strain in addition to the dominant negative chaining phenotype. 
Some cells within a chain produced a slight bulging phenotype, which is indicative of an increase in PG 
hydrolytic activity (Figure 2.1A, red arrows).  These bulging cells, like in RipA dysregulated cells, can go 
on to lyse (Figure 2.1D), though this does not lead to detectable cell death by CFU enumeration (Figure 
2.1C). It is possible that displacement of endogenous wildtype RipA from complexes at the septum leads 
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to activity at ectopic sites in a subset of cells. Alternatively, RipA overexpression could stimulate other 
endogenous PG hydrolases. 
 
RipA is proteolytically processed in vivo 
When we used a RipA polyclonal antibody that recognizes a C-terminal epitope, we observed truncated 
RipA species from mycobacteria by Western blotting. When we overexpressed RipASm, we found several 
bands smaller than the predicted full length protein (Figure 2.3A, lane 3). Likewise, we saw these 
truncated bands when we overexpressed RipASm C408A in M. smegmatis (Figure 2.3A, brackets).  These 
products were not due to non-specific cytoplasmic degradation of overexpressed RipA, as we fractionated 
RipASm C408A overexpressing cells and found that RipA processed species were enriched in the cell wall 
fraction (data not shown). The efficiency of fractionating mycobacteria was confirmed by Western blotting 
against RpoB (cytosolic) and mycobacterial antigen 85 (cell wall) markers. Thus, these results suggest 
that RipA undergoes physiological post-translational processing in the periplasmic or cell wall 
compartment. 
 
To further demonstrate that RipA processing is physiological and not an artifact of overexpression, we 
used Western blotting to estimate the size of RipA in wildtype M. smegmatis whole cell lysates. In mid-
exponential phase cells, RipA formed a smear of ~30 kDa (Figure 2.3A, lane 2, red arrow) with no 
detectable full length protein present. This signal was specific for RipA, as cells depleted for RipA (Figure 
2.3A, lane 1) had decreased signal compared to wildtype cells (Figure 2.3A, lane 2) when equal amounts 
of total protein were analyzed (Figure 2.3B). Furthermore, processed endogenous RipA partitioned to the 
cell wall compartment (data not shown). The smear of processed RipA suggests there are multiple 
processing sites. This may represent multiple cleavage products or further modifications to the protein. A 
recent crystal structure of RipA suggests a protease labile loop exists between the N inhibitory and C 
terminal PG hydrolase domains; this loop is hypothesized to be the site of cleavage in vivo, which is 
required for RipA enzymatic activation [25]. We mutated candidate residues in the loop in an attempt to 
identify cleavage sites but were unsuccessful in blocking RipA processing.  
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Figure 2.3.  RipASm but not RipATB is proteolytically processed in M. smegmatis.   
(A) Whole cell lysates were made from cells depleted for RipA (Depl), wildtype M. smegmatis (WT), and 
cells overexpressing either wildtype RipASm (RipASm), RipATB (RipATB), or catalytically inactive RipASm 
C408A (C408A).  The lysates were probed with anti-RipA polyclonal antibody. Full length RipA (arrow), 
and proteolytically cleaved endogenous RipA (red arrow) and recombinant species (brackets) were 
detected. (B) Coomassie stain of RipA-expressing M. smegmatis cells showing total protein loaded.  
Lanes are identical to (A).  As RipASm C408A induction is particularly strong, this sample was deliberately 
underloaded to prevent its signal in (A) from overwhelming detection of less abundant species. (C) 
Western blots with anti-RipA (left panel) and anti-FLAG antibodies (right panel).  Culture filtrates were 
collected from wildtype M. smegmatis (WT) and cells in which chromosomal RipA was C-terminally fused 
to a FLAG epitope (FL).  A truncated RipA species that is shifted by the FLAG tag was observed 
(asterisk). 
 
 
Truncated RipA species were found associated with the cell wall compartment and in culture filtrates.  In 
the culture filtrate, a RipA fragment appeared as a single band at approximately 25 kDa (Figure 2.3C, 
asterisk). We demonstrated this signal was specific by C-terminally tagging endogenous RipA on the 
chromosome of M. smegmatis with a FLAG epitope. This 25 kDa species exhibited altered mobility due to 
the epitope and could be detected by both anti-RipA (Figure 2.3C, left panel) and anti-FLAG antibodies 
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(Figure 2.3C, right panels). These results indicate that RipA exists physiologically in a smaller form than 
the predicted full length protein.  
 
RipA requires processing for activity 
The observation of RipA cleavage suggested this process could be required for the protein’s function in 
vivo. To test whether RipA processing is correlated with division, we titrated overexpression of RipASm 
C408A and quantified the amount of induction needed to mediate chaining. We found that low level 
overexpression with 30 ng/mL inducer was sufficient to cause chaining (Figure 2.4A) without saturating 
the processing machinery, since these cells did not accumulate full length RipA (Figure 2.4B). Instead, 
mildly overexpressed RipA was processed down to two sets of smaller species at around 23 kDa and 12 
kDa (Figure 2.4B). We also saw a dose-dependent saturation of the endogenous processing capacity, 
with high induction leading to accumulation of full length RipA (Figure 2.4B), as well as loss of processed 
endogenous RipA (data not shown).  When we quantified recombinant protein levels by comparing 
densitometry with endogenous RipA protein (Figure 2.4C), we found that even mild RipASm C408A 
overexpression at 30ng/mL of inducer (processed recombinant protein is approximately 10% of 
endogenous wild type RipA levels) was sufficient to cause chaining and cellular toxicity (Figure 2.4A). 
Together with qPCR data showing that RipASm C408A induction does not affect endogenous RipA 
transcription (data not shown), these data suggest direct competition between the RipAsm C408A mutant 
and endogenous RipA for processing machinery, and that the processed, not full length, form of RipA is 
required for division. 
 
However, though correlated with function, the processed species we observed could be the product of an 
inactivating event. To test this, we took advantage of the observation that the M. tuberculosis homologue 
of RipA (RipATB) functions differently in M. smegmatis than its native counterpart, despite having the 
same general domain architecture. In contrast to RipASm, which is toxic when overexpressed, 
overexpression of RipATB in M. smegmatis, surprisingly caused no toxicity or cell morphological 
differences (Figure 2.5A,B), despite similar protein levels (Figure 2.3A). We examined whether RipASm 
toxicity was correlated with its processing by performing Western blot analysis on RipATB overexpressing 
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M. smegmatis. In contrast to overexpression of RipASm, when wildtype RipATB is overexpressed we 
observed only a single full length band at 55 kDa (Figure 2.3A, right arrow). The absence of processing 
correlates with the lack of detectable RipATB toxicity in M. smegmatis. Thus, we hypothesize that 
proteolytic cleavage is required for activating RipA in vivo.  
 
However, it could be formally possible that RipATB cannot recognize M. smegmatis peptidoglycan or is not 
intrinsically active enough in M. smegmatis to cause morphological defects. To test if RipATB can be 
enzymatically functional in M. smegmatis, we deleted the predicted N-terminal inhibitory segment by 
fusing the truncated active domain of RipATB to the RipA secretion signal peptide (RipATB-AD). As a 
control, we also produced a construct in which the M. smegmatis RipA active domain (RipASm-AD) can be 
secreted. None of the strains produced growth defects when uninduced (data not shown). As expected 
RipASm-AD, like full length RipASm, was fully functional when induced and disrupted cell wall integrity, 
leading to bulging of the cells and a concomitant growth defect (Figure 2.6A,B). When RipATB-AD was 
secreted, we found that it was also functional and behaved in the same way as RipASm-AD (Figure 
2.6A,B). Thus, the catalytic domain of RipATB can be active in M. smegmatis, but full length RipATB is not 
toxic because it does not undergo efficient processing in M. smegmatis. 
 
RipA processing in M. tuberculosis requires additional steps 
Given the potentially toxic nature of hyperactive RipA we hypothesized that RipA processing and 
activation may be less robust in slow-growing mycobacteria in order to match their much slower rate of 
growth and consequent lower requirement for peptidoglycan hydrolysis. To investigate this model, we first 
determined whether RipA is processed in M. tuberculosis by overexpressing RipATB.  By Western blot 
analysis, we found multiple immunoreactive smaller species of RipATB, suggesting processing in M. 
tuberculosis (Figure 2.7D, brackets). However, the induction of RipATB in M. tuberculosis did not produce 
morphological changes or growth defects, even after five days of induction (Figure 2.7A,B). This 
overexpression produced about 3 fold more protein (most of which is in the processed form) than 
endogenous full length RipA (Figure 2.7E), which is similar to the amount of overexpression needed to 
observe cell chaining in M. smegmatis with the RipASm C408A allele (Figure 2.4C). The lack of 
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Figure 2.4.  Proteolyzed RipASm C408A overexpression correlates with morphological toxicity. 
(A) Micrographs of M. smegmatis grown in various concentrations of inducer to overexpress RipASm 
C408A-FLAG.   Scale bar represents 2 µm. (B) Total cell lysates from M. smegmatis overexpressing 
RIpASm C408A-FLAG under various inducer concentrations were probed with anti-FLAG antibody. Both 
full length (arrow) and processed RipASm C408A species (brackets) were detected, including two major 
processed species:  a band at 25 kDa and a doublet around 12 kDa. (C) Samples from (B) were probed 
with anti-RipA antibody and densitometry analysis performed. The levels of full length (black), processed 
(red) and total (blue) recombinant RipASm C408A proteins were compared to endogenous RipA levels. 
The fold overexpression of RipASm C408A relative to endogenous RipA was graphed as a function of 
inducer concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 ! 58 
Figure 2.4 (Continued) 
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Figure 2.5.  RipA is differentially active in a species-specific manner.   
(A) Fluorescence micrographs of M. smegmatis strains induced with aTc to overexpress M. tuberculosis 
RipA (RipATB) or M. smegmatis RipA (RipASm). Membranes were stained with TMA-DPH. Scale bar 
represents 2 µm. (B) M. smegmatis strains in (A) were induced with aTc to overexpress RipATB and 
RipASm constructs.  Growth of these strains was monitored over time by OD600. 
 
 
morphological changes in M. tuberculosis is also in contrast with the marked lethality of RipASm 
overexpression in M. smegmatis (Figure 2.1). 
 
One explanation for this dichotomy may be that the slow growth of M. tuberculosis might mask 
morphological or growth defects caused by RipA overexpression. To test this possibility, we bypassed 
RipA processing by secreting truncated RipATB-AD in M. tuberculosis. Induction of RipATB-AD produced a 
severe growth defect in M. tuberculosis (Figure 2.7C), and concomitant cell rounding (Figure 2.7A) similar 
to that seen when RipASm was overexpressed in M. smegmatis. These results show that unchecked RipA 
activity is toxic even to slow-growing mycobacteria. Since full length RipATB induction does not produce 
this toxicity, M. tuberculosis may have intrinsically less robust RipA processing than in M. smegmatis. 
Indeed, in M. tuberculosis, we observed a band of 55kDa on Western blots probed with anti-RipA 
antisera. This band is the same size as full length RipATB and appears in both uninduced and induced 
samples (Figure 2.7D, arrow). As this form was not detected in wildtype M. smegmatis lysates (Figure 
2.3A), it may represent endogenous, unprocessed full length RipA. The same full length band was also 
observed in M. bovis BCG cell lysates. These data, along with the active domain overexpression analysis, 
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support the idea that slow-growing mycobacteria process RipA less efficiently in order to keep this 
potentially lethal activity in check. 
 
 
 
Figure 2.6.  Truncation causes RipATB to become active in M. smegmatis.   
(A) M. tuberculosis and M. smegmatis RipA were truncated to the active endopeptidase domain (AD) and 
fused to the RipA secretion signal to generate RipATB-AD and RipASm-AD. Micrographs of M. smegmatis 
overexpressing RipATB-AD or RipASm-AD were taken at 6 and 20 hours post induction with aTc. 
Membranes were visualized by FM4-64 staining. Scale bar represents 2 µm. (B) M. smegmatis strains 
were constructed to overexpress full length RipATB and RipASm and truncated RipATB-AD, RipASm-AD 
constructs under the control of aTc.  Growth of these strains in the presence of inducer was assessed 
over time by OD600.  
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Discussion 
Bacteria rely on peptidoglycan (PG) for shape and structure.  The prevailing view of PG remodeling 
requires the concerted action of synthetic enzymes ligating new subunits into the existing PG lattice 
followed by hydrolysis of the PG sacculus by autolysins to allow cellular expansion or division.  This 
process is accomplished through the action of large holoenzyme complexes in the periplasm consisting of 
both PG synthetic and hydrolytic enzymes. Disruption of PG synthesis in these complexes can 
dysregulate cognate PG hydrolases, which can then become autolysins that lyse the cell [26]. Thus, the 
coordination and regulation of PG hydrolases is a critical process for survival of the bacterium.   
 
Here we find that RipA in M. tuberculosis and M. smegmatis can behave as an autolysin, resulting in the 
formation of spherical cells and lysis when overexpressed or dysregulated. Overexpression of a RipA 
dominant negative mutant not only causes loss of septal resolution and chaining but also leads to 
uncontrolled activity of endogenous PG hydrolases and lysis in a subset of cells. Thus, RipA requires 
downstream interactions to govern its correct function during septal resolution, as well as prevent lethal 
ectopic hydrolase activity. The relatively low amount of dominant negative RipA (about 10% of 
endogenous RipA) required for chaining suggests that the cell has finely tuned the amount of active RipA 
in the cell to near the level required for division; even loss of 10% of these active RipA species (which is 
manifest in a partial loss of endogenous RipA processing (Figure S7A) leads to a block in septal 
resolution. While it is clear that RipASm C408A overexpression can interfere with endogenous RipA 
activation, given its known interactions with two other PG remodeling enzymes that localize to the 
septum—RpfB and PBP1 [18,24,27]—it is possible the dominant negative mutant also incorporates into 
and inhibits functional PG remodeling complexes. A combination of these two activities may contribute to 
the RipASm C408A mutant’s potency at inducing chaining at relatively low levels of induction. 
 
Supporting the presence of regulatory RipA septal complexes, we showed chemical inhibition of 
peptidoglycan incorporating PBPs (of which the RipA binding partner PBP1 is a member) results in cell 
rounding and lysis. Loss of PG synthetic activity within a PG remodeling complex may allow cognate PG  
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Figure 2.7. Processed RipA is toxic to M. tuberculosis.    
(A) Full length RipATB and truncated RipATB-AD was overexpressed in M. tuberculosis for several days 
with addition of aTc.  Cells were analyzed by microscopy for changes in morphology.  Membranes were 
stained with FM4-64. Scale bar represents 2 µm. (B) Growth of M. tuberculosis induced with aTc and 
overexpressing full length RipATB was measured by OD600. (C) Growth of M. tuberculosis induced with 
aTc and overexpressing truncated RipATB-AD was measured by OD600. (D) M. tuberculosis RipA (RipATB) 
was overexpressed in M. tuberculosis by induction (lane 2) with aTc for 48 hours.  RipATB was then 
detected by anti-RipA Western blot analysis.  Uninduced lysates were used a control (lane 1).  Full length 
RipA (arrow) and processed forms (brackets) were detected. (E) Total overexpressed protein was 
quantified from (D) by performing densitometry analysis on bands apparent in the induced strain that are 
absent from the uninduced control.  Fold change in total RipATB overexpression relative to endogenous 
full length RipA signal was graphed. 
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Figure 2.7 (Continued) 
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hydrolases (such as RipA) to become hyperactive and lyse the cell. We found that RipA depleted cells 
were specifically protected against meropenem-induced killing, but remained sensitive to other unrelated 
stresses.  The depletion of the RipA likely affects the expression of RipB, which resides downstream in 
the same operon and has the same in vitro enzymatic specificity as RipA [14]. However, RipB is not 
essential for growth [28], and we have previously shown that RipA appears to be more phenotypically 
active than RipB in vivo. RipA, but not RipB, can complement the growth inhibition and cell chaining 
defects observed in the ripAB depletion strain [18]. While we cannot discount the possibility that RipB 
contributes to meropenem-mediated killing, it seems more likely that RipA is the main enzyme 
responsible for this lethal phenotype. Together, our data suggests that meropenem-induced killing is RipA 
dependent. However, we do observe a slight but significant difference in growth between RipA depleted 
cells in the presence and absence of meropenem (Figure 2.2C, lanes 2 and 4) that suggests there may 
also be some RipA independent growth inhibition (but not lysis) due to meropenem treatment. This may 
reflect the fact that meropenem can target several transpeptidases [21,22]. Despite this, since RipA 
appears to mediate meropenem’s bactericidal capacity, and thus appears to be a more attractive target 
for drug development—we would expect that a chemical activator of RipA might act synergistically with 
meropenem treatment. From these data alone, it may be possible that a RipA inhibitor would be 
contraindicated in combination with meropenem, as it would antagonize the effect of PBP blockade, but 
we have previously observed that RipA depletion can sensitize cells to carbenicllin, a β-lactam antibiotic 
that also targets various transpeptidases [18]. In previous assays, in contrast to meropenem, carbenicillin 
sensitization required long term RipA depletion—it had no bactericidal effect on cells depleted for RipA in 
the same time scale as our meropenem studies. These data suggest that extended treatment with a RipA 
inhibitor may weaken cells enough to cause sensitivity to PBP inhibitors to which the cell was previously 
resistant. It would be interesting to determine whether RipA blockade can, in fact, synergize with existing 
PG targeting antibiotics in vivo.  
 
Because of the threat of lethal autolysin activity, cells can control PG hydrolases through several, 
interconnected regulatory mechanisms. RipA is no exception, as we have found that in addition to protein 
interactions that modulate its function, RipA requires proteolytic activation.  RipA exists primarily as 
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smaller processed forms in M. smegmatis. Recent work with RipA in vitro has mapped a protease labile 
loop between a putative N terminal blocking domain and the C terminal p60 PG hydrolase domain [25]. 
The size of our truncated RipA species could contain the predicted size of the p60 domain itself after 
cleavage within this loop, but we were unable to determine the exact cleavage site(s) for RipA proteolytic 
activation in vivo using site directed mutagenesis—mutation of two pairs of highly scissile aspartate-
proline peptide bonds [29] at DP301 and DP315 to alanines had no effect on the ability of RipA to be 
cleaved in M. smegmatis (data not shown).  This is consistent with the activation of Auto amidase in 
Listeria monocytogenes, which is also produced as a zymogen and becomes active only after proteolytic 
processing and removal of an N terminal inhibitory domain [30]. For Auto it was not possible to isolate 
single amino acid substitutions that abolish processing; instead, only deletion of the loop prevented 
proteolytic cleavage [30], which suggests that the activation loop is intrinsically labile and might be 
cleaved by many different proteases. Like Auto amidase, RipA’s labile loop can be cleaved by many 
proteases in vitro [25], and thus may be a target of several proteases in vivo. This may explain why we 
see a smear of RipA truncated species in wildtype mycobacteria, as opposed to a single truncated band.  
 
Given the work of Ruggiero et al [25], it was likely that RipA is produced as a zymogen in vivo, like Auto 
amindase. However, another recent report suggested a different effect of the N terminal domain in 
blocking RipA enzymatic activity [14,25]. While both studies agreed that the N terminal domain appears to 
partially block the C terminal endopeptidase active site, the authors reached opposite conclusions as to 
whether the N terminus is inhibitory. Ruggiero et al [25] found that truncated RipA containing only the C 
terminal p60 domain was able to cleave purified PG, while full length RipA had minimal activity [25]. In 
contrast, Böth et al [14] showed that full length RipA was capable of degrading small synthetic PG 
fragments, and truncation of the N terminus produced no increase in enzymatic activity. However, in the 
latter work, the authors did not perform enzymatic digests using full length RipA on purified PG, as 
performed by Ruggiero et al. It is possible that the reported differences between these studies reflects the 
ability of small PG fragments to enter the RipA active site, despite partial occlusion by the N terminal 
domain, while access of larger substrates such as crosslinked and polymerized PG is blocked. Our 
results favor the zymogen model, as we have found that processing of the N terminal domain is required 
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for full RipA enzymatic activation in vivo. Likewise, the lack of processing of RipATB in M. smegmatis likely 
accounts for the absence of its toxicity upon overexpression. While it is possible that full length RipA 
could serve some degradation function on smaller substrates in vivo, our results suggest that its main 
peptidoglycan remodeling activity requires removal of the N terminus, which contains a functional 
inhibitory domain.  
 
Furthermore, using the less efficiently processed RipATB homologue, we showed that protein interactions 
are not only necessary for regulating functional septal complexes but also promote RipA proteolytic 
activation. Full length RipASm is toxic when overexpressed in M. smegmatis, but full length RipATB does 
not produce the same phenotype. However, when we bypassed processing and expressed the truncated 
RipATB active domain in M. smegmatis, we observed a full gain of toxicity. These results suggest that the 
interactions between RipASm and the cellular factors necessary for processing do not occur with the 
RipATB homologue. Since septation is a highly conserved process, these data may not indicate different 
binding partners in slow and fast growing mycobacteria but rather that the M. smegmatis and M. 
tuberculosis binding partners have evolved together and may have higher affinities for one another.  
  
Together, our work demonstrates that RipA regulation occurs at multiple levels post-transcriptionally. We 
did not see any transcriptional downregulation in cells transitioning into non-replicating conditions (data 
not shown). In fact, there was a significant increase in RipA transcription during the transition to stationary 
phase, but the functional consequence of this observation remains unknown. Furthermore, while 
overexpression of the dominant negative RipASm C408A allele modulates processing of endogenous 
RipA, this is due to competition for processing and not transcriptional feedback, even at high induction 
conditions (data not shown). This lack of transcriptional modulation is consistent with the observation that 
ripA expression has only limited variation across dozens of published experimental conditions 
(summarized on TBDB [31]), including general and antibiotic stresses. The only conditions under which 
ripA expression have been found to change are under non-replication conditions and, recently, when cells 
are blocked in cell division [32]. In the latter work, Plocinska et al found that ripA can be regulated by the 
MtrAB two component system. Specifically, inhibiting septum formation prevents MtrB, which localizes at 
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the septum, from activating the MtrA response regulator, leading to ripA downregulation. The authors 
proposed an interesting model in which ripA transcription could be upregulated by MtrB when it 
assembles at the division site; however, it remains unclear whether MtrAB regulation of ripA transcription 
occurs during normal growth or, instead, represents a stress response when cell division is inhibited. 
While the question of ripA transcriptional regulation during vegetative growth remains to be tested, our 
work suggests that post-translational mechanisms like processing may represent a key way of controlling 
RipA hydrolytic activity during growth. Therefore, we propose that protein-protein interactions help 
establish RipA function at the septum, where it is then aided in becoming proteolytically cleaved in the 
periplasm (Figure 2.8). After enzymatic activation, functional RipA can rely on both upstream and 
downstream protein interactions to help place it in the correct context during cell division—inhibition of 
cognate PG synthases can lead to dysregulated cell wall hydrolysis. The benefit of having multiple levels 
of RipA regulation is that the cell can exert a tighter control over RipA’s activation and potential autolysin 
activity.   
 
 
 
Figure 2.8.  Model for RipA activation through proteolytic processing and protein interactions  
RipA is produced as a full length zymogen with an N-terminal secretion signal.  Once in the periplasm, 
RipA can bind to its interaction partners, leading to recruitment of proteases that cleave the extended loop 
between an N-terminal blocking domain and the C-terminal peptidoglycan hydrolase domain.  The 
cleaved RipA C-terminal domain is now active and functions by cleaving the septal peptidoglycan, 
splitting the daughter cells, perhaps in conjunction with other hydrolases. 
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We found that RipA in M. tuberculosis is subject to less proteolytic activation than in M. smegmatis. The 
slow-growing mycobacteria like M. tuberculosis and M. bovis BCG might well have slower rates of PG 
hydrolysis and, consequently, reduced RipA activity.  Indeed, we find significant amounts of full length 
RipATB in slow-growing mycobacterial lysates, a form not present in M. smegmatis lysates. Furthermore, 
while expression of the active domain of RipATB leads to severe growth inhibition with concomitant 
bulging, overexpression of full length RipATB has no such effect in M. tuberculosis, suggesting that slow-
growing mycobacteria proteolytically activate less RipA than their fast-growing counterparts. The 
mechanism behind this additional control over RipA activation is not known, but may be at the level of 
expression or functional kinetics of the protease(s) responsible for RipA cleavage. In fact, there is an 
additional stretch of amino acids in RipASm compared to RipATB, which sits at the beginning of the N 
terminal inhibitory domain. Ultimately, an integrated mechanism for controlling PG hydrolases may 
represent a broad paradigm among cell wall degrading proteins. Multiple levels of regulation might be 
required to synchronize their activity to the cellular requirement while avoiding overactivity and toxicity. In 
support of this, expression of a dominant negative RipA allele at 10% of the endogenous RipA levels 
leads to abnormal chaining.  Thus, M. smegmatis appears to carefully titrate the amount of processed 
RipA to nearly the minimum levels it requires for division, 
 
Finally, beyond division mechanics, post-translational PG hydrolase regulation has the added benefit of 
inducing changes quickly in response to changing environmental conditions, especially in times of low 
transcription such as non-replicative conditions [33,34]. The byproducts of PG hydrolysis can act as 
sensors for the bacterial environment, whether in vitro or within a host. For example, in B. subtilis, 
muropeptides have been found to be sufficient to induce spore resuscitation [35,36] while in M. 
tuberculosis, RpfB, a lysozyme that is known to be a RipA interacting partner [27], is required for regrowth 
from both in vitro and in vivo non-replication states [37,38]. The exact mechanism behind mycobacterial 
resuscitation remains unclear, but muropeptide-based signaling could play a major role. In fact, we found 
processed RipA species in the culture filtrates and recent work by Mir et al demonstrated that the addition 
of muropeptides to dormant M. tuberculosis facilitated resuscitation, possibly through the binding and 
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signaling of the essential mycobacterial integral membrane kinase, PknB [39]. Thus, soluble PG 
remodeling proteins might play a role in fostering communication across a bacterial population.   
 
In summary, this work has further defined two connected, but distinct, mechanisms to regulate the activity 
of RipA, a potential autolysin that is essential for septal resolution in mycobacteria. The complexity of this 
regulation, which involves protein interactions as well as proteolytic activation, underscores the 
importance of carefully coordinating cell wall hydrolysis during growth and division. By dissecting the 
molecular regulation of PG hydrolases, we gain fundamental insight into how the bacterial cell wall is 
dynamically maintained and also open up avenues for novel chemotherapeutics, especially against major 
human pathogens such as M. tuberculosis. 
 
 
Materials and Methods 
Strains and Culture Conditions 
E. coli XL-1 Blue (Stratagene, Santa Clara, CA) were grown at 37C in LB broth or agar and used for 
cloning.  Selection was performed using kanamycin (50 mg/mL), hygromycin (100 mg/mL), ampcillin (100 
mg/mL) or zeocin (25 mg/mL) when appropriate.  Mycobacterium smegmatis mc2155 was grown at 37 °C, 
unless otherwise indicated, in Middlebrook 7H9 broth supplemented with ADC (albumin-dextrose-
catalase) and 0.05% Tween80.  Selection of M. smegmatis was achieved by supplementation of 
kanamycin (25 mg/mL), hygromycin (50 mg/mL) or zeocin (25 mg/mL).  M. tuberculosis H37Rv and M. 
bovis BCG were grown in liquid Middlebrook 7H9 broth and plated on Middlebrook 7H10 agar 
supplemented with OADC (oleic acid-albumin-dextrose-catalase) (BD Biosciences, Franklin Lakes, NJ).  
M. smegmatis in which the RipA endogenous promoter has been replaced by a tetracycline induclble 
promoter was previously constructed and characterized in [18]. 
 
Recombinant DNA Constructs 
Mtb RipA (Rv1477) and Msmeg RipA (MSMEG_3145) mutants were constructed through PCR stitching 
using the following primers:   
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Mtb C383A RipA Forward (CCGTCGGCTTCGACGCCTCAGGCCTGGTGTTG)  
Mtb C383A Reverse (CAACACCAGGCCTGAGGCGTCGAAGCCGACGG)  
Msmeg RipA C408A Forward (ACCGTCGGCTTCGACgcCTCGGGTCTGATG) 
Msmeg C408A Reverse (CATCAGACCCGAGgcGTCGAAGCCGACGGT).   
 
Msmeg RipA DP301AA DP315AA double point mutants were constructed by PCR stitching using the 
following primers: 
Msmeg RipA DP315AA Forward 
(GCGATCCCGAGCGCGTTCGTCAGCGGTGcCgCCATCGCGATCATCAAC) 
Msmeg RipA DP300AA Reverse 
(GAACGCGCTCGGGATCGCAGGCAGGGTCgCGgCCCACACGGCCCAGTT) 
 
Secreted, RipA catalytic domain constructs were made using the M. smegmatis RipA secretion signal 
amino acids 1-51—Reverse primer: GAACCTgatatcGACGAGCGTGGCGAG.  The RipATB active domain 
contained amino acids 332-472, while RipASm active domain contained amino acids 357 to 494.  
 
Tetracycline inducible strains were created by cloning RipA genes into the Tet On plasmid, pSE100.  For 
time-lapse microscopy, green fluorescenct protein was cloned downstream RipASm C408A to create a 
transcriptional reporter.   GFP was also cloned downstream in frame with RipASm to create a translational 
fusion.  These inducible plasmids were then transformed into mycobacteria in which the plasmid pMC1s, 
which encodes the tetR gene, had already been integrated at the L5 site.  
 
Protein Expression 
Recombinant gene products were expressed using a published anhydrotetracycline inducible system [40].  
Anhydrotetracycline induction was performed with 100 ng/mL of anhydrotetracycline unless otherwise 
indicated. 
 
Meropenem Treatment and CFU Enumeration 
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M. smegmatis with chromosomal ripA under the control of a tetracycline inducible promoter was grown in 
7H9 ADC in the presence of 100 ng/mL anhydrotetracycline (aTc) to an OD of 0.2.  The culture was split, 
and the RipA sample was treated with 10 mg/mL of meropenem (Sigma) for 6 hours.  For the RipA 
depleted cells, the culture was pelleted at 5000 rpm for 10 minutes and resuspended in 7H9 ADC without 
aTc.  These cells were grown for 6 hours at 37 °C to deplete for RipA.  Once depletion was confirmed by 
microscopic examination of the culture for chaining, 10 mg/mL meropenem was added and the culture 
was incubated at 37 °C for 6 hours.  After 6 hours of meropenem treatment, both RipA replete and 
depleted cultures were serially diluted and plated onto LB supplemented with hygromycin, kanamycin and 
100 ng/mL aTc.  Plates were incubated for 3 days at 37 °C and colonies were counted.  As a control, 
RipA replete and depleted cells were also treated with 0.08% SDS, 0.08 µg/mL streptomycin (Sigma) or 
500 µg/mL carbenicillin (Sigma). 
 
Protein Fractionation and Preparation 
Cell free culture supernatants were precipitated with 10% TCA (tricholoroacetic acid) overnight at 4 °C.  
Precipitates were pelleted at 15,000xg for 15 minutes at 4 °C and washed once with ice cold acetone.  
The acetone wash was decanted, and the pellet was air dried at room temperature.  Precipitated protein 
was resuspended in reducing SDS loading buffer at 65 °C, for 10 minutes. 
 
M. smegmatis was fractionated by French press three times.  Unbroken cells and insoluble material were 
pelleted at 1000xg for 10 minutes.  The supernatant was collected and insoluble cell wall material pelleted 
at 27,000xg at 4 °C for 40 minutes.  The remaining supernatant was centrifuged at 100,000xg for 1 hour 
at 4 °C to isolate the membrane fraction.  The supernatant contained the soluble cytosolic fraction. 
 
Immunoblotting and Densitometry Analyses 
Rabbit polyclonal antibody was made from and affinity purified using a peptide derived from the Msmeg 
RipA epitope: NAGRKIPSSQMRRG (Genscript, Piscataway, NJ).  Anti-RipA antibody was diluted to 
1mg/mL and used at a dilution of 1:1000.  Anti-FLAG antibody (Sigma, St. Louis, MO) was used 
according to manufacturer’s instructions.  Protein samples were mixed with 4x Laemmli SDS PAGE buffer 
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(Boston BioProducts, Inc, Boston MA) and boiled for 5 minutes. M. bovis BCG and M. tuberculosis protein 
samples were boiled for 20 minutes.  Proteins were separated on 12% Tris-glycine polyacrylamide gels, 
transferred to PVDF membrane (Pall Corp, Pensacola, FL), probed with anti-sera and developed with 
SuperSignal chemiluminescent reagent (Thermo, Pittsburg, PA).  Densitometry on Western blot signal 
was performed using Multiguage software (Fujifilm). 
 
Microscopy and Imaging 
For TMA-DPH (Invitrogen, Carlsbad, CA) staining, bacteria were centrifuged and media removed.  
pPellets were resuspended in 50 mM TMA-DPH in PBS and incubated in the dark for 10 minutes.  Cells 
were also stained in FM4-64Fx (Invitrogen) at a concentration of 5 mg/mL in PBS for 10 minutes, and 
then fixed and stored in 4% paraformaldehyde.  Samples were imaged using a Nikon TE-200E 
microscope with a 100x (NA1.4) objective and captured with an Orca-II ER cooled CCD camera 
(Hamamatsu, Japan).  Shutter and image acquisition were controlled using Metamorph Software 
(Molecular Devices).  Final images were prepared using Adobe Photoshop 7.0. 
 
Time Lapse Microscopy  
Four Gene Frames (Fisher Scientific) were stacked onto a glass slide and filled with Middlebrook 7H9 in 
low melting point agar, supplemented with 50 mg/mL of hygromycin and 100 ng/mL aTc.  A glass 
coverslip was flattened atop the agar to create a smooth surface and then removed after the agar set.  
The agar pad was sliced into eighths and seven of the pieces were removed to provide an air reservoir.  
Onto the remaining pad, exponential phase M. smegmatis was pipetted and allowed to adsorb until the 
surface of the pad appeared dry.  Finally, a glass coverslip was applied and the slide was imaged on the 
microscope in an environmental chamber warmed to 37 °C (Applied Precision, Inc.). 
 
Time-lapse images were acquired using a DeltaVision epifluorescence microscope with an automated 
stage enclosed with a 100x oil objective (Plan APO NA1.40).  Cells were imaged every 10 minutes for up 
to 18 hours using brightfield and fluorescence illumination (461-489 nm; Applied Precision, Inc.) and 
images recorded with a CoolSnap HQ2 camera (Photometric).  Focus was maintained using the software-
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based autofocus (Applied Precision, Inc).   
 
Real Time PCR 
M. smegmatis samples were collected at the indicated growth phases (log, OD600=0.5; early stationary, 
OD600=2; Stationary, 24 hours of OD600 > 7) and stored in RNA Protect Bacteria Reagent (Qiagen, 
Valencia, CA) at -80 °C.  The pellets were then mechanically disrupted by beadbeatting for three 1-minute 
cycles, and RNA isolated using the RNeasy Mini Kit (Qiagen), with one additional DNAse treatment 
(Qiagen) on the column before elution and a second DNAse digestion with Turbo DNase according to 
manufacturer’s instructions (Ambion, Foster City, CA).  Reverse transcription was carried out using the 
High Capacity cDNA Reverse Transcription kit (Applied Biosystem, Foster City, CA).  Quantitative PCR 
reactions were set up in Power SyBr green PCR master mix (Applied Biosystems) and run and analyzed 
on a Step One Plus real time system (Applied Biosystems). 
ripA expression was measured using the following primers: 5’ CAGATCGGTGTGCCCTACTC; 5’ 
GGCGAACATGTAGAGCATCAG; or against the 3’ UTR region: 5’ GCTCGAGGCCCCTTACAC; 5’ 
GGAGCGCAAAGTAATCCCATCAG 
 
ripA expression was normalized to sigA levels, which utilized the following primers: 5’ 
AAGACACCGACCTGGAACTC; 5’AGCTTCTTCTTCCTCGTCCTC. 
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Section 2.3 The role of RipA’s N- and C-termini in modulating RipA activity 
 
RipA’s N-terminal domains of unknown function 
The N-terminal region of RipA that is proteolyzed contains two domains of unknown function that exist 
mainly in mycobacteria [25]. The second of these two domains was found to block the active site of RipA 
[25]. We hypothesized that the N-terminus formed important protein-protein interactions (that may or may 
not impact RipA’s rate of proteolysis). Overexpression of just the N-terminus could deplete RipA from its 
endogenous complexes critical for cell division. To test this hypothesis, I generated a construct to 
overexpress the N-terminal region of M. smegmatis RipA tagged to RFP and overexpressed this RipA 
truncation in M. smegmatis cells. Upon treatment with the small molecule inducer anhydrotetracycline, I 
found that cells were markedly inhibited for growth and exhibited polar bulges (Figure 2.9A,B). These 
data suggest that RipA’s N-terminus did not form protein-protein interactions at the level sufficient to 
deplete RipA from its normal protein complexes, as the cells did not chain (the RipA depletion 
phenotype). While the precise role of RipA’s N-terminal domains of unknown function remains obscure, 
overexpression of this region of the protein is highly toxic to cells.  
 
 
 
Figure 2.9 Overexpression of RipA’s N-terminus induces cell death 
(A) Overexpression of RipA’s N-terminus tagged with RFP in M. smegmatis cells with the addition of the 
small molecule anhydrotetracycline (aTc). Cells were analyzed for cell shape changes with light 
microscopy. (B) Overexpression of the N-terminal region of RipA inhibits cell proliferation in M. 
smegmatis. Population doubling was measured by OD600 at the timepoints indicated. 
 
 ! 75 
 
 
Figure 2.10 RipA’s C-terminus is required for normal septal resolution 
(A) Wildtype M. smemgatis cells and M. smegmatis cells that lack RipA’s C-terminal 25 amino acids were 
imaged by light microscopy. Membranes were visualized with FM4-64. Scale bar represents 2µm. (B) 
Population doubling rates of the RipA truncation and wildtype M. smegmatis cells were measured by 
OD600 every 30 minutes. (C) Western blot analysis of RipA proteolysis of wildtype M. smegmatis, cells that 
overexpress RipA, and the truncation of RipA’s last 25 amino acids. RipA bands were visualized with a 
RipA antibody. 
 
 
 
The C-terminal interaction domain of RipA is required for normal activity 
Previous studies from the lab demonstrated that the C-terminal 25 amino acids of RipA were critical for 
interacting with both RpfB as well as PonA1. These two RipA-interacting partners have opposing 
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enzymatic activity – RpfB is a PG hydrolase whereas PonA1 is a PG synthase. Furthermore, it was 
shown that PonA1 modulated the in vitro synergistic hydrolysis of PG carried out by RpfB and RipA. 
These findings produced an interesting model wherein PonA1 was critical for the survival of 
mycobacterial cells because it governed the lytic activity of RipA. This could be particularly important in 
M. smegmatis, where RipA proteolysis appears to occur at a different rate than in M. tuberculosis.  
 
Furthermore, PonA1 is required for the viability of M. smegmatis in culture whereas it is predicted to be 
dispensable for growth of M. tuberculosis in culture. This differential essentiality could correlate with the 
differential rate of RipA activation in these species. To test these hypotheses, I attempted to generate a 
deletion of endogenous RipA’s C-terminal 25 amino acids. I successfully isolated this RipA truncation, 
which demonstrated that the RipA-PonA1 interaction is not required for the survival of M. smegmatis. 
There must be additional reasons for the essentiality of ponA1 in this species. Loss of the PonA1 and 
RpfB interaction surface did appear to alter RipA activity – the RipA truncation cells form short chains 
(Figure 2.10A), indicating that RipA is not fully capable of hydrolyzing the septal PG joining the daughter 
cells. However, these truncation cells appear to double at rates highly similar to wildtype M. smegmatis 
(Figure 2.10B), which may be due to the levels of RipA proteolysis that are near to wildtype levels (Figure 
2.10C). 
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Chapter 3 
 
The peptidoglycan synthase PonA1 governs cell elongation in mycobacteria 
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Abstract 
Cell growth and division are required for the progression of bacterial infections. Most rod-shaped bacteria 
grow by inserting new cell wall along their mid-section. However, mycobacteria, including the human 
pathogen Mycobacterium tuberculosis, produce new cell wall material at their poles. How mycobacteria 
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control this different mode of growth is incompletely understood. Here we find that PonA1, a penicillin 
binding protein (PBP) capable of transglycosylation and transpeptidation of cell wall peptidoglycan (PG), 
is a major governor of polar growth in mycobacteria. PonA1 is required for growth of Mycobacterium 
smegmatis and is critical for M. tuberculosis during infection. In both cases, PonA1’s catalytic activities 
are both required for normal cell length, though loss of transglycosylase activity has a more pronounced 
effect than transpeptidation. Mutations that alter the amount or the activity of PonA1 result in abnormal 
formation of cell poles and changes in cell length. Moreover, altered PonA1 activity results in dramatic 
differences in antibiotic susceptibility, suggesting that a balance between the two enzymatic activities of 
PonA1 is critical for survival. We also find that phosphorylation of a cytoplasmic region of PonA1 is 
required for normal activity. Mutations in a critical phosphorylated residue affect transglycosylase activity 
and result in abnormal rates of cell elongation. Together, our data indicate that PonA1 is a central 
determinant of polar growth in mycobacteria, and its governance of cell elongation is required for robust 
cell fitness during both host-induced and antibiotic stress.  
 
 
Introduction 
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a significant threat to 
human health. The World Health Organization estimates that 1.5 million individuals die of TB every year, 
and that roughly 2 billion people are latently infected with M. tuberculosis (Mtb) [1]. Despite the 
substantial global burden of TB, little is known about the bacterium’s basic physiological pathways, 
including cell growth and division.  
 
Two processes govern cell growth: elongation of the cell and then division of that cell into two daughter 
cells. Cell division involves the synthesis and then splitting of a peptidoglycan layer (a macromolecule 
composed of disaccharides crosslinked by short peptides), called the septum, which occurs roughly at 
mid-cell. Bacteria elongate by incorporating new cell wall material into their existing cell wall, which is 
often a layer or layers of complex saccharides that surrounds the cell’s plasma membrane. Many rod-
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shaped bacteria grow by elongating their mid-section; however, mycobacteria have a different body plan 
and elongate by incorporating new cell wall precursors at the cell poles [2,3].  
 
Cell growth and division rely on the synthesis of new cell wall. The bacterial cell wall is required for cell 
survival and determines bacterial shape. Peptidoglycan (PG) is a major component of bacterial envelopes 
and is central to the integrity of the cell wall. PG is remodeled in response to stress and undergoes 
rounds of synthesis and hydrolysis every cell cycle to promote cell elongation and division [2,3]. Although 
coordination of PG synthesis has been extensively studied in other bacterial species, this process, 
particularly during elongation, remains relatively unexplored in mycobacteria.  
 
One key enzyme that plays a central role in elongation and septation is PonA1, which localizes to the cell 
pole and septum, where it interacts with the essential PG hydrolase RipA [4,5]. Our previous work 
suggested that PonA1 was essential in Mycobacterium smegmatis (Msm) [4], indicating that we could use 
Msm as a convenient tool to define cellular activity specific to PonA1. Studying PonA1 enables us to 
determine how the cell governs one of the most critical steps in PG synthesis – elongation of the cell pole.  
 
PonA1 is a penicillin binding protein (PBP), a member of a family of proteins that promotes cell growth 
and division through the synthesis of PG [2,3].  PonA1 has two catalytic domains that carry out the two 
extracellular necessary reactions for peptidoglycan synthesis: transglycosylation (TG) and 
transpeptidation (TP). TG reactions link the repeating disaccharide units that form the glycan backbone of 
peptidoglycan. Pentapeptide tails descend from the glycan chains and are crosslinked by TP reactions 
[2,3]. In addition to its two catalytic domains, PonA1 contains a long unconserved cytoplasmic tail. The 
cytoplasmic tail is phosphorylated [6], an unusual modification for PBPs that may play a role in PonA1’s 
cellular function. 
 
Here we provide evidence that PonA1 is required for cell proliferation in Msm and is necessary for normal 
survival of Mtb during infection. It plays multiple roles in determining cell length and defining new growth. 
PonA1 is an early polar localizing factor that can nucleate elongation complexes to construct new cell 
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poles, whose elongation rates are modulated by PonA1’s phosphorylation. Changes in PonA1 activity 
impact cell shape and growth, likely through insults to the cell wall peptidoglycan, that ultimately results in 
reduced cell fitness during infection and stress. Collectively, our data suggest that cell elongation in 
mycobacteria requires PonA1, whose catalytic and regulatory activities modulate the function of cell 
growth complexes. 
 
Results 
Normal growth of M. smegmatis and M. tuberculosis requires PonA1 
Transcriptional depletion of ponA1 (MSMEG_6900, Entrez Gene ID 4536904) was previously shown to 
severely impact proliferation of Msm and induces the formation of lemon-shaped or ballooning cells, 
suggesting that PonA1 plays a critical role in cell growth in mycobacteria [4]. To determine whether 
PonA1 is essential for growth of Msm, we used an allelic replacement system [7] that allows exchange of 
PonA1 alleles on the bacterial chromosome (Figure 3.1A). We generated two exchange vectors, one 
encoding wildtype ponA1 and a negative control vector lacking ponA1. Exchanging wildtype ponA1 with a 
similar wildtype ponA1 fully restored bacterial growth; however, exchange of ponA1 with the negative 
control vector abolished bacterial growth (Figure 3.1A). The few remaining colonies on the negative 
control plate were confirmed ponA1+ by PCR (seven colonies from approximately 4x108 transformed 
cells). These data show that growth of Msm requires ponA1. However, transposon mutagenesis data 
from M. tuberculosis H37Rv (Mtb) suggested that ponA1 (Rv0050, Entrez Gene ID 887065) could be 
disrupted without compromising proliferation of Mtb in culture [8], but that such a disruption would impact 
survival in a mouse model of TB [9]. We therefore tested whether ponA1 could be deleted from the Mtb 
genome by recombineering (see Materials and Methods for details). We successfully isolated a ΔponA1 
Mtb mutant and confirmed that ΔponA1 Mtb cells grew similarly to wildtype Mtb under standard laboratory 
culture conditions (S1A,B Figure in Appendix 2). However, ΔponA1 Mtb cells replicated less robustly than 
wildtype Mtb in the lungs of C57Bl6 mice at 15 and 42 days post infection (dpi) and were moderately 
impaired in dissemination to the spleen at 42 dpi (Figure 3.1B), indicating that loss of PonA1 impacted 
Mtb fitness during infection. Together, these data show that PonA1 is necessary for normal growth of 
Msm in culture and promotes normal fitness of Mtb during infection.  
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PonA1’s synthesis of glycan chains is essential for M. smegmatis viability and for normal cell 
length of M. tuberculosis 
PonA1’s essentiality in Msm is unusual, since PBPs in many bacterial species, including Escherichia coli 
[10], Bacillus subtilis [11], Vibrio cholerae [12], and even the highly related, polar growing actinomycete 
Corynebacterium glutamicum [13] have largely redundant roles. The Msm genome encodes two other 
bifunctional PBPs, PonA2 and PonA3, with presumably similar catalytic activities [14], whereas Mtb 
encodes just PonA1 and PonA2 [15]. To identify which function of PonA1 was essential in Msm, we 
produced a panel of PonA1 mutants with varying catalytic functionality (S2A Figure) for use in the allelic 
exchange system shown in Figure 3.1A. Mutations in homologous active site residues eliminated catalytic 
activity in in vitro assays for E. coli PBP1a [16] and PBP1b [17]. In E. coli, genetic ablation of TP activity 
did not alter TG activity [16,17], whereas elimination of TG activity also abolished the enzyme’s TP 
activity in vitro, presumably because the substrate for the TP reaction was not produced [16,17]. 
However, whether loss of TP activity also abolishes TG activity in the cell remains unclear. 
 
To test whether TG, TP or both activities were required to sustain growth, we transformed Msm with the 
exchange vectors and tested for appropriate chromosomal integration by antibiotic selection (see 
Materials and Methods). We found that only a PonA1TP- allele (predicted to lack TP activity) was capable 
of rescuing bacterial growth while PonA1TG- and PonA1TG-TP- alleles (which lack either TG or both 
activities) failed to rescue bacterial survival (Figure 3.2A). These data suggest that PonA1’s 
polymerization of glycan strands is required in Msm, but that its crosslinking of PG is dispensable. This is 
consistent with a previous report of an Msm mutant with a transposon insertion in ponA1 that generates a 
truncated protein that includes the TG domain but lacks the TP domain [18]. This mutant is likely still 
capable of transglycosylation, as the TG domain still exists, but loss of penicillin binding confirmed that its 
transpeptidation functionality was ablated [18].  
 
In Mtb, PonA1’s synthesis of glycan chains is required for normal bacterial growth. Mtb cells that 
expressed a PonA1TG- allele exhibited moderately impaired viability and dissemination during infection, 
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Figure 3.1. PonA1 is essential in M. smegmatis and required for normal growth of M. tuberculosis. 
(A) An allelic exchange system in M. smegmatis provides an efficient method to test the importance of 
PonA1 for bacterial survival. (B) C57Bl6 mice were aerosol infected with H37Rv wildtype, ΔponA1, 
ΔponA1::ponA1wt, and ΔponA1::ponA1TG- (an allele of PonA1 with a catalytic active site mutation in the 
transglycosylase (TG) domain), and CFU were enumerated were from lung and spleen homogenates at 
15 and 42 days post infection (dpi). Statistical significance was calculated by a one-tailed t-test (lungs at 
15 dpi, H37Rv compared to ΔponA1 *** indicates p-value = 0.0005; lungs 42 dpi, H37Rv compared to 
ΔponA1 ** indicates p-value = 0.0089, and ΔponA1::ponA1wt compared to ΔponA1::ponA1TG- ** indicates 
p-value = 0.0042. Spleens at 42 dpi, H37Rv compared to ΔponA1 *** indicates p-value = 0.0001, and 
ΔponA1::ponA1wt compared to ΔponA1::ponA1TG- * indicates p-value = 0.0122).  
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similar to ΔponA1 cells, when compared to isogenic wildtype (Figure 3.1B). This fitness defect could be 
associated with abnormal cell length, as ΔponA1 and ΔponA1 L5::ponA1TG- cells are shorter than their 
isogenic wildtypes by 14% and 21%, respectively (Figure 3.2B) but showed no gross cell shape changes 
or substantial population doubling defects (S1A,B,C Figure). The ΔponA1 L5::ponA1TG- cells also 
produced somewhat less phthiocerol dimycocerosate (PDIM) (S3 Figure), a cell wall lipid that is important 
for robust growth during infection. Lower PDIM production by this strain may contribute to the decreased 
fitness of these cells in the host, although we do not suspect that low PDIM is related to TG- PonA1 as 
low PDIM production has been described in unrelated genetic mutants [19]. Furthermore, ΔponA1 Mtb 
cells exhibit a cell length defect but produce PDIM at levels similar to or slightly above wildtype H37Rv, 
suggesting that PDIM loss is not necessarily correlated with decreased cell length. The change in cell 
length observed with ΔponA1 and ΔponA1 L5::ponA1TG- cells suggests that PonA1’s polymerization of 
glycan chains is required for normal cell length in Mtb. Altered peptidoglycan structure in these shorter 
cells likely underlies their decreased ability to resist host-induced stresses.  
 
Correct cell length depends on PonA1’s crosslinking of peptidoglycan  
The differential essentiality of PonA1’s TG and TP activities in the cell suggested that they could be 
uncoupled. Uncoupling of the TG and TP activities for PonA1 may be unusual. in vitro studies have 
shown that in other bifunctional PBPs, the TP domain crosslinks the nascent glycan strands produced by 
the cis-TG domain, and it cannot function in the absence of TG activity [16,17,20]. Accordingly, we 
hypothesized that uncoupling of PonA1’s catalytic activities could impact cell elongation and/or division, 
resulting in altered cell morphology. We imaged Msm cells that expressed PonA1wt or PonA1TP- and 
quantified cell length. We found that PonA1TP- Msm were 24% shorter on average than isogenic wildtype 
(Figure 3.2C,D) and had impaired population doubling (S2B,C Figure) although similar levels of protein 
were expressed (S2D Figure). These data suggest that PonA1’s crosslinking of PG is required for normal 
cell length, and that the balance of PonA1 catalytic activities could have a role in controlling cell length 
and withstanding stress. Impaired PonA1 crosslinking in Mtb decreased cell length as well. Cells that 
expressed a PonA1TP- or PonA1TG-TP- allele were 11% or 6% shorter on average, respectively, than 
isogenic wildtype (Figure 3.2B). These data indicate that while PonA1’s TG activity is critical for cell  
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Figure 3.2. PonA1’s glycan synthesis is required in M. smegmatis and catalytic activity promotes 
normal cell elongation. (A) Allelic exchange (see Figure 3.1A) with vectors encoding alleles of PonA1 
with varying catalytic activities (TG-, transglycosylase mutant; TP-, transpeptidase mutant; TG-TP-, 
transglycosylase and transpeptidase double mutant) in M. smegmatis. (B) M. tuberculosis strains were 
grown in culture and total cell length was measured: H37Rv wildtype (234 cells), ΔponA1 (241 cells; 
approximate p-value < 0.0001 by the Kolmogorov-Smirnov test), ΔponA1 L5::ponA1wt (212 cells), ΔponA1 
L5::ponA1TG- (220 cells; approximate p-value < 0.0001 by the Kolmogorov-Smirnov test), ΔponA1 
L5::ponA1TP- (227 cells; approximate p-value < 0.0001 by the Kolmogorov-Smirnov test), and ΔponA1 
L5::ponA1TG-TP- (209 cells; approximate p-value < 0.0001 by the Kolmogorov-Smirnov test). (C) Msm cells 
that express PonA1TP- were assessed for morphological changes via light microscopy. Scale bar, 2 µm. 
(D) Cell length was measured for ΔponA1 L5::ponA1TP- cells (229 cells) and compared to wildtype M. 
smegmatis cell length (wt Msm, 251 cells; approximate p-value < 0.0001 by the Kolmogorov-Smirnov 
test) or isogenic wildtype cell length (ΔponA1 L5::ponA1wt, 247 cells; approximate p-value < 0.0001 by the 
Kolmogorov-Smirnov test). 
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viability and normal cell length (Figure 3.1B and Figure 3.2), its TP activity also has a role in maintaining 
correct cell length in Mtb, although these mutations do not significantly alter population doubling rates 
(S1B,C,D Figure).  
 
PonA1’s transpeptidase domain is dispensable for cell survival 
As PonA1’s TG activity was necessary for the viability of Msm, we hypothesized that the TG domain as 
the sole periplasmic domain would be sufficient to rescue bacterial growth. Furthermore, our previous 
work indicated that PonA1 dampened the hydrolytic activity of the RipA-RpfB complex in vitro [4], 
suggesting that PonA1’s modulation of RipA’s lytic activity could also contribute to the requirement of 
PonA1 in Msm. PonA1’s TP domain mediates the interaction with RipA [4]. To test whether Msm could 
survive with only PonA1’s TG domain in the periplasm, we generated a truncation mutant of PonA1 that 
eliminated the TP domain (PonA11-360) (S2A Figure). We tested whether this truncation could complement 
loss of PonA1 via allelic exchange (Figure 3.1A). We found that PonA11-360 could support bacterial 
survival and growth. However, cells that expressed PonA11-360 exhibited cell shape defects (Figure 3.3A) 
and were 38% shorter than isogenic wildtype cells (Figure 3.3B). These morphological changes 
translated to diminished population growth rates (S2E,F Figure); however, these phenotypic differences 
were not due to difference in protein expression of the truncated PonA1 allele (S2G Figure). In sum, 
these data suggest that PonA1’s TG activity is necessary and that the TG domain is the critical 
periplasmic domain required for the survival of Msm. PonA1 modulation of RipA activity may be an 
important cellular role for PonA1, but it is not absolutely required for viability of Msm, which has other 
means of controlling RipA lytic activity [5].  
 
Linear polar elongation requires balanced PonA1 activity 
Our data together suggest that PonA1 is critical for robust growth and that its catalytic activity is required 
for normal cell length. Do these critical catalytic activities lead to a dominant negative phenotype such 
that replacing wildtype PonA1 in cell growth complexes induces cellular toxicity? We tested this 
hypothesis by overproducing PonA1 in Msm. The overproduction of the PonA1TG-TP- double mutant 
induced the formation of ectopic cell poles (Figure 3.4A) and severely inhibited population growth rates 
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(Figure 3.4B), as did the single catalytic mutants. However, we observed the same phenotypes with 
overproduction of wildtype PonA1 (Figure 3.4A,B). This is in contrast to overproduction of the PonA1 
homologue PBP1b in E. coli, which exhibits a dominant negative phenotype when overexpressed; 
namely, catalytically inactive PBP1b, but not wildtype PBP1b, inhibited growth and induced cell lysis [21]. 
These data suggest the cellular activity of PonA1 is different than its PBP1b homologue in E. coli. The 
growth inhibition with PonA1 overproduction in Msm correlated with the observation that the wildtype 
ponA1 complement in Mtb (ΔponA1 L5::PonA1wt), which is driven by a strong promoter, did not fully 
complement wildtype growth at later time points in both lungs and spleens (Figure 3.1B). These data 
suggest that overproduction of PonA1 in Mtb also impacted cell fitness. Collectively, these results indicate 
that the cell must tightly regulate PonA1 levels and activity to maintain robust cell growth. 
 
 
 
 
Figure 3.3. PonA1’s periplasmic domains modulate cell shape in mycobacteria. (A) Wildtype PonA1 
was replaced with a PonA1 truncation containing the cytoplasmic tail and TG domain (PonA11-360) via 
allelic exchange. Cells were analyzed via light microscopy. Scale bar, 2 µm. (B) Cell length of PonA11-360 
cells (266 cells) was quantitated and compared to cell length of isogenic wildtype (251 cells; approximate 
p-value < 0.0001 by the Kolmogorov-Smirnov test). These measurements were taken on a different day 
than Figure 3.2C,D, hence the slight difference in isogenic wildtype cell length. 
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Figure 3.4. Excess PonA1 induces ectopic polar growth in M. smegmatis.  
(A) PonA1 was overexpressed in Msm cells, and cells were visualized with light microscopy. Scale bar, 2 
µm. (B) Population growth was determined for the overexpression strains (black, teal, green, and gold 
lines), uninduced wildtype overexpression strain (gray unfilled circle), and widltype M. smegmatis (gray 
filled circle) by taking OD600 measurements every 30 minutes. (C) The frequency of multi-poled cells was 
quantitated by counting appropriately misshapen cells in light microscopy images (statistical significance 
was assessed by one-way analysis of variance with Bonferroni’s multiple comparison test, and multiplicity 
adjusted p-values are reported. PonA1wt compared to PonA1TG-, p-value = 0.0039; PonA1TG- compared to 
PonA1TP-, p-value = 0.0225; PonA1TG- compared to PonA1TG-TP-, p-value = 0.0042). (D) The localization 
pattern of PonA1-RFP was assessed by fluorescence microscopy.  
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Although PonA1’s enzymatic activity is not required for ectopic pole formation in Msm, it influenced the 
frequency of ectopic poles. Cells that overproduced PonA1TG- induced the formation of multi-poled cells at 
a higher frequency than other alleles of PonA1 (Figure 3.4C). Taken together, these results suggest that 
some balance between TG and TP activities is required to induce pole formation. However, no enzymatic 
activity is required for this phenomenon, suggesting another role for PonA1, perhaps as a scaffold or 
recruitment factor within protein complexes that promote cell pole growth.  
 
Previous work showed that ectopically-produced PonA1-RFP localized to the pole and septum [4]. A 
chromosomally RFP-tagged ponA1 also exhibits polar and mid-cell localization (S3D Figure). To 
determine whether PonA1 localized at the ectopic growth pole, we imaged Msm cells that overproduced 
PonA1-RFP. We observed that PonA1-RFP localized to each ectopic tip of the growing pole (Figure 
3.4D). Furthermore, PonA1 localized to the pole prior to its degeneration into ectopic poles (S5A Figure, 
follow pole with white arrow), suggesting that PonA1 is an early localizing factor that promotes elongation 
of the cell pole. Ectopic polar growth occurred predominantly from one pole and not both poles (Figure 
3.4A, S4 and S5 Figures), which correlated with the expected pattern of asymmetric polar elongation 
[22,23], and cells that did not overexpress PonA1 did not exhibit ectopic polar growth (Figure 3.4A, S5B 
Figure). Occasional cells with bulges or ectopic poles exhibited no RFP signal at those foci. PonA1’s 
localization to the pole prior to the generation of ectopic poles indicates that PonA1 is intimately involved 
in not just elongating the pole, but in formation of the cell pole itself, potentially through interaction with 
DivIVA, which is required for pole formation in mycobacteria [23]. Furthermore, overexpression of PonA1 
did not induce misplaced septa, suggesting that the majority of PonA1 is targeted to the cell pole during 
normal growth. 
 
Ectopic polar growth upon overproduction of PonA1 in Msm is distinct from that observed in E. coli, where 
ectopic branches appeared when combinations of PBP1a and several low molecular weight PBPs were 
jointly deleted [24,25]. These data suggest that PonA1’s role in mycobacterial growth is distinct from the 
homologous bifunctional PBPs in E. coli. This phenotype may be due to the fundamentally different way 
that mycobacteria elongate – from the cell pole and not along the lateral body as in E. coli.   
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Mycobacteria control cell elongation through post-translational modification of PonA1 
One method the cell may use to regulate PonA1 activity is through post-translational modification. Mtb 
PonA1’s cytoplasmic tail was recently identified as a substrate for the serine-threonine protein kinase 
PknB [6]. Prisic et al suggested the H37Rv genome had a misannotated start site for rv0050, which was 
corroborated by another report that identified an alternative protein translation start site in the 5’ UTR of 
ponA1 [26]. We have used a construct beginning 426 nucleotides upstream of the annotated start site, 
which captures the phosphorylation site, reported translational start site, and yields a predicted 
transmembrane domain [27] (S6A Figure), a necessary feature of all PBPs [28]. We accordingly aligned 
the mc2155 genome for Msm PonA1; the start site was shifted 126 nucleotides upstream, which aligned 
well with -426 Mtb PonA1 (S6A,B Figure). Furthermore, the -426 Mtb PonA1 complemented growth of 
Msm lacking endogenous PonA1, which demonstrated that the -426 Mtb PonA1 allele was functional 
(S6A,B Figure). The -426 Mtb PonA1 protein was also produced at equivalent levels to Msm PonA1 (S6C 
Figure). To test whether -426 Mtb PonA1 was phosphorylated, we purified from E. coli the cytoplasmic 
domain tagged to MBP along with his-MBP-tagged kinase domains of all the functional serine-threonine 
kinases of Mtb. Phospho-transfer profiling of MBP-Mtb PonA1cyto with the kinases revealed that PknB 
efficiently phosphorylated -426 Mtb PonA1 in vitro (Figure 3.5A). The specificity of the phosphorylation on 
MBP-Mtb PonA1cyto’s T34 residue (S6B Figure) was verified by mass spectrometric analysis (S7D 
Figure).  
 
Because PknB’s phosphorylation of other targets modulates key steps in cell growth and division [2], we 
hypothesized that PonA1’s phosphorylation might play a role in regulating cell elongation or division. We 
tested this hypothesis by constructing two different alleles of Msm PonA1, one in which phosphorylation is 
blocked by substitution of an alanine residue for the targeted threonine (T50A) and another where an 
aspartate substitution might mimic the effects of phosphorylation (T50D) and confirmed these isoforms 
were stable (S6C Figure).  We swapped these for the native allele and measured Msm cell length. Cells 
that expressed the T50A allele were longer than isogenic wildtype, whereas cells that expressed the 
T50D allele were shorter than isogenic wildtype (Figure 3.5B). Because the observed changes in cell 
length did not alter gross optical density measurements of these cell populations (S8A Figure), we used  
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Figure 3.5. Phosphorylation regulates the rate of cell elongation. (A) Phospho-transfer profiling 
assays were performed with the kinase domains of the major serine-threonine protein kinases of M. 
tuberculosis (Mtb Pkn) to assess phosphorylation of Mtb MBP-PonA1cyto. (B) Cell length of M. smegmatis 
cells that express a T50A allele of ponA1 (134 cells; approximate p-value = 0.0145 by the Kolmogorov-
Smirnov test) was compared to isogenic wildtype cells (219 cells). Length of cells that express a T50D 
allele (139 cells) was compared to isogenic wildtype (approximate p-value = 0.0082 by the Kolmogorov-
Smirnov test). (C) Cells that expressed a T50A (127 cells) or Δcyto allele (202 cells) in addition to 
isogenic wildtype cells (174 cells) were stained with a cell surface dye and visualized by timelapse 
microscopy. Elongation rate was quantitated and compared to isogenic wildtype (T50A cells, approximate 
p-value = 0.0002 by the Kolmogorov-Smirnov test; Δcyto, approximate p-value < 0.0001 by the 
Kolmogorov-Smirnov test). (D) Total cell length was measured of M. tuberculosis cells that expressed a 
T34A allele (211 cells; approximate p-value = 0.0066 by the Kolmogorov-Smirnov test) or a T34D allele 
(207 cells; approximate p-value < 0.0001 by the Kolmogorov-Smirnov test) and compared to isogenic 
wildtype (202 cells). (E) Msm cells that encode a T50A,TP- allele were visualized by light microscopy. 
Multiple septa are highlighted with white arrows.  
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timelapse microscopy to measure single cell elongation and division events. Cells were labeled with a 
green fluorescent amine-reactive dye that stains the cell surface and does not diffuse over time. This 
allows the visualization of new cell growth (S8B Figure) [22,29]. After labeling, cells were imaged in 
custom microfluidic devices, and cell elongation and cell division events were quantified over time (S8B 
Figure; see Materials and Methods for details). Msm cells that expressed PonA1T50A allele elongated 15% 
faster than isogenic wildtype (Figure 3.5C). This faster elongation rate correlated with increased cell 
length at division (S8C Figure), and did not alter generation time at the single cell level (S8D Figure). 
Timelapse microscopy analysis did not show substantial growth differences between the PonA1T50D 
mutant and isogenic wildtype cells.Truncation of the cytoplasmic tail of PonA1 (PonA1Δcyto), which 
generated a stable protein (S6C Figure), phenocopied the increased elongation rate (Figure 3.5C), 
supporting the role of PonA1’s cytoplasmic domain, and likely its phosphorylation, in downregulating cell 
elongation. Cells that expressed PonA1T50A or PonA1Δcyto elongated predominantly from the old pole (S8E 
Figure) instead of the new pole (S8F Figure), in agreement with the expected growth pattern for 
mycobacteria [22,23]. These data indicate that loss of PonA1’s phosphorylation does not alter the 
subcellular localization of elongation complexes or PonA1’s localization in the elongation complex itself. 
Thus, it appears that PonA1’s cytoplasmic domain is not critical for localizing PonA1 in the elongation 
complex or for interactions with other factors in that complex, but instead likely interacts with cytoplasmic 
factors that are involved in modulating the activity of the elongation complex. For example, it could 
mediate interaction with DivIVA, a key determinant of polar growth in mycobacteria [23]. 
 
PonA1’s phosphorylation plays a similar role in Mtb. We measured the length of cells that expressed a 
T34A allele or a T34D allele. We found that the T34A mutant increased cell length by 5% compared to 
isogenic wildtype, while Mtb that encoded the T34D allele were 11% shorter than isogenic wildtype 
(Figure 3.5D). These data correlate with the observation in Msm. Furthermore, expression of T34A Mtb 
PonA1 in Msm increased cell length of Msm while expression of T34D Mtb PonA1 decreased Msm cell 
length. Collectively, these data suggest that PonA1’s phosphorylation reduces elongation in both Mtb and 
Msm and provides the cell with a facile method to modulate cell length, an important response to certain 
stress conditions, including in-host survival [30].  
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Because PonA1’s phosphorylation was not essential for protein function, but did modulate cell elongation 
rate, we hypothesized that PonA1’s phosphorylation regulated its enzymatic activity. To test this, we 
generated a double mutant in which the phosphorylation and transpeptidase active sites were ablated. 
Msm cells that expressed this double PonA1 mutant (PonA1T50A,TP-) were defective for normal cell 
separation. Cells formed short chains with cells of mixed length containing several septa (Figure 3.5E). 
This is distinct from the short cell phenotype of TP- cells (Figure 3.2C,D) and the elongated cell 
phenotype of T50A cells (Figure 3.5B), neither of which form short chains. Additionally, the Msm 
PonA1T50A,TP- cells had diminished growth rates compared to either of the single mutants or isogenic 
wildtype (S9A,B Figure), although similar protein levels were produced (S9C Figure). These data suggest 
that the peptidoglycan synthesized by this PonA1 mutant diminishes efficient cleavage. This could 
indicate that PonA1’s phosphorylation regulates its TG activity – the remaining enzymatic activity in this 
mutant – and that the observed division defects result from imbalanced synthesis of peptidoglycan.  
 
 
Altering PonA1 activity changes antibiotic susceptibility 
Because changes to PonA1’s phosphorylation status or synthetic ability altered cell shape and viability, 
we investigated whether these mutations would impact cell physiology under stress conditions, 
particularly antibiotic treatment. We previously demonstrated that single nucleotide polymorphisms in 
ponA1 identified in clinical isolates alter Mtb’s fitness during rifampicin treatment [31]. We tested if altered 
Mtb PonA1 enzymatic or regulatory activity would also impact cell fitness in the presence of rifampicin. 
Indeed, Mtb cells that expressed PonA1TG- or PonA1T34D were 5 and 4 fold more tolerant to rifampicin 
treatment than isogenic wildtype, respectively (S10A Figure). In contrast, the inactivation of PonA1’s TP 
activity or blockade of phosphorylation did not alter cell survival in the presence of rifampicin (S10A 
Figure). In sum, these data suggest that altering PonA1 catalytic and regulatory activity changes cell 
fitness when exposed to the clinically relevant antibiotic rifampicin, although the mechanism remains 
unclear. 
 
We also hypothesized that changes in PonA1 activity would alter susceptibility to cell wall stress, 
including antibiotics that target PG synthesis. Genetically ablating Mtb PonA1’s TP activity or its 
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Figure 3.6 PonA1’s TP activity is required for normal teicoplanin tolerance. (A) The minimum 
inhibitory concentration of teicoplanin for Mtb wildtype or ponA1 mutant strains. The fold change in MIC 
for Mtb ΔponA1 was calculated by comparison with H37Rv. The fold change in MIC for all other Mtb 
strains was calculated by comparison with isogenic wildtype (Mtb ΔponA1 L5::ponA1wt). (B) The minimum 
inhibitory concentration of teicoplanin for Msm ponA1 mutant strains. The fold change in MIC was 
calculated by comparison with isogenic wildtype (Msm ΔponA1 L5::ponA1wt).  
 
 
phosphorylation site decreased by 8- or 4-fold, respectively, the minimum inhibitory concentration (MIC) 
of teicoplanin, a glycopeptide that inhibits PG crosslinking [32] (Figure 3.6). The increased sensitivity to 
teicoplanin suggests that imbalanced peptidoglycan synthesis occurred in TP- as well as T34A cells, 
indicating that phosphorylation may regulate PonA1’s TG activity (the remaining catalytic activity of the 
TP- mutant). A shifted teicoplanin MIC was also observed in Msm where the TP- allele exhibits a 16-fold 
change in MIC (Figure 3.6), although the Msm T50A allele did not phenocopy the shifted teicoplanin MIC. 
However, Msm cells that expressed PonA1T50A alleles were more susceptible to a range of meropenem 
concentrations (S10B Figure), supporting the idea that balanced PonA1 activity is required for 
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architecturally sound peptidoglycan to resist stress. We also tested whether inhibiting glycan synthesis 
would impact cellular fitness of PonA1 mutants, but observed minimal efficacy of the small molecule 
inhibitor moenomycin A (S10C Figure). 
 
Our data suggested that PonA1 activity modulated cell fitness in the presence of drugs. We tested 
whether changes to PonA1 activity would alter cell fitness under other chemical stresses that target the 
cell wall. Upon treatment with SDS, Msm cells that expressed PonA1TP- and PonA1T50A exhibited a 
modest decrease in survival (S11A,B Figure). D-amino acids have also been shown to modulate cell wall 
homeostasis [34], and we tested the fitness of PonA1TP- cells in the presence of D-Met. Msm PonA1TP- 
cells grew less robustly and did not reach the same optical density at stationary phase as compared to 
isogenic wildtype cells (S11C,D Figure). Furthermore, PonA1TP- cells exhibited aberrant cell shape in 
deep stationary phase. After four days of growth in culture, Msm PonA1TP- cells became wider and shorter 
compared to isogenic wildtype (S11E Figure, white arrows). These data together indicate that normal 
PonA1 catalytic and regulatory activity is required for the synthesis of structurally robust peptidoglycan to 
ensure cellular survival in the face of multiple stresses.  
 
 
Discussion 
The paradigms of cell growth and division in rod-shaped bacteria are based on organisms that grow 
fundamentally differently than mycobacteria. Consequently, our understanding of mycobacterial growth – 
and the cell’s ability to repress growth – remains elementary. We have addressed this knowledge gap by 
investigating how a key cell wall synthase, PonA1, promotes and regulates cell growth in mycobacteria.  
 
PonA1 is non-redundant during cell growth 
We found that PonA1 is essential in Msm and required for normal proliferation in the lung as well as 
dissemination outside of the lung during an Mtb infection (Figure 3.1). These data suggest that the major 
PBPs in mycobacteria do not have truly redundant functions. This is similar to E. coli where distinct 
complexes employ PBP1a or PBP1b in E. coli [3], as well as recent work in V. cholerae [12] and Listeria 
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monocytogenes [35] that show PBP1a and PBP1b have specialized biological roles during infection. 
Furthermore, this implies a revision of the classic understanding of the PBPs as redundant factors. 
Imperfect redundancy during stress could be exploited to identify unique physiological roles for the PBPs 
in a variety of bacterial species. 
 
The differential essentiality of PonA1 in Msm and Mtb for growth in culture is somewhat surprising, but 
does suggest a difference in expression or functionality of other PBPs, such as the highly homologous 
protein PonA2, in these species. The role for bifunctional PBPs in Mtb cell elongation is probably jointly 
fulfilled by PonA1 and PonA2, whereas Msm has evolved to solely depend on PonA1. Even though 
PonA1 exhibits different essentiality in Mtb and Msm, the role of PonA1 is likely highly similar in the two 
species. We found that Mtb PonA1 complements survival of Msm depleted of endogenous PonA1 (S7 
Figure), and the two proteins are 70% identical at the sequence level (S6 Figure). Furthermore, our data 
suggest that the physiological role of PonA1 in both Msm and Mtb is very analogous.  
 
Governance of cell length and shape 
Our data suggest that PonA1’s polymerization of glycan strands plays a key role in determining cell length 
(Figure 3.2, Figure 3.7A). Indeed, overproduction of TG-inactive PonA1 in Msm yields cells 38% shorter 
when compared to isogenic wildtype (Figure 3.4A and S4A,B Figures). These cells’ length defect is not 
solely due to their higher frequency of ectopic pole formation, as even cells without ectopic poles are 
noticeably shorter than isogenic wildtype (S4A Figure). Balanced PonA1 catalytic activity, however, is 
required for normal cell length. Whereas TG seems to play a large role in modulating cell length, PonA1’s 
TP activity is also required for normal cell length (Figure 3.2). This supports the model wherein efficient 
PG synthesis occurs when one enzyme is catalytically capable of both synthesizing and crosslinking 
nascent glycan strands [3]. The linking of PonA1’s activities provides tight control over cell length and the 
protection of cell integrity and growth.  
 
We found that PonA1-specific PG crosslinking is not required in mycobacteria, although it does promote 
normal cell length. This suggests that other factors either can compensate for lack of PonA1 crosslinking 
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when absent or that PonA1 normally functions in the elongation complex with another crosslinking 
enzyme [2], as is true for other bacterial species [3,20]. Because mycobacterial peptidoglycan is 
estimated to contain predominantly 3–3 crosslinks [36,37], formed by L,D-transpeptidases, these ‘non-
classical’ 3–3 crosslinking enzymes may be active in the elongation complex under wildtype conditions. 
Indeed, deletion of LdtB in Mtb results in shorter cells [38].  
 
Linear cell growth 
We found that PonA1 catalytic activity is required for normal cell length and that PonA1 is an early acting 
factor that promotes extension of the cell pole. Overproduction of PonA1-RFP localizes to the cell pole 
when the cell is still rod-shaped (S5 Figure). These cells then generate an ectopic pole, which is also 
marked by PonA1-RFP. We also see the formation of ectopic poles when PonA1-FLAG is overproduced 
(Figure 3.4, S4 Figure), suggesting that this observation is not an artifact of the fusion partner. Combined 
with the fact that enzymatically inactive PonA1 induces ectopic pole formation, these data suggest that 
PonA1 is important for nucleating elongation complexes, and that PonA1 is a major factor that promotes 
pole elongation in mycobacteria. Because overproduction of enzymatically inactive PonA1 still results in 
ectopic pole formation, it is clear that other factors are involved in physically synthesizing new cell wall at 
these foci. This could be endogenous PonA1, but other factors are also likely involved in elongation. 
Identification of PonA1’s interacting partners would illuminate the composition of the elongation complex 
in mycobacteria and provide further understanding of how cell length and cell shape maintenance are 
controlled. For example, it would be of great interest to determine whether PonA1 and DivIVA interact, 
even transiently, in the elongation complex. DivIVA is required for the rod-shape of mycobacteria [23] but 
has no enzymatic activity. It must coordinate cell growth with the enzymes that synthesize new cell wall 
[23]. PonA1, as a key factor that promotes cell elongation, may be one such factor that DivIVA helps 
position or facilitate its activity at the pole. 
 
Even at hyper-physiological levels, PonA1 is properly recruited to the cell pole, as PonA1-RFP localizes 
at the pole before it degenerates into ectopic poles (S5 Figure). Furthermore, ectopic poles are not 
produced along the cell body. This suggests that the machinery that recruits PonA1 to the cell pole is not 
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Figure 3.7. A model for how PonA1 promotes cell elongation in mycobacteria. (A) We propose a 
model wherein PonA1 localizes early to the growth tip and promotes pole elongation through PG 
synthesis. PonA1 may recruit other factors to form the elongation complex or they are recruited 
independently of PonA1 (factors not shown). Together with these factors, polar elongation proceeds 
(orange cells). PonA1 furthers cell elongation through its synthesis of PG. PonA1’s synthesis of glycan 
strands (colored subunits, panels 1-3) and its crosslinking of those glycan strands (black lines, panels 2-
3) promote normal cell length. These catalytic activities are potentially modulated through PonA1’s 
phosphorylation (arrow), which acts to regulate the rate of cell elongation. (B) Excess PonA1 stimulates 
ectopic cell elongation (orange cells). The frequency of ectopic pole formation increases with imbalanced 
PG crosslinking and may result from changes in local peptidoglycan architecture (panels 1-2, factors 
removed from panel 2 for clarity). These architectural changes may act like a sink that ‘recruits’ additional 
protein-interactors of PonA1 or additional elongation complex components to spur cell elongation at 
ectopic sites (panel 3, dark gray factors).  
 
 
saturated even at increased levels of PonA1 nor is PonA1’s recruitment mechanism rate-limiting for 
elongation under physiological levels of PonA1. Additionally, the ectopic growth pole normally forms at 
one cell pole, although occasional cells with both cell ends sporting ectopic growth poles have been 
observed; however, these cells tend to have multiple septa (S4C Figure, white arrows). These data 
support a model of mycobacterial elongation where the cell poles are asymmetrically active, at least for a 
time [2,22,29].  
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Interestingly, the frequency of ectopic poles correlates with specific imbalanced PonA1 activity. The 
development of ectopic poles was highest with a PonA1 isoform that can crosslink PG but cannot 
polymerize glycan strands. Although we have not shown that loss of PonA1 TG activity does not also 
abolish PonA1 TP activity in the cell (as has been shown for E. coli enzymes in vitro), the fact that the 
TG-TP- double mutant did not yield a similar level of ectopic poles, suggests the TG- allele possesses 
different cellular activity and may not be a completely inactive enzyme. It could possess some level of 
imbalanced PG crosslinking. These data suggest that imbalanced crosslinking might contort local PG 
architecture, which may change the curvature of the membrane enough to misdirect elongation 
complexes to those foci (Figure 3.7B). Alternatively, PonA1 may nucleate elongation complexes at these 
contorted foci to then extend a functional growth pole. Although these ectopic poles elongate over time, 
they eventually block cell growth. These data suggest that PonA1’s coordination of polar growth must be 
tightly regulated to maintain linearity of the bacterial cell. This may be accomplished through proper 
protein-protein interactions and regulation of PonA1 activity.  
 
Phosphorylation regulates elongation rate 
We found that cell growth is regulated through PonA1’s phosphorylation. Phosphorylation of PBPs is 
unusual, and only mycobacteria have so far been reported to phosphorylate their PBPs [6], suggesting 
that phosphorylation could regulate the activity of these proteins in mycobacteria. We found that the 
absence of PonA1’s phosphorylation increased the rate of single cell elongation (Figure 3.5), suggesting 
that PonA1’s phosphorylation normally dampens cell elongation in both Msm and Mtb. Cells of both 
species that harbor PonA1 alleles that cannot be phosphorylated (Msm T50A and Mtb T34A) are longer, 
suggesting that phosphorylation negatively regulates cell elongation (Figure 3.5). PonA1’s 
phosphorylation is consistent with PknB’s phosphorylation of other members of the PG biosynthetic 
pathway [39,40]. In fact, PknB regulates PG synthesis at each key point of the pathway: precursor 
synthesis (GlmU) [40], export (MviN) [39] and polymerization (PonA1). Interestingly, PknB’s 
phosphorylation of these three distinct factors is inhibitory, providing consistent regulation of PG 
biogenesis at multiple steps. It would be of interest to determine if PonA1 phosphorylation correlates with 
stages of the cell cycle; PonA1 may be phosphorylated as the cells begin the switch from elongation to 
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septation, where cells need to slow down elongation. Alternatively, PonA1’s phosphorylation status may 
cycle with rounds of peptidoglycan synthesis during growth. Further work is required to test these models 
in addition to determining if PonA1’s phosphorylation impacts Mtb fitness during growth during infection.  
 
How PonA1’s phosphorylation specifically regulates cell elongation is unknown, although our data 
suggest that it could act to regulate its TG activity. In the absence of PonA1 phosphorylation, its TG 
functionality could be hyperactive. This could lead to increased cell length observed with T50A cells 
(Figure 3.5) and correlates with the shortness of Mtb cells expressing TG- (Figure 3.1) or overexpressing 
TG- Msm cells (Figure 3.4, S4 Figure). Additionally, when the T50A mutation is combined with TP-, Msm 
cells exhibit substantial defects in division (Figure 3.5), which could be a result of hyper-active glycan 
chain synthesis without corresponding crosslinking by PonA1’s cis-TP domain, altering the normal cellular 
response to PG synthesis. Differences in antibiotic susceptibility correlate between PonA1’s 
phosphorylation and TG activity as well. In Mtb, PonA1T34D and PonA1TG- cells exhibit the same rifampicin 
tolerance (S10A Figure), whereas T34A and TP- have the same teicoplanin profile (Table 1). In sum, 
these data suggest a model wherein PonA1’s phosphorylation regulates its TG activity (Figure 3.7A). How 
this could be achieved remains unclear, although it is possible that conformational changes occur upon 
phosphorylation. Alternatively, PonA1 phosphorylation may impact the stability of the elongation complex 
or of PonA1’s retention in the elongation complex, which could underlie the changes in cell length 
observed when cells express phosphorylation mutants. In any case, this is an unusual example of 
cytoplasmic regulation of periplasmic protein activity, though, given the number of phosphorylated 
proteins found in mycobacteria, this might be a common theme in these organisms. 
 
Altering PonA1 activity changes antibiotic susceptibility 
Changes to PonA1 regulatory or enzymatic activity are required for robust growth during antibiotic 
treatment, suggesting that PonA1 mediates tolerance to drugs that target penicillin binding proteins or PG 
synthesis. We found a marked enhanced susceptibility of Mtb and Msm TP- cells to teicoplanin. 
Enhanced sensitivity of PonA1 TP- cells may reflect an increased cellular toxicity from imbalanced 
peptidoglycan synthesis. Recent work suggested that beta-lactams are particularly effective because they 
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not only target TP domains of penicillin binding proteins but they also block crosslinking of nascent glycan 
strands, leading to an accumulation of uncrosslinked or improperly crosslinked strands that are then 
degraded, causing a futile cycle of synthesis and degradation that consumes resources [33]. Teicoplanin 
treated PonA1 TP- cells may be experiencing this cellular toxicity. Because the TP- allele is likely still 
capable of transglycosylation, it can synthesize nascent glycan strands that will then be blocked from 
crosslinking when cells are treated with a crosslinking inhibitor. This could lead to an accumulation of 
uncrosslinked glycan strands and induce cellular toxicity, resulting in the increased teicoplanin sensitivity 
these cells exhibit. Because the T34A allele demonstrates a similar shifted MIC, it suggests that glycan 
strand synthesis is also altered in this mutant. Loss of phosphorylation may lead to enhanced TG activity, 
with a consequent imbalance of crosslinking of the new glycan chains when cells are treated with 
teicoplanin. Furthermore, the endogenous mycobacterial beta-lactamase is ineffective with drugs like 
teicoplanin, increasing their potential usefulness. These data suggest that transpeptidation inhibitors, 
such as teicoplanin, could be a fruitful avenue for TB drug development.   
 
 
Materials and Methods 
 
Bacterial strains and culture conditions 
M. smegmatis mc2155 was cultured in Middlebrook 7H9 salts (Becto-Dickinson) supplemented with ADC 
(5 g/L albumin, 2 g/L dextrose, 3 g/L catalase), 0.25% glyercol, and 0.05% Tween-80 or plated on LB 
agar. M. tuberculosis H37Rv was cultured in Middlebrook 7H9 salts supplemented with OADC (oleic acid, 
albumin, dextrose, catalase [BD Biosciences, Franklin Lakes, NJ]), 0.25% glycerol, and 0.05% Tween-80 
or plated on 7H10 agar. Selection was performed at 50 µg/ml hygromycin, 25 µg/ml kanamycin, 20 µg/ml 
zeocin or 20 µg/ml nourseothricin for both liquid and solid media. E. coli XL-1 Blue (Stratagene, Santa 
Clara, CA) or Top10 (Invitrogen, Carlsbad, CA) were used for cloning and were cultured in LB broth or 
agar. Selection for E. coli occurred at 100 µg/ml hygromycin, 50 µg/ml kanamycin, 20 µg/ml zeocin or 50 
µg/ml nourseothricin for both liquid and solid media. All strains were grown at 37°C. The generation of 
single copy PonA1 mutant strains is described further below. To generate multicopy PonA1 strains, 
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alleles of ponA1 were subcloned into an anhydrotetracycline inducible pMS2 derivative plasmid [41]. 
These plasmids were transformed into an M. smegmatis mc2155 strain with the pMC1s plasmid [41], 
encoding the tetR repressor, integrated at the L5 phage integration site. 
 
Recombinant DNA constructs 
M. smegmatis PonA1 (MSMEG_6900) and M. tuberculosis PonA1 (Rv0050) catalytic mutants were 
generated using site directed mutagenesis and PCR stitching. M. smegmatis PonA1 truncation mutants 
were generated by PCR. The double T50A,TP- Msm PonA1 construct was generated via PCR stitching. 
For all Mtb PonA1 constructs, the -426 start site was used. All constructs used in this study were cloned 
under the strong promoter pUV15 modified to contain TetR operator sites [41] (although no TetR is 
encoded in the cells’ genomes so expression of ponA1 is constitutive). All PCR reactions were performed 
with KOD XtremeTM Hot Start DNA polymerase (EMD Millipore, Billerica, MA). All M. smegmatis and M. 
tuberculosis PonA1 constructs listed above were cloned as translational fusions with either the FLAG 
epitope or monomeric red fluorescent protein (RFP). The FLAG epitope and RFP do not obstruct PonA1 
function, as both tags recombineered onto the C-terminus of ponA1 on the chromosome complement 
Msm survival. 
 
Deletion of ponA1 in M. tuberculosis 
A ponA1 (Rv0050) knockout construct was generated by PCR and subcloning. Because ponA1 exists in 
an operon, the 5’ and 3’ 25 nucleotides of ponA1 were preserved in the knockout construct. The 500 
nucleotides upstream of ponA1 were PCR amplified with a 3’ NdeI restriction endonuclease site. The 500 
nucleotides downstream of ponA1 were PCR amplified with a 5’ PvuI restriction endonuclease site. A 
hygromycin resistance cassette flanked by loxP sites was amplified with a 5’ NdeI site and a 3’ PvuI site. 
These three fragments were subcloned by digesting with NdeI and/or PvuI. The final ligated product was 
PCR amplified and used to replace ponA1 in the Mtb H37Rv genome via recombineering [42]. Cells were 
plated on 7H10 plates with 50 µg/ml hygromycin. After incubation at 37°C for three weeks, colonies were 
inoculated into 2 ml of selective 7H9. Cell lysates were generated and screened by PCR for correct 
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recombinants. One out of 11 colonies was positive for recombination; loss of ponA1 from the genome 
was verified by PCR and whole genome sequencing. 
 
Ethics Statement 
The Institutional Animal Care and Use Committee of Harvard University approved and monitored all 
protocols, personnel, and animal use. The animal facilities are AAALAC accredited, and work was 
performed under the NIH Office of Laboratory Animal Welfare (OLAW) permit number A-3431-01. 
 
Mouse infections 
Six week old wildtype female C57Bl6 mice (Jackson Laboratories, Bar Harbor, ME) were aerosol infected 
with low doses of M. tuberculosis H37Rv wildtype, H37Rv ΔponA1::Hyg, H37Rv ΔponA1::Hyg 
L5::ponA1wt, and H37Rv ΔponA1::Hyg L5::ponA1TG-. Strains were confirmed as PDIM positive by mass 
spectrometry prior to infection using established protocols [43]. Fifteen mice were infected per strain, and 
five mice were sacrificed at 1 day, 15 days, and 42 days post infection, respectively. To minimize 
suffering, animals were first put to sleep with isoflurane before sacrifice. Lungs and spleens were 
homogenized and serially diluted on selective 7H10 plates (for the genetically modified strains) or 7H10 
plates lacking antibiotics (for H37Rv wildtype) for CFU enumeration.  
 
Allelic exchange in M. smegmatis 
A marked copy of PonA1 was first integrated in the chromosome at the L5 phage integration site. The 
endogenous locus of PonA1 was then replaced with a different antibiotic cassette via recombineering. 
This dual marked strain was then transformed with an L5-integrating vector that is marked with a third 
antibiotic cassette. This second integration event replaces the original integrated allele, and selection for 
the third antibiotic recovers cells with the desired allele (Figure 3.1A). Exchange at the L5 site is imperfect 
and to confirm desired transformants, cells are patched onto plates containing the first L5 integrant 
marker or the second L5 integrant marker. Cells that are mono-resistant to the second L5 integrant 
antibiotic are counted as correct transformants; frequencies of correct transformation are calculated by 
comparison to wildtype ponA1 control transformations.  
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Timelapse microscopy and data analysis 
For the data in Figure 3.5 and S8 Figure, vegetatively growing M. smegmatis cells were washed twice in 
1X PBS with 0.1% Tween 20, stained with 50 µg/ml Alexa488 (Invitrogen), and filtered twice through a 10 
µm filter to obtain single cells. Cells were inserted into custom microfluidic devices (see Reference [22]) 
and imaged at 37°C with constant flow of selective 7H9. Cells were imaged with a DeltaVision 
PersonalDV microscope using the 60x objective (Plan APO NA1.42) every 10 minutes for a minimum of 
18 hours. Images were captured with a CoolSnap HQ2 camera (Photometric). Cell elongation and 
division events were annotated using ImageJ (National Institutes of Health) with the ObjectJ plugin 
(Norbert Vischer and Stelian Nastase, University of Amsterdam, 
http://simon.bio.uva.nl/objectj/index.html). Cell elongation was measured as new unstained cell wall 
material; cell division was defined as the first frame when physical invagination of the cell wall was visible. 
A custom Python script was used to analyze the annotations. 
 
For the data in S4 Figure, M. smegmatis cells were imaged using a CellASIC® microfluidic system (EMD 
Millipore, Billerica, MA). Vegetatively growing cells were cultured for four hours ± 100 ng/mL 
anhydrotetracycline (aTc) inducer to overexpress PonA1TG--RFP prior to growth in the CellASIC® 
chambers. Cells were imaged every 15 minutes for 17 hours with constant flow of selective 7H9 ± 100 
ng/mL aTc. Images were captured by a Nikon Eclipse TI microscope using the 60x objective, which is 
maintained at 37°C with an objective heater. Images were captured with a CoolSNAP SQ2 camera. The 
image montage in S4 Figure was compiled with FIJI [44]. 
 
Light microscopy and image analysis 
For imaging, cells were washed once in 1x PBS and resuspended in 1X PBS ± 2.5 µg/ml FM4-64Fx 
(Invitrogen) to visualize the plasma membrane. After resuspension, cells were incubated in the dark for 
10 minutes prior to imaging. For M. tuberculosis, cells were first fixed overnight in 1% formalin in the 
biosafety level 3 facility before removal and consequent imaging. Cells were imaged on a Nikon TE-200E 
microscope using the 100x (NA1.40) objective. Images were captured with an Orca-II ER cooled CCD 
camera (Hamamatsu, Japan). Exposure and image acquisition were controlled with Metamorph Software 
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(Molecular Devices). Final images were prepared in Adobe Photoshop CS3. To quantitate cell length, the 
fluorescent images of cells stained with FM4-64Fx were used. Cell length was calculated using ImageJ 
software (National Institutes of Health) and converted to microns using the appropriate pixel to micron 
conversion. Length was measured from cell pole to the opposite cell pole or from cell pole to septum, if 
present. Cell synchronization is not yet possible for mycobacteria; hence, cell lengths were measured for 
unsynchronized populations. To quantitate the frequency of multi-poled cells, cells were both imaged and 
scored blind to eliminate potential bias. The figure shows data from five combined experiments. 2652 
cells were imaged and counted for PonA1wt, 2910 cells for PonA1TG- cells, 2054 for PonA1TP- cells, and 
2379 for PonA1TG-TP- cells. The control represents data collected from uninduced cells. Overexpression of 
PonA1 was induced with 100 ng/mL aTc. 
 
in vitro kinase assays and detection of PonA1’s phosphorylation site 
N-terminally his-MBP-tagged kinase domains of the nine canonical serine-threonine protein kinases from 
Mtb were expressed and purified from E. coli using a nickel column and then an S75 size exclusion 
column, in kinase buffer (50 mM Tris pH7.5, 150 mM NaCl, 20% glycerol). His-MBP-PonA1 (cytoplasmic 
domain) was expressed and purified from E. coli using Ni-NTA beads (Novagen) according to the protocol 
recommended by the manufacturer. Protein levels were measured by A280, and kinase reactions were 
started by mixing 1 µg of kinase, 10 µg of his-MBP-PonA1(cyto), 1mM MnCl2 and 1mM ATP. Reactions 
were incubated at room temperature for 1 hour and stopped by addition of Laemmli buffer. Samples were 
heated, separated by SDS-PAGE, and detected by western blot using α-phospho-threonine antibody 
(Cell Signaling Technology).  Kinase reactions for mass spectrometry were performed the same way, 
using only his-MBP-PknB and his-MBP-PonA1(cyto). The his-MBP-PonA1 protein band was cut out of the 
polyacrylamide gel and in-gel trypsin digested. Samples were analyzed by liquid chromatography 
(LC)/MS/MS with an Agilent 6520 Accurate-Mass Quadrupole Time-of-Flight instrument. Peptides were 
separated on a POROSHELL 300SB-C18 (2.1 × 75 mm, 5 µm) at a 0.5 mL/min flow rate, by using a 
linear gradient of increasing acetonitrile in water. Spectrum Mill software (Agilent) was used to identify 
peptides.  
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Antibiotic treatment and determination of bacterial cell fitness 
The antibacterial effects of teicoplanin (Sigma Aldrich, St. Louis, MO) and moenomycin A (Sigma Aldrich, 
St. Louis, MO) were determined by culturing exponentially growing M. tuberculosis or M. smegmatis cells 
in complete 7H9 in non-treated 96 well plates (Genesee Scientific, San Diego, CA) in the presence of 
serially diluted drug, in duplicate. Plates also contained duplicate untreated wells as controls. M. 
tuberculosis was grown to OD600 of 0.5 before culturing ± drug at a calculated starting OD600 of 0.006 for 
six days at 37°C with shaking. M. smegmatis was grown to OD600 of 0.5 before culturing ± drug at a 
calculated starting OD600 of 0.05 for 16 hours at 37°C with shaking. Bacterial growth was evaluated by 
adding 0.002% resazurin (Alamar Blue, Sigma Aldrich, St. Louis, MO) to each well. M. tuberculosis plates 
were incubated with resazurin for 18-24 hours. M. smegmatis plates were incubated with resazurin for 3-5 
hours. Wells were scored as blue or purple indicating metabolically inactive cells and pink as 
metabolically active cells. The inhibitory effects of meropenem (Sigma Aldrich, St. Louis, MO) were 
determined by growing M. smegmatis to an OD600 of 0.5 before culturing ± drug at a calculated starting 
OD600 of 0.1. Cells were grown in complete 7H9 in 96 well honeycomb plates (Growth Curves USA, 
Piscataway, NJ) ± drug, in triplicate, at 37°C with shaking in a Bioscreen growth curve machine (Growth 
Curves USA, Piscataway, NJ). Optical density was measured by absorbance at 600nm every 30 minutes 
for 48 hours. The inhibitory effects of rifampicin (Sigma Aldrich, St. Louis, MO) were determined by 
growing M. tuberculosis to an OD600 of 0.5 before culturing ± drug at a calculated starting OD600 of 0.1. 
Cells were grown in complete 7H9 in 24 well untreated plates ± drug, in triplicate, at 37°C with shaking. 
Optical density was measured after six days, and growth was normalized to untreated control wells. 
 
Optical density measurements 
Population growth curves for M. smegmatis strains were performed in 96 well honeycomb plates (Growth 
Curves USA, Piscataway, NJ), in triplicate, at 37°C with shaking in a Bioscreen growth curve machine 
(Growth Curves USA, Piscataway, NJ). Cells were grown to an OD600 of 0.5 before beginning the growth 
curve at a calculated starting OD600 of 0.1. Cells were grown in complete 7H9 with the appropriate 
antibiotic selection. Optical density was measured by absorbance at 600nm every 30 minutes for 48 
hours. Error bars are often too small to see. Population growth curves for M. tuberculosis strains were 
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performed in 30 ml inkwells (Corning Life Sciences, Corning, NY), in triplicate, at 37°C with shaking. Cells 
were grown to an OD600 of 0.5 before beginning the growth curve at a calculated starting OD600 of 0.1. 
Cells were grown in complete 7H9 with the appropriate antibiotic selection. Optical density was measured 
daily by absorbance at 600nm. 
 
Immunoblotting 
Cells were pelleted, washed once in 1X PBS, and lysed by bead-beating. 6X Laemmli buffer was added 
to the whole cell lysate and then boiled for 10 minutes. Proteins were separated on a 12-14% Tris-Glycine 
SDS PAGE gels (BioRad, Hercules, CA), transferred to PVDF membrane (Pall Corp, Pensacola, FL), 
incubated with anti-FLAG antibodies (Sigma Aldrich, St. Louis, MO) at 1:15,000 dilution, washed thrice in 
1X PBST, and incubated with a 1:1000 dilution of a secondary antibody conjugated to HRP (Pierce, 
Rockford, IL). Membranes were incubated with SuperSignal chemiluminescent reagent (Thermo Fisher 
Scientific, Rockford, IL) for 5 minutes in the dark and imaged on a FluorChem8900 (AlphaInnotech, Santa 
Clara, CA). 
 
Data representation and statistical analysis 
Prism 6.0 software (GraphPad Software, La Jolla, CA) was used to graph and analyze numerical data. 
Statistical tests in the Prism software were used to calculate significance of measurements as described 
in the Figure Legends. The doubling times in S2 Figure and S9 Figure were generated by fitting an 
exponential growth function (in Prism) to all datapoints between 5 and 13 hours of OD600 measurements.  
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Section 4.1 Overview and Attributions 
 
Overview 
This chapter is comprised of a manuscript that I wrote, and Eric contributed helpful editorial input. We will 
submit this manuscript soon. 
 
 
Attributions 
I generated all the M. tuberculosis mutant and knockout strains. I generated the ΔponA1 transposon 
genomic library, which Tom Ioerger sequenced. I developed a pipeline in the lab, with invaluable help 
from Michael Chao, Kasia (Catherine) Baranowski, and the Microbiology and Immunobiology 
Department’s IT team, to go from raw sequencing data to genome-mapped sequence reads. Kasia 
Baranowski generated the ΔponA2 and ΔldtB transposon mutant libraries, and we analyzed the data 
together. Jarukit Long and Christopher Sassetti provided wildtype transposon library data (I mapped the 
raw sequencing data). I performed all experiments and analyses in Figures 4.4, 4.5, 4.6, 4.7, and 4.8. 
Others offered key help at certain experimental junctures (see Acknowledgements). 
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Abstract 
Successful synthesis of the major bacterial cell wall macromolecule peptidoglycan (PG) is an essential 
process for all walled bacteria. PG, composed of saccharide strands crosslinked by peptides, is one of 
the most elemental components of a bacterial cell. While PG metabolism has been extensively studied in 
model organisms, it remains poorly understand in mycobacteria, a group that includes the important 
human pathogens Mycobacterium tuberculosis (Mtb) and Mycobacterium leprae. In an effort to 
understand how Mtb coordinates its peptidoglycan synthesis, we focused on the key PG synthases 
PonA1, PonA2, and LdtB. In Mycobacterium smegmatis, a saprophytic mycobacterium, PonA1, but not 
PonA2, is required for bacterial growth in culture. However, Mtb controls its PG biogenesis differently 
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because PonA1 and PonA2 are both dispensable for growth in culture. 3–3 PG crosslinks, such as those 
synthesized by LdtB, are the predominant crosslink in mycobacterial PG, suggesting these enzymes are 
active throughout the cell cycle. These 3–3 transpeptidases can be inhibited by cabapenems, but little is 
known about their cellular roles and regulation to facilitate drug optimization. We hypothesized that 
unique genetic interactions among these key biosynthetic proteins would help define mycobacterial PG 
metabolism. To identify these interactions, we performed whole genome transposon mutagenesis 
screens in ΔponA1, ΔponA2, and ΔldtB Mtb cells and found distinct factors that were required to sustain 
bacterial growth in the absence of each of these enzymes. We show that either PonA1 or PonA2 is 
required for growth of Mtb and that each of them correlate 4–3 and 3–3 crosslinking with LdtB. Our data 
also suggest Mtb coordinates synthesis of its different cell envelope layers, likely using PonA1 and its 
genetic interacting partners to do so. This work improves our understanding of how Mtb builds its cell wall 
and its role in ensuring robust bacterial fitness. 
 
 
Introduction 
Mycobacterium tuberculosis (Mtb) is the etiologic agent of tuberculosis (TB), which remains one of world’s 
greatest health burdens. The World Health Organization estimates that one third of the world’s population 
harbor Mtb and that 1.5 million individuals died of TB last year [1]. Mtb’s success as a pathogen is due in 
part to its cell wall, which is notorious for its complexity and has been implicated in antibiotic resistance 
[2]. The cell wall is a critical interface for host-pathogen interactions, and pressure from the host 
environment induces architectural changes that may promote Mtb’s survival in the host [2]. As a key 
interaction surface between host and pathogen, understanding the synthesis and biochemistry of the cell 
wall could facilitate our understanding of how the cell wall promotes Mtb’s survival during infection. 
 
An essential component of bacterial cell walls, including Mtb’s, is peptidoglycan (PG), a complex 
macromolecule that provides structural support and resistance to turgor pressure [3]. Aberrations to 
peptidoglycan can be lethal to the bacterial cell [4–6]. Hence, its synthesis and proper maintenance are 
critical to bacterial survival. Peptidoglycan consists of long glycan chains, composed of two different 
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saccharides, which are crosslinked via pentapeptide tails that descend from the glycan chains. These 
peptide tails can be joined with two different linkages: a 4–3 crosslink (joining the fourth and third amino 
acid of the respective peptide tails) or a 3–3 crosslink (joining the third amino acids on neighboring 
peptide tails), which is the predominant form of peptidoglycan crosslinks in mycobacteria [7,8].  
 
Due to its fundamental importance to bacteria, the synthesis and structure of peptidoglycan has been 
examined for decades, predominantly in organisms like Escherichia coli or Bacillus subtilis. However, less 
is known about the synthesis of this major cell wall macromolecule in pathogenic organisms, including 
Mtb [2]. We previously showed that a major mycobacterial peptidoglycan synthase, PonA1 (capable of 
polymerizing both the glycan strands as well as the 4–4 crosslinks between strands), was required for 
growth of the saprophytic Mycobacterium smegmatis (Msm) in culture [4] (Chapter 3) but that PonA1 was 
dispensable for growth of Mtb in culture, but was required for normal fitness of Mtb during infection 
(Chapter 3). These data suggested that different methods of controlling PG biogenesis existed in Mtb 
compared to Msm, and this paradigm likely extends to the multiple layers of Mtb’s cell envelope.  
 
Furthermore, the unusual prevalence of 3–3 peptide linkages in mycobacterial PG shows that the 
construction of PG is different in mycobacteria than many other rod-shaped organisms. Because different 
enzymes synthesize the 4–3 and 3–3 crosslinks, the composition of the cell wall synthase machinery is 
likely different in mycobacteria than the “classic” cell wall synthesis complexes found in other organisms 
[2]. The wide prevalence of 3–3 crosslinks in mycobacterial PG throughout different growth stages [8] 
suggests that these enzymes are active during normal growth, however little is known about their cellular 
roles or regulation during growth and peptidoglycan biogenesis. Of the five encoded 3–3 transpeptidases 
in Mtb [9], most studies have focused on LdtB, as it mediates tolerance to transpeptidation inhibitors [9–
11], is required for normal virulence in a mouse model of TB [10], and is important for normal cell shape 
[11]. The cellular role of the remaining 3–3 transpeptidases remains unclear [12], although LdtA also 
appears required for normal cell shape [11].  
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The 3–3 transpeptidases accept different substrates [12] and have different active sites and domain 
structure [12–15] than the classical 4–3 transpeptidases. Consequently, their antibiotic susceptibility 
differs [16]. The classic antibiotic penicillin targets 4–3 transpeptidases (the “penicillin binding proteins”), 
but 3–3 transpeptidases have less affinity for penicillin and related small molecules. Penicillin insensitivity 
is aggravated in Mtb because of endogenous beta-lactamases [17,18], which hydrolyze the core beta-
lactam ring of penicillin. However, 3–3 transpeptidases are susceptible to carbapenems [12,19-21], 
including meropenem and imipenem, which are more resistant to BlaC hydrolysis than penicillins [19]. 
Recent studies have shown that Mtb grown in culture is susceptible to carbapenems, including 
extensively drug resistant Mtb [19], which is on the rise [1]. However, the efficacy of these drugs is limited 
for TB disease in mice and humans [22,23], necessitating further optimization. To that end, we need a 
better understanding of the activity of these 3–3 transpeptidases during growth and cell wall biogenesis.    
 
To investigate how Mtb governs cell wall biogenesis, we used major 4–3 and 3–3 transpeptidases as 
probes of peptidoglycan synthesis. We performed genome-wide screens in Mtb cells that lack either the 
bifunctional PG synthase PonA1, its homologue PonA2, or the 3–3 transpeptidase LdtB. We identified 
discrete genetic interacting factors for these enzymes, suggesting that these synthases have distinct 
cellular roles in assembling Mtb’s peptidoglycan. Furthermore, we find that Mtb cannot survive if both 
ponA1 and ponA2 are disrupted, indicating that these enzymes play a critical, and complementary, role in 
PG biogenesis. We further provide evidence that synthesis of 4–3 and 3–3 crosslinks is correlated in Mtb. 
PonA1 and LdtB are both important for normal growth, while loss of PonA2 and LdtB is lethal to bacterial 
cells. In sum, our findings provide an understanding of how Mtb governs biogenesis of its complex 
peptidoglycan and how its coordinated synthesis by 4–3 and 3–3 transpeptidases promotes robust 
bacterial growth. 
 
 
Results 
Whole genome mutagenesis identifies PonA1’s PG biogenesis partners in M. tuberculosis 
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Unlike Msm, PonA1 is not required for proliferation of Mtb during growth in culture, but is required for 
normal bacterial growth during infection [4] (Chapter 3). These data suggest that Mtb has fundamentally 
different ways of controlling its cell wall biogenesis than does Msm. To uncover the factors responsible for 
the differential control of PG biogenesis in Mtb, we undertook an unbiased whole genome screen in 
ΔponA1 Mtb cells. We mutagenized ΔponA1 Mtb cells with a transposon that inserts at TA dinucleotides 
throughout the genome. We then used highthroughput sequencing to map the genomic location of the 
transposon insertions [24] (see Materials and Methods for details) (Figure 4.1). Analysis of the transposon 
insertion profiles [25] between wildtype and ΔponA1 Mtb revealed ten factors predicted to be required in 
cells that lack PonA1 (Figure 4.2A, “essential” factors). Most of these factors are associated with or 
predicted to be involved with cell wall synthesis. For example, factors involved in peptidoglycan (rv3682), 
arabinogalactan (rv0806) or mycolic acid (rv0642) synthesis in addition to cell wall precursor production 
(rv1086) were predicted as required in ΔponA1 cells (Figure 4.2A). These data suggest that the cell 
requires either PonA1 or PonA2 for peptidoglycan synthesis, analogous to the situation in E. coli [26]. 
These data also indicate that the cell may use PonA1 and its genetic interacting factors, like rv0806, to 
coordinate synthesis of the multiple layers of the mycobacterial cell wall.  
 
This unbiased screening approach also eight identified factors whose transposon disruption in ΔponA1 
cells appeared beneficial to the cell. Their transposon insertion rate was higher in ΔponA1 cells than 
wildtype cells (Figure 4.2A, “enriched”). For example, the transcription factor EspR had higher levels of 
transposon insertions in cells that lack ponA1 compared to wildtype Mtb. This could indicate that EspR 
regulates ponA1 transcription and that cells without ponA1 can afford to lose espR function at a higher 
rate than wildtype cells. 
 
Identification of PonA2’s PG synthesis partners in M. tuberculosis 
The homologous bifunctional PBPs in E.coli, PBP1a and PBP1b, seem to function in different subcellular 
complexes [3] and have been shown to have discrete interaction partners [27,28]. We hypothesized that 
PonA1 and PonA2 would also have discrete interacting factors. Indeed, our previous work showed that 
PonA1 localizes to two distinct subcellular compartments, the septum and the cell pole, where it likely has  
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Figure 4.1. Schematic of experimental determination of genetic and chemical interactions in M. 
tuberculosis. Transposon mutagenesis is a powerful method to identify interactions between specific 
genes in a bacterial genome. Transposons are introduced into the Mtb genome via phage. The genomic 
location of the transposon insertion is determined via highthroughput sequencing and mapping of 
sequence reads to the genome. Genetic interactions can be identified by a differential transposon 
insertion profile in a gene (e.g. gene B) in wildtype cells versus mutant cells (e.g. ΔgeneD::AbxR). The 
loss of geneB and geneD, either through transposon disruption or directed knockout, is lethal to cells 
whereas cells survive the single gene mutations. Genetic interactions can be confirmed in two different 
ways, either by the complementary reverse whole genome screen or by targeted knockouts. Cellular 
assays, for example with drug inhibition of a pathway of interest (here, cell wall synthesis), can determine 
the relative contribution of genetic interacting factors to the cell pathway being targeted. AbxR, antibiotic 
resistance cassette. 
 
 
 
 
 
 
 
 
 
 
 
 ! 125 
Figure 4.1 (Continued) 
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Figure 4.2. Quantitation of the genetic interactions of the peptidoglycan synthases PonA1. (A) 
PonA1’s genetic interactions were determined by transposon mutagenesis and quantitated by assessing 
the difference in sequence reads at each locus in the genome. Loci whose sequence reads were 
significantly different between wildtype and ΔponA1 cells (p-value < 0.001 by the Mann-Whitney U test, 
red circles) are plotted according to their p-value and fold change in sequence reads from wildtype 
(calculated from the geometric mean). Many loci did not have a significant change in reads between 
ΔponA1 and wildtype (gray circles). (B) Specific quantitation values and predicted cell pathways for each 
significantly different locus. 
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different interacting partners [4] (Chapter 3). To identify PonA2’s genetic interactors, we performed a 
similar whole genome screen as that performed in ΔponA1 cells (Figure 4.1). We expected to identify 
ponA1 in this screen, as a reverse confirmation of the genetic interaction between ponA1 and ponA2 from 
our ΔponA1 screen (Figure 4.1). Indeed, we identified ponA1 in the ΔponA2 screen (Figure 4.3A), 
however, we identified multiple additional factors predicted to be required in ΔponA2 cells (Figure 4.3B). 
These included factors that were both similar to (rv3490 and rv1248) and different from the factors 
predicted to genetically interact with ponA1. Together, these data strongly suggest that PonA1 and 
PonA2 coordinate peptidoglycan synthesis in Mtb, and that the cell requires at least either ponA1 or 
ponA2 to be expressed. The lower number of factors that genetically interacted with PonA2 may indicate 
that PonA1 forms more interactions in the cell and/or is more active during normal growth in Mtb, as is 
true in Msm [29] (Chapter 3).  
 
PonA2 is required for PG synthesis in the absence of PonA1 
In addition to a reverse genetic screen, a complementary method to test the predicted essentiality of 
candidate factors (i.e. ponA2’s predicted requirement in ΔponA1 cells) is to generate targeted knockouts 
(Figure 4.1). Because deletion of a candidate gene in ΔponA1 cells would be lethal (Figure 4.1), we 
employed an allelic exchange strategy to test the essentiality of the screen’s predictions (Figure 4.4). Our 
complementary genetic screens confirmed the genetic interaction between ponA1 and ponA2 (Figure 4.1, 
4.2, 4.3). Hence, PonA2 was an excellent example to test the robustness of the allelic exchange system 
to demonstrate that either PonA1 or PonA2 is absolutely required for proliferation of Mtb as predicted 
(Figure 4.5A). We therefore generated a ponA2 knockout in a strain whose only copy of ponA1 is at the 
L5 phage integration site (ΔponA1 L5::ponA1wt, Figure 4.4). We also generated a ponA2 knockout in 
wildtype H37Rv Mtb as a control. ΔponA2 and ΔponA1 L5::ponA1wt ΔponA2 cells grew at rates similar to 
wildtype Mtb (Figure 4.5B) and exhibit similar rod-shaped morphology to wildtype cells (Figure 4.5C), 
although loss of ponA2 does moderately impact cell width (Figure 4.5D).  
 
We then tested whether we could remove ponA1 from the genome of ΔponA1 L5::ponA1wt ΔponA2 cells 
using allelic exchange [30] (Figure 4.4). When we transformed these cells with a vector that encoded 
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Figure 4.3 Quantitation of the genetic interactions of the peptidoglycan synthase PonA2. (A) 
PonA2’s genetic interactions were determined by transposon mutagenesis and quantitated by assessing 
the difference in sequence reads at each locus in the genome. Loci whose sequence reads were 
significantly different between wildtype and ΔponA2 cells (p-value < 0.001 by the Mann-Whitney U test, 
blue circles) are plotted according to their p-value and fold change in sequence reads from wildtype 
(calculated from the geometric mean). Gray circles denote non-significant loci. (B) Specific quantitation 
values and predicted cell pathways for each significantly different locus. 
 
 
 
ponA1, bacterial growth was robust. However, transformation with a negative control vector that encoded 
the unrelated tetR gene blocked bacterial growth (Figure 4.5E). Similar transformations in the ΔponA2 
strain yielded robust bacterial growth (Figure 4.5E), confirming that lack of growth in the tetR transformed  
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Figure 4.4. Allelic exchange system tests lethality of double mutants. The endogenous locus of 
ponA1 is replaced with a hygromycin resistance cassette (HygR) flanked by LoxP sites. A kanamycin 
(KanR)-marked copy of ponA1 is integrated at the L5 phage site. The HygR is removed from the 
chromosome by Cre recombinase. The gene of interest (ponA2 is diagrammed here as an example) is 
replaced with HygR. The resulting strain is transformed with a vector that integrates at the same L5 phage 
integration site that encodes a zeocin (ZeoR)-marked ponA1 or the negative control gene tetR. If the gene 
of interest is required in the absence of ponA1, cells wil not grow when transformed with the tetR vector. 
 
 
ΔponA1 L5::ponA1wt cells was specific to the loss of ponA1. These data indicate that PonA2 is required in 
the absence of PonA1 in Mtb and that both enzymes have complementary roles in PG biogenesis in Mtb, 
which is distinct from the roles of these enzymes in Msm [4,29] (Chapter 3).  
 
Rv1086 is required for cell wall synthesis in cells that lack PonA1 
Cell wall synthesis cannot proceed without the critical lipid carrier to which cell wall precursors are 
attached [31]. The Mtb lipid carrier decaprenyl phosphate is distinct from that observed in many other rod- 
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Figure 4.5. The peptidoglycan synthase PonA2 functions in place of PonA1 in ΔponA1 cells. (A) 
Sequence reads (gray or red vertical bars) that represent individual transposon insertions are visualized 
at the rv3680-rv3683 genomic region, which spans ponA2, in ΔponA1 cells (red) or wildtype cells (gray). 
Each possible transposon insertion site (TA dinucleotide) is depicted as short black vertical lines. Genes 
are displayed as gray arrows. The scale bar indicates density of sequence reads. (B) Population growth 
of wildtype H37Rv, ΔponA2, and ΔponA1 L5::ponA1wt ΔponA2 cells in standard laboratory media was 
measured by OD600 daily. (C) Cell morphology for cells in (B) was analyzed with light microscopy. Scale 
bar, 2µm. (D) Single cell length and width of ΔponA2 and wildtype cells was quantitated. ΔponA2 cells, 
although rod-shaped, are moderately wider than wildtype (approximate p-value < 0.0001 by the 
Kolmogorov-Smirnov test). (E) Colony forming units (CFU) were enumerated from transformation plates 
of an allelic exchange with either a vector that encodes ponA1 (+ponA1) or a negative control vector that 
encodes the unrelated tetR (+TetR) in the ΔponA1 L5::ponA1wt ΔponA2 strain or the ΔponA2 strain (both 
plates had lawn growth, and CFU counts were arbitrarily set to 6000).  
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Figure 4.5 (Continued) 
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Figure 4.6. The Z-isoprenyl diphosphate synthase Rv1086 is required in ΔponA1 cells. (A) 
Transposon insertions represented by their sequence reads (gray or red vertical bars) are visualized at 
the rv1085-rv1087 genomic region, in ΔponA1 (red) or wildtype cells (gray). Each possible transposon 
insertion site is depicted as short black vertical lines. Genes are displayed as gray arrows. The scale bar 
indicates density of sequence reads. (B) Population growth of wildtype, Δrv1086, and ΔponA1 
L5::ponA1wt Δrv1086 cells in standard laboratory media was measured by OD600 daily. (C) Cells in (B) 
were imaged with light microscopy. Scale bar, 2µm. (D) Cell length and width of wildtype and Δrv1086 
cells were quantitated. No significant difference in either measurement was found. (E) Allelic exchange 
with a +ponA1 or +tetR vector in Δrv1086 cells or the ΔponA1 L5::ponA1wt Δrv1086 cells.  
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Figure 4.6 (Continued) 
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shaped organisms such as E. coli, which uses undecaprenyl phosphate [31]. Rv1086, a Z-isoprenyl 
diphosphate synthase carries out the first committed step in the synthesis of this lipid carrier [31-33], and 
our screen predicted Rv1086 was required in cells that lack PonA1 (Figure 4.2A, 4.6A). To test this 
prediction, we generated a knockout of rv1086 in the ΔponA1 L5::ponA1wt background as well as in 
wildtype Mtb as a control. Cells lacking rv1086 in either background grew similarly to wildtype Mtb (Figure 
4.6B) and exhibited similar cell shape (Figure 4.6C,D). We then tested whether we could eliminate ponA1 
from the chromosome of ΔponA1 L5::ponA1wt Δrv1086 cells by allelic exchange. Transformation of this 
strain with a ponA1+ vector fully rescued bacterial growth, whereas transformation with the negative 
control vector completely blocked growth (Figure 4.6E). Transformation of Δrv1086 Mtb with either vector 
did not impact bacterial growth (Figure 4.6E). These data demonstrate that rv1086 is specifically required 
in cells that lack ponA1. These results may indicate that the remaining bifunctional PG synthase in these 
cells, PonA2, requires a dedicated pool of precursors (perhaps because its kinetic rate of polymerization 
is slower than PonA1’s) or that defects in cell wall synthesis result in an accumulation of lipid-linked cell 
wall precursors [34], to which the cell responds by necessitating lipid carrier synthesis.   
 
Because decaprenyl phosphate forms the lipid base for both peptidoglycan and arabinogalactan 
precursors [35,36], we hypothesized that Δrv1086 cells may display differential susceptibility to antibiotics 
known to target both of these synthetic pathways (see Figure 4.1). To test this hypothesis, we treated 
Δrv1086 and wildtype Mtb with ethambutol, which targets AG synthesis [37], as well as teicoplanin and 
meropenem, which target PG synthesis [19,38]. We found that Δrv1086 cells were 8-fold more sensitive 
to ethambutol and teicoplanin and 4-fold more sensitive to meropenem compared to wildtype Mtb (Figure 
4.7), supporting its role in synthesis of the lipid carrier required for both PG and AG and that defects in 
lipid carrier synthesis impact multiple macromolecules of the cell wall. 
 
CpsY is likely required for cell wall biogenesis in the absence of PonA1 
CpsY has been annotated as a putative UDP-glucose-4-epimerase that may interchange glucose and 
galactose and other close homologues appear to not exist in the Mtb genome [39]. However, CpsY 
orthologues exist in other pathogenic mycobacteria, including Mycobacterium leprae, Mycobacterium 
 ! 135 
bovis, and Mycobacterium marinum, but does not exist in the nonpathogenic Msm (tuberculist.epfl.ch). 
UDP-glucose is directly utilized for the galactan moiety of arabinogalactan [36], and we chose to 
investigate whether CpsY is involved in cell wall synthesis. The whole genome screen predicted CpsY to 
be required in ΔponA1 cells (Figure 4.2, 4.8A). We attempted to generate a cpsY knockout in ΔponA1 
L5::ponA1wt cells three times without success. However, we did delete cpsY from wildtype Mtb, 
suggesting that the knockout construct was correct. There may be slight differences in ponA1 expression 
in the complemented mutant strain (ΔponA1 L5::ponA1wt) that prevented the deletion of cpsY. Cells that 
lack cpsY grow at rates similar to wildtype Mtb (Figure 4.8B) and also exhibit similar rod morphology 
(Figure 4.8C), although the loss of cpsY did moderately impact cell width  (Figure 4.8D). These data 
suggest that cpsY was not required for normal bacterial growth and that its role in cell wall biogenesis 
likely becomes critical when cell wall synthesis has been compromised in some manner (e.g. deletion of 
ponA1).  
 
 
 
 
Figure 4.7. Cell wall active antibiotics interact differently with cell wall synthase mutants. ΔponA1, 
ΔponA2, ΔldtB, Δrv1086, and ΔcpsY Mtb cells were treated with meropenem, teicoplanin, or ethambutol. 
Fold change in minimum inhibitory concentration (MIC) for each drug was calculated by comparing each 
mutant’s MIC to wildtype H37Rv’s MIC for each drug. 
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Figure 4.8. The putative UDP-galactose epimerase CpsY is likely required in ΔponA1 cells. (A) 
Transposon insertions represented by their sequence reads (gray or red vertical bars) are visualized at 
the rv0804-rv0807 genomic region, which spans CpsY, in ΔponA1 (red) or wildtype cells (gray). Each 
possible transposon insertion site is depicted as short black vertical lines. Genes are displayed as gray 
arrows. The scale bar indicates density of sequence reads. (B) Population growth of wildtype and ΔcpsY 
Mtb cells in standard laboratory media was measured by OD600 daily. (C) Cells in (B) were assessed for 
morphology changes with light microscopy. Scale bar, 2µm. (D) Width and length of single cells in (B) and 
(C) was quantitated. Loss of cpsY moderately increased cell width (approximate p-value < 0.0001 by the 
Kolmogorov-Smirnov test).  
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Because of CpsY’s interesting putative biochemical activity and its apparent role in pathogenic 
mycobacterial cell wall synthesis, we hypothesized that cells that lack cpsY would display differential 
tolerance to drugs that target cell wall biogenesis (see Figure 4.1). ΔcpsY cells did not show substantial 
changes in susceptibility to either ethambutol, teicoplanin, or meropenem (Figure 4.7), which may 
suggest that other enzymes compensate for CpsY activity in the presence of these drugs. 
 
Correlated synthesis of classical and non-classical crosslinks is required for normal bacterial 
growth 
We previously hypothesized that non-classical PG transpeptidases (that generate 3–3 peptidoglycan 
crosslinks instead of the ‘classical’ 4–3 crosslinks) may play a role in normal cell growth and could 
participate in the elongation complex [2]. Furthermore, because the monofunctional 4–3 transpeptidases 
PBPA and PBPB both localize to the septum in mycobacteria [40,41], the bifunctional enzymes PonA1 
and PonA2 may be the only 4–3 crosslinking enzymes active during cell elongation. Because of this 
spatial separation and because mycobacterial PG contains frequent 3–3 crosslinks [7,8] we were 
interested in directly testing the hypothesis that a 3–3 crosslinking transpeptidase may be required in cells 
that lack a major bifunctional 4–3 transpeptidase. To that end, we investigated the role of LdtB (rv2518) in 
cells that lack PonA1.  
 
To test whether LdtB was critical for cell growth in the absence of PonA1 (Figure 4.9A), we generated an 
ldtB knockout in ΔponA1 L5::ponA1wt cells. We also deleted ldtB from the genome of wildtype Mtb as a 
control. Cells that lack ldtB grew at rates similar to wildtype, although loss of ldtB did diminish population 
growth at later growth stages. This defect was rescued in ΔponA1 L5::ponA1wt cells likely due to the 
strong promoter that drives ponA1 at the L5 integration site (Figure 4.9B). ΔldtB cells also exhibit cell 
shape defects (Figure 4.9C).  Loss of ldtB diminishes cell length, as has been previously reported [11], 
and substantially increases the width of the cell (Figure 4.9D). These data support a role for LdtB in 
maintaining proper cell shape and demonstrate that appropriate 3–3 PG crosslinking during cell growth 
and division is required for robust proliferation. We then tested whether we could remove ponA1 from the 
ΔponA1 L5::ponA1wt ΔldtB cells via allelic exchange. The cells transformed with the ponA1+ vector grew  
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Figure 4.9. The non-classical transpeptidase LdtB is critical in ΔponA1 cells. (A) Transposon 
insertions represented by their sequence reads (gray or red vertical bars) are visualized at the rv2516-
rv2520 genomic region, which spans ldtB, in ΔponA1 (red) or wildtype cells (gray). Each possible 
transposon insertion site is depicted as short black vertical lines. Genes are displayed as gray arrows. 
The scale bar indicates density of sequence reads. (B) Population growth of wildtype, ΔldtB, and ΔponA1 
L5::ponA1wt ΔldtB cells in standard laboratory media was measured by OD600 daily. (C) Cell shape of cells 
in (B) was visualized with light microscopy. Scale bar, 2µm. (D) Single cell length and width was 
quantitated for wildtype and ΔldtB cells. Cell width of ΔldtB cells was significantly different (approximate 
p-value < 0.0001 by the Kolmogorov-Smirnov test) as was cell length (approximate p-value < 0.0001 by 
the Kolmogorov-Smirnov test) compared to wildtype Mtb. (E) Colony forming units (CFU) from an allelic 
exchange with a +ponA1 or +tetR vector in the ΔldtB strain or the ΔponA1 L5::ponA1wt ΔldtB strain were 
counted at 3 weeks (left panel). CFU were not visible on the tetR transformed ΔponA1 L5::ponA1wt ΔldtB 
plate, which was incubated another 2 weeks (right panel, the +ponA1 plate is shown again for 
comparison). Low CFU on the ponA1 transformed ΔldtB strain may be due to variability in the assay or 
could be a function of the lower density these cells reach at later growth stages (see data in (B)). 
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Figure 4.9 (Continued) 
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robustly after the usual 21 days (Figure 4.9E). However, the cells transformed with the negative control 
vector had formed barely visible colonies at 21 days. After 35 days, these ΔponA1 L5::tetR ΔldtB colonies 
had grown to the normal size. These data show that loss of LdtB’s activity in cells that have also lost 
PonA1 dramatically impacts cellular fitness, and that double mutants have a quantitative growth defect.  
 
LdtB’s genetic interactions 
Because our data demonstrated that Mtb required both ponA1 and ldtB for robust growth and 
maintenance of cell shape, we hypothesized that ldtB may also form similar genetic interactions with 
other PG synthases. To test this hypothesis, we generated a transposon mutant library in the ΔldtB strain 
and computationally assessed ldtB’s genetic interactions. We identified several cell wall associated genes 
that were predicted to be required in ΔldtB cells (Figure 4.10). Interestingly, ponA2 was identified as 
essential in cells that lack ldtB (Figure 4.11A), which is phenocopied by the lack of transposon insertions 
in ldtB in cells that lack ponA2 (Figure 4.11B). While ponA1 was not predicted to be essential in ΔldtB 
cells (as our data also confirmed; Figure 4.9E), the magnitude of sequence reads in ponA1 decreased 
(Figure 4.11C), indicating that loss of PonA1 function due to transposon disruption impacted survival of 
ΔldtB cells.  
 
Furthermore, four factors overlap between those identified as essential in ΔponA2 and ΔldtB cells, more 
than the overlap between ponA1 and ponA2 or ponA1 and ldtB, strongly supporting that ldtB and ponA2 
function in a highly similar cellular pathway. ΔldtB and ΔponA2 cells also display similar susceptibility 
profiles to teicoplanin, meropenem, and ethambutol, which is different than ΔponA1 cells (Figure 4.7, 
Chapter 3). These data biologically support that LdtB and PonA2 function in a highly similar pathway 
within the cell and correlates with our biological evidence that ponA1 and ldtB are together required for 
optimal growth. In sum, these data show that the cell requires either LdtB or one of the bifunctional 
peptidoglycan synthases (PonA1 or PonA2) for robust growth and may indicate that 4–3 and 3–3 
crosslinking enzymes must coordinate their activity to promote bacterial survival as well as normal 
vegetative proliferation of Mtb. 
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Figure 4.10 Quantitation of the genetic interactions of the nonclassical transpeptidases LdtB. (A) 
LdtB’s genetic interactions were determined via whole genome transposon mutagenesis. Loci whose 
sequence reads were significantly different between wildtype and ΔldtB cells (p-value < 0.001 by the 
Mann-Whitney U test, green circles) are plotted according to their p-value and fold change in sequence 
reads from wildtype (calculated from the geometric mean). Loci without a significant change in reads are 
depicted as gray circles. (B) Specific quantitation values and predicted cell pathways for each significantly 
different locus. 
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Figure 4.11. LdtB genetically interacts with PonA2. (A) Transposon insertions represented by their 
sequence reads (gray or green vertical bars) are visualized at the rv3681-rv3684 genomic region, which 
spans ponA2, in ΔldtB (green) or wildtype cells (gray). Each possible transposon insertion site is depicted 
as short black vertical lines. Genes are displayed as gray arrows. The scale bar indicates density of 
sequence reads. (B) Transposon insertions represented by their sequence reads (gray or blue vertical 
bars) are visualized at the rv2516-rv2519 operon, which spans ldtb, in Δpona2 (blue) or wildtype cells 
(gray). (C) Transposon insertions represented by their sequence reads (gray or green vertical bars) are 
visualized at the rv0049-rv0052 operon, which spans ponA1, in ΔldtB (green) or wildtype cells (gray).  
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Discussion 
Our genetic experiments and chemical assays have elucidated cell wall synthesis networks in Mtb, which 
have highlighted unique biology between divergent peptidoglycan synthases as well as possible 
interactions the cell utilizes to synchronize the synthesis of its multiple cell envelope layers.  
 
Putative EspR regulation of PonA1 activity 
In addition to the cell wall synthase enzymes identified as essential in our screens, these genetic and 
computational methods allow the discovery of factors whose loss could be beneficial to a particular 
mutant. For example, disruption of EspR is better tolerated in ΔponA1 cells than in wildtype cells (Figure 
4.2A). Our previous work indicated that PonA1’s intracellular activity must be tightly regulated to maintain 
normal bacterial growth and correct cell shape. Dysregulated PonA1 activity leads to ectopic polar growth 
and inhibition of bacterial proliferation (Chapter 3). EspR may be involved in maintaining normal PonA1 
activity in the cell and hence is less important in the absence of PonA1. EspR is known to regulate a 
variety of cell wall associated factors [42]. We searched for the reported EspR consensus binding site and 
identified three putative EspR binding sites in the ponA1 promoter region (using a ponA1 start site at -426 
nucleotides of the H37Rv genome annotation; see Chapter 3 for details). These three consensus sites fall 
at a similar upstream distance from ponA1 as other reported EspR targets [42], supporting a putative role 
for EspR regulation of ponA1 transcript (consensus site 1: ATTTGCGAC, 1430 nucleotides upstream; 
consensus site 2: ATTTGCTCA, 1387 nucleotides upstream; consensus site 3: CTTTGCTCC, 920 
nucleotides upstream). Two additional weaker consensus binding sites also exist in the ponA1 promoter 
region (weaker consensus site 1: CTTCGCCAC, 548 nucleotides upstream; weaker consensus site 2: 
GTTCGCGGT, 146 nucleotides upstream). Further experiments are needed to determine whether EspR 
indeed binds in this promoter region and influences ponA1 transcript levels. 
 
PonA1 and PonA2 have unique cellular roles 
Although PonA1 and PonA2 are not individually required for growth of Mtb in culture, both of them cannot 
simultaneously be deleted from the cell (Figure 4.2, 4.5). Hence, Mtb controls its peptidoglycan synthesis 
differently than its saprophytic relative Msm, in which PonA1 is required for growth in culture. This may 
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relate to the different ecological niches these two organisms reside in. It seems advantageous to have 
two functioning enzymes that can promote essential cell wall synthesis, and the variable host 
environment may demand the flexibility that two separate enzymes can provide [2].  
 
Two hypotheses can be posited for the presence of two homologous enzymes in a genome. Either a 
certain level of enzymatic activity is required and multiple enzymes ensure sufficient activity for cell 
growth or, alternatively, the two enzymes exist in distinct, but potentially overlapping, cellular pathways. 
Although PonA1 and PonA2 can complement each other’s activity, several pieces of evidence indicate 
that they have distinct cellular roles, including their susceptibilities to host-like stresses or infection [29,43] 
(Chapter 3), as well as structural differences [44] and different impacts on cell shape (Figure 4.5, Chapter 
3). These data may support a model wherein PonA1 and PonA2 exist in different subcellular complexes, 
as do the major bifunctional PBPs in E. coli [3]; perhaps PonA2 functions more in PG synthesis during 
cell division whereas PonA1 is required for PG synthesis during cell elongation.  
 
The hypothesis that PonA1 and PonA2 hold distinct cellular roles is also supported by our whole genome 
screening data. Diverse cell wall synthase genes, such as cpsY and rv1086, become required in cells that 
lack PonA1, but not in cells that lack PonA2 (Figure 4.2). Indeed, few factors overlap between PonA1 and 
PonA2, and while our screens are not comprehensive, the saturation of our libraries (Figure 4.12A,B) 
indicates that we have likely identified all major candidates that genetically interact with ponA1 and 
ponA2. The number of ponA1 genetic interactions identified in cell wall synthesis genes suggests that 
cells without PonA1 have defects in several layers of the cell envelope (PG [ponA2], AG [cpsY], and MA 
[mmaA4, the mycolic acid modifying enzyme, and fbpA, involved in mycolic acid transport, both 
demonstrated altered read counts compared to wildtype], Figure 4.2). On the other hand, cells that lack 
PonA2 seem to exhibit fewer cell wall synthesis defects (Figure 4.3). The cell morphology phenotypes of 
ΔponA1 (Chapter 3) and ΔponA2 cells (Figure 4.5) combined with the level of cell wall synthetic genetic 
interactions (Figure 4.3) suggest that PonA1 may be the major cell wall synthase during active growth of 
Mtb. This may be due to differences in kinetic rates of PG polymerization between the enzymes or 
differential activity during different growth stages of the bacterium.  
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Figure 4.12. The transposon libraries are highly saturated. (A) The fraction of possible insertion sites 
(TA dinucleotides) that were actually disrupted by transposons was calculated per gene and plotted. 
These histograms can be used to estimate visually the true saturation of each library. Visual estimation of 
the ΔponA1 library’s saturation is circa 70%. The ΔponA2 library is about 78% saturated. The ΔldtB 
library is circa 55% saturated, and wildtype Mtb is around 70% saturation. (B) The chromosomal 
distribution of sequence reads from the libraries was visualized with DNAPlotter.  
 
 
Synthesis defects in distinct cell envelope macromolecules result in quantitative defects 
Coordinated synthesis of the multiple Mtb cell envelope layers is critical for successful growth of the 
bacterium [45]. Our data predicted that simultaneous defects in PG and AG or MA synthesis abolish 
bacterial growth. The difference in sequence reads at the cpsY locus strongly suggests that CpsY is 
 ! 146 
required for survival of ΔponA1 cells (Figure 4.8A). Furthermore loss of cpsY alters cell morphology, 
supporting its role in cell wall synthesis. Cells that lack PonA1 are 4-fold more susceptible to ethambutol 
(Figure 4.7), which indicates that an enzyme like CpsY, which becomes essential in these cells, functions 
in arabinogalactan synthesis. ΔcpsY cells do not exhibit an altered susceptibility to ethambutol (Figure 
4.7), which suggests other enzymes compensate for its activity in a single mutant. These data together 
suggest that coordinated synthesis of arabinogalactan and peptidoglycan is required for cell survival, and 
that the cell may utilize CpsY and PonA1 to govern that coordination.  
 
Lipid carrier synthesis promotes survival in cells with compromised cell envelope assembly 
Our screen predicted that rv1086, involved in decaprenyl phosphate synthesis, was essential in ΔponA1 
cells, which we confirmed (Figure 4.6). These data indicate that cell wall synthesis that occurs in the 
absence of ponA1 is divergent enough from wildtype levels that the cell attempts to promote envelope 
biogenesis by requiring the activity of Rv1086. Why does the cell specifically require the activity of the first 
dedicated enzyme in lipid carrier synthesis? One hypothesis is that the lipid carrier is being sequestered 
in the absence of ponA1 due to faulty cell wall synthesis. This same lipid carrier is required for both AG 
and PG precursors [35,36,46] (Figure 4.13A), although for AG precursors, it is first decorated with specific 
moieties [36] that shunts the carrier specifically into AG synthesis. If insufficient pools of UDP-glucose 
exist (for example, in the absence of cpsY), the cell cannot continue arabinogalactan production and 
these lipid carriers will accumulate in the membrane (Figure 4.13A). Analogously, defects in 
peptidoglycan synthesis can also lead to sequestration of lipid carriers. Cells that lack PonA1 may exhibit 
abnormal rates of PG precursor incorporation, leading to a buildup of PG intermediates and depletion of 
the essential lipid carrier (Figure 4.13B). These data lead to a model wherein abnormal biogenesis of 
either PG or AG results in the buildup of lipid-linked precursors, similar to that observed in other 
organisms [34,47]. The cell attempts to overcome this limitation by requiring the activity of the first 
enzyme in lipid carrier synthesis (Figure 4.6).  
 
Altogether, these data support a model wherein PonA1 and PonA2 guide cell wall synthesis with different 
spatial, and perhaps temporal, resolution. Their interacting partners and the rate of their respective 
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complex’s cell wall synthesis appear different. Determining the spatiotemporal resolution of cell 
membrane associated proteins is technically challenging in mycobacteria, but would allow us to better 
understand the physiology of cell growth and cell wall synthesis in Mtb.  
 
 
 
Figure 4.13. Robust cell wall synthesis requires adequate lipid carrier pools and correlation of 
classical and nonclassical PG transpeptidation. (A) Decaprenyl phosphate carries both peptidoglycan 
and arabinogalactan precursors in normal cell wall synthesis. (B) Changes in the activity of PonA1 or 
CpsY could result in the accumulation of lipid-linked precursors, damaging cell wall synthesis and cellular 
fitness. (C) Production of the critical nonclassical 3–3 peptide crosslinks, such as those synthesized by 
LdtB, must be correlated with the production of classical 4–3 crosslinks made by enzymes like PonA1 for 
robust cell growth. 
 
 
Correlated synthesis of 4–3 and 3–3 crosslinking promotes bacterial growth 
Because of the prevalence and importance of 3–3 crosslinks in Mtb biology, we previously hypothesized 
that 3–3 crosslinking enzymes likely play a predominant role during growth of Mtb [2]. Here, we tested 
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this hypothesis by assessing whether cell survival would be compromised in the absence of ponA1 and 
ldtB. We demonstrated that Mtb ΔponA1 ΔldtB cells exhibit substantial growth defects, requiring almost 
twice as long to form colonies as wildtype or single mutant Mtb cells (Figure 4.9). These data suggest that 
PonA1 and LdtB correlate their PG crosslinking activity during normal growth and that their combined 
activity is required for normal cell fitness (Figure 4.9). These data are the first evidence that 4–3 and 3–3 
transpeptidation is correlatively controlled in Mtb. Our genetic identification of the interaction between 
PonA2 and LdtB substantiates our findings – the cell clearly coordinates the 4–3 and 3–3 crosslinking of 
its peptidoglycan during growth. Much more remains to be discovered about how Mtb jointly governs 
these two enzymatic activities. Do Ldt enzymes exist in classical cell elongation complexes or in separate 
complexes? Do “classical” and “non-classical” peptidoglycan synthases interact? What are the 
spatiotemporal dynamics of these two distinct biochemical activities and how does the cell govern them?  
 
The quantitative differences in the PonA1-LdtB and PonA2-LdtB interactions again suggest spatial 
resolution of these pathways. Investigating the spatial and temporal resolution of cell wall synthesis in Mtb 
is not only important for bacterial physiology, but could inform how cell wall active antibiotics work. These 
drugs interact with cell wall synthesis pathways to differing extents (Figure 4.5). Developing drugs that will 
target the most active cell wall synthesis pathways – and the most active enzymes in those pathways – is 
critical for clinical advances against tuberculosis.  
 
 
Materials and Methods 
Bacterial Strains and Growth Conditions 
M. tuberculosis H37Rv was cultured in Middlebrook 7H9 salts supplemented with OADC (oleic acid, 
albumin, dextrose, catalase [BD Biosciences, Franklin Lakes, NJ]), 0.25% glycerol, and 0.05% Tween-80 
or plated on 7H10 agar. Selection was performed at 50 µg/ml hygromycin, 25 µg/ml kanamycin, or 20 
µg/ml zeocin for both liquid and solid media. E. coli Top10 (Invitrogen, Carlsbad, CA) were used for 
cloning and were cultured in LB broth or agar. Selection for E. coli occurred at 100 µg/ml hygromycin, 50 
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µg/ml kanamycin, or 20 µg/ml zeocin for both liquid and solid media. All strains were grown at 37°C. The 
construction of the ΔponA1 and ΔponA1 L5::ponA1wt Mtb strains were described in Chapter 3.  
 
Transposon Mutagenesis 
The H37Rv transposon libraries were generated using the ϕMycoMarT7 phagemid as previously 
described [48]. About 100,000 colonies were collected for each of the transposon libraries. 
 
Genomic Library Construction and Highthroughput Sequencing 
Genomic DNA (gDNA) was harvested from the transposon libraries as described [24]. To generate gDNA 
fragments amendable to highthroughput sequencing, the gDNA was sheared, end-repaired, A-tailed, and 
ligated to oligo adapters as described [24]. We amplified the transposon-containing gDNA through two-
step PCR as described [24]. To identify the genomic position of the transposons, we subjected the 
amplified gDNA fragments to highthroughput sequencing using the Illumina (San Diego, CA) platform. A 
single replicate library was constructed for each strain and used in all downstream analyses. 
 
Mapping and Counting Transposon Insertions 
For the ΔponA1 library, a FASTQ file was generated from the raw sequencing data using a custom 
Python script (all other libraries were sequenced on Illumina machines that automatically generated 
FASTQ files). Sequencing data were filtered for transposon-specific information and trimmed of all 
transposon sequence except for the TA dinucleotide insertion site using a custom Python script. Trimmed 
reads were then mapped to the H37Rv Mtb genome using Bowtie2 [49], which randomly assigns reads 
that map to multiple genomic sites. The ΔponA1 library had 3.2M mapped reads with an average read 
count of 50. The ΔponA2 library had 2.4M mapped reads with an average read count of 37. The ΔldtB 
library had 1.3M mapped reads with an average read count of 20. The wildtype Mtb library had 4.4M 
mapped reads with an average read count of 69. 
 
The number of transposon insertions at each genomic TA site were counted using custom Python scripts. 
First, the genomic location of all TA dinucleotides are identified (the H37Rv FASTA sequence was 
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downloaded from NCBI). Second, the mapped transposon insertions are counted at each TA site and are 
associated with their appropriate genetic feature (e.g. a gene or intergenic region) (the H37Rv gene list 
was downloaded from the JCVI institute). Transposon insertions were visualized on DNAplotter [50] or 
Artemis [51] by converting the TA counts to the programs’ appropriate data structure using custom 
Python scripts. 
 
Assessment of Library Saturation 
The complexity of the libraries was initially assessed by calculating the number of TA sites that contained 
a transposon insertion. The ΔponA1 library had 54% of the genome’s TA sites disrupted with a 
transposon. The ΔponA2 library had 57% of the genome’s TA sites disrupted. The ΔldtB library had 42% 
of the genome’s TA sites disrupted. 54% of the TA sites in the wildtype library were disrupted. To gain a 
gene-level resolution of the transposon disruption profile, the fraction of disrupted TA sites per gene was 
calculated as previously described [52] using a custom Python script and Excel functions. The middle of 
the right-hand peak can be used to visually estimate the true saturation of the libraries (because 
insertions in essential genes cannot be sequenced since the bacteria are not viable, calculating the 
percent TA disruption is an underestimate of true saturation). The estimated true saturations of each 
library are reported in the legend for Figure 4.10.  
 
Analysis of Differentially Inserted Genes 
Loci that were differentially disrupted between wildtype and mutant Mtb cells were assessed using a 
published method [25]. This method uses a Mann-Whitney U-test and normalization based on simulated 
control libraries [25] (see Appendix C of the manual provided in Reference [7] for how to utilize 
resampling and the Mann-Whitney U test without using the pipeline’s Hidden Markov Model (HMM). 
HMMs are robust for sequentially selected libraries but are a less robust statistical method for the 
analysis of independently generated libraries [e.g. different strain backgrounds, as performed here]). We 
performed 100 simulations and asked for loci that were designated statistically significantly different from 
wildtype (p-value < 0.001) in at least 90 of the 100 simulations. For each locus in the libraries, the 
geometric mean of sequence reads was calculated. The fold change (ratio) in sequence reads for each 
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locus was then calculated from the respective geometric mean of the locus in the mutant and wildtype 
libraries.   
 
Construction of Gene Knockouts in M. tuberculosis 
A hygromycin resistance cassette flanked with LoxP sites marked the ponA1 deletion in the ΔponA1 
L5::ponA1wt strain. To allow further knockouts, the hygromycin cassette was removed by transforming the 
strain with a vector that encoded Cre recombinase and a counter-selectable sucrose-sensitive marker. 
After selection for the Cre vector, several clones were confirmed to be hygromycin sensitive. Those 
clones were then counter-selected on sucrose to remove the Cre recombinase vector. The strain is still 
referred to as ΔponA1 L5::ponA1wt throughout the text. This loxed strain was then transformed with a 
gentamicin-resistant RecE/T plasmid for recombineering. The recombineering substrates are described 
further below. After recombineering, cells were plated on selective 7H10. To screen the colonies, 50 µl of 
log-phase cells were baked at 80°C for two hours to generate cell lysates for PCR. Positive clones were 
identified by multiple reactions. Clones were screened for the presence of the appropriate genomic 
position of the 5’ and 3’ recombineering construct flanks and for the absence of wildtype 5’ and 3’ 
sequence at those junctures. Clones that matched these criteria were then PCR screened for the 
absence of the gene of interest, to verify that a gene duplication event elsewhere in the chromosome had 
not occurred. Wildtype H37Rv was used as a control in all PCR reactions. PCR screening was performed 
with GoTaq® polymerase (Promega, Madison, WI) or KOD XtremeTM Hot Start DNA polymerase (EMD 
Millipore, Billerica, MA). 
 
Recombinant DNA constructs 
The ponA2 knockout cassette was amplified from a custom designed phage [53] by PCR. The cpsY 
knockout cassette was constructed by PCR stitching 500 nucleotides of the 5’ and 3’ genomic sequence 
surrounding cpsY to the 5’ and 3’ ends of a hygromycin resistance cassette flanked by LoxP sites, 
respectively. The rv1086 and ldtB knockout cassettes consisted of 500 nucleotides of the 5’ and 3’ 
genomic sequence surrounding rv1086 or ldtB flanking a hygromycin cassette. Gen9 (Cambridge, MA) 
synthesized these constructs as a circular vector with PmeI sites at each end of the knockout cassettes. 
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The vector was then digested with PmeI (New England Biolabs, Ipswich, MA) to generate a linear product 
for recombineering.  
 
ponA1 was subcloned into the L5-integrating pMC1s vector as described in Chapter 3. A zeocin 
resistance cassette was amplified with SgfI and PflMI enzyme sites. Subcloning with AsiSI (an 
isoschizomer of SgfI) and PflMI (New England Biolabs, Ipswich, MA) replaced the kanamycin resistance 
cassette on the modified ponA1+ pMC1s and the original pMC1s vector (encoding tetR) [54] with the 
zeocin resistance cassette.   
 
Allelic exchange in M. tuberculosis 
Allelic exchange occurs via transformation of vectors at the L5 phage integration site. The ΔponA1 
L5::ponA1wt loxed strain that underwent further recombineering events to delete ponA2, rv1086, and ldtB 
as described above was used for allelic exchange. This strain’s allele of ponA1 is marked with 
kanamycin. Transformation of this strain with an L5-integrating vector that encodes ponA1 or the negative 
control gene tetR marked with a zeocin antibiotic cassette and selecting for this second integration event 
will replace the original kanamycin-marked ponA1 integrated allele with the desired zeocin-marked allele. 
After transformation, cells were recovered in non-selective 7H9 for 24 hours and then plated on selective 
7H10. Colony forming units (CFU) were counted after 21 days for all plates, except for the ΔponA1 
L5::tetR  ΔldtB cells that were counted at 35 days. Simultaneous control transformations with the same 
L5-integrating vectors encoding either ponA1 or tetR were performed in ΔponA2, Δrv1086, ΔcpsY (data 
not shown), and ΔldtB cells. 
 
Optical density measurements 
Population growth curves for Mtb strains were performed in 30 ml inkwells (Corning Life Sciences, 
Corning, NY), in triplicate, at 37°C with shaking. Cells were grown to an OD600 of 0.5 before beginning the 
growth curve at a calculated starting OD600 of 0.1. Cells were grown in 7H9 with the appropriate antibiotic 
selection. Optical density was measured daily by absorbance at 600nm. 
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Light microscopy and image analysis 
Cells were first fixed overnight in 1% formalin at 4°C in the Biosafety Level 3 facility before removal. Cells 
were imaged on a Nikon TE-200E microscope using the 100x (NA1.40) objective. Images were captured 
with an Orca-II ER cooled CCD camera (Hamamatsu, Japan). Exposure and image acquisition were 
controlled with Metamorph Software (Molecular Devices). Final images were prepared in FIJI [55]. Cell 
length was calculated using ImageJ software (National Institutes of Health) and converted to microns 
using the appropriate pixel to micron conversion. Length was measured from cell pole to the opposite cell 
pole or from cell pole to septum, if present. Cell synchronization is not yet possible for mycobacteria; 
hence, cell lengths were measured for unsynchronized populations.  
 
Antibiotic treatment and determination of minimum inhibitory concentration 
The antibacterial effects of meropenem, teicoplanin, and ethambutol (Sigma Aldrich, St. Louis, MO) were 
determined by culturing exponentially growing M. tuberculosis cells in complete 7H9 in non-treated 96 
well plates (Genesee Scientific, San Diego, CA) in the presence of serially diluted drug, in duplicate. 
Plates also contained duplicate untreated wells as controls. M. tuberculosis was grown to OD600 of 0.5 
before culturing ± drug at a calculated starting OD600 of 0.006 for six days at 37°C with shaking. Bacterial 
growth was evaluated by adding 0.002% resazurin (Alamar Blue, Sigma Aldrich, St. Louis, MO) to each 
well. Plates were incubated with resazurin for 18-24 hours. Wells were scored as blue or purple indicating 
metabolically inactive cells and pink as metabolically active cells. 
 
Data representation and statistical analysis 
Prism 6.0 software (GraphPad Software, La Jolla, CA) was used to graph and analyze numerical data. 
Statistical tests in the Prism software were used to calculate significance of measurements as reported in 
the figure legends.  
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Section 5.1 Overview  
Bacterial cells must tightly govern how cell growth and division occurs in order to ensure survival. 
Improperly controlled growth and division yields unviable daughter cells and the consequent diminution or 
even eradication of population growth. How does the cell control the complex processes – and the myriad 
factors that effect them – required for growth and division? One critical method is the spatiotemporal 
control of enzymes that carry out synthesis of the cell wall – the architectural frame that promotes cell 
elongation and division.  
 
The bacterial cell wall is a complex structure often thought of as a safety net – it protects the bacterial cell 
from adverse exogenous agents (such as antibiotics) as well as providing resistance to interior turgor 
pressure. While these properties are critical, the cell wall is also the scaffold that growth and division of 
single cells is based upon. Cell wall synthesis physically lengthens the cell, allowing expansion of a single 
bacterial cell into two cells. Without new cell wall synthesis, it is impossible for bacterial cells to elongate 
or divide.  
 
The physically demanding process of cell wall synthesis requires multiple discrete enzymatic activities. 
Our current understanding of cell wall biogenesis is that the current layers of the cell wall must remain 
intact, to prevent cell lysis and death, while new cell wall material is incorporated. However, to incorporate 
new cell wall material into the cell envelope, some level of directed hydrolysis of the existing cell wall 
must occur (Figure 5.1). Where this hydrolysis and new synthesis of the cell envelope occurs in the cell 
must be finely controlled to prevent aberrations and consequent damages to cell shape and cell fitness. 
My work has focused on how the cell governs these cell wall hydrolases and synthases. This chapter will 
focus on the biological context of my findings and discuss how my work expands our understanding of 
how mycobacteria spatiotemporally control cell envelope biogenesis during growth and division. 
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Figure 5.1 Cell wall synthesis requires local hydrolysis of the existing cell envelope. New glycan 
strands (red) are crosslinked to the existing peptidoglycan matrix (green). Old crosslinks (hot pink) are 
then hydrolyzed to allow full incorporation of the new glycan strand into the peptidoglycan layer adjacent 
to the cell membrane (gray). [image adapted from [1] ] 
 
 
Section 5.2 Results Summary and Perspectives  
 
Spatial governance of cell wall biogenesis 
Because mycobacteria incorporate new cell wall material at their cell poles, instead of along their mid-
section like many rod-shaped bacteria (Chapter 1), the paradigms that govern how mycobacteria grow 
are different than the systems governing growth in other rod-shaped organisms. 
 
How, then, is cell wall synthesis directed to this specific space (the cell pole)? A major factor that spatially 
determines growth at the pole is Wag31, the mycobacterial DivIVA homologue. DivIVA proteins in other 
species are known to direct new cell wall synthesis at the cell pole or hyphal tip [2–4]; proper spatial 
oriention occurs through DivIVA’s recognition of membrane curvature [5,6]. Analogously, Wag31 
recognizes the curvature of the mycobacterial pole and promotes its extension [6]. However, Wag31 has 
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no enzymatic activity and is located in the cytoplasm. Therefore, it must form complexes with or direct cell 
wall biogenesis factors to the cell pole to for the construction of new cell wall.  
 
Several pieces of evidence point to an intriguing possibility that Wag31 and PonA1 could physically 
interact. Wag31 has been shown to interact with the cytoplasmic tail of a different penicillin binding 
protein, PBP3, at the cell septum [7] – where Wag31 localizes as the septum is maturing into a pole [8]. It 
is possible that Wag31 also interacts with PonA1, through PonA1’s long cytoplasmic domain. The 
overexpression of enzymatically inactive PonA1 generates ectopic polar growth (Chapter 3). These data 
suggest that excess PonA1 protein is able to stimulate the formation of viable elongation complexes – 
which are likely formed upon the Wag31 anchor, as Wag31 is required for normal polar growth [6].  
However, it is possible that these viable elongation complexes are built through an indirect interaction 
with Wag31. While the majority of PonA1’s cytoplasmic tail can be truncated without diminishing cell 
survival (Chapter 3), a full deletion of this region has not been assessed (twenty-three cytoplasmic amino 
acids remain in the PonA1Δcyto construct). Further experiments are required to determine whether PonA1 
and Wag31 do indeed interact and where in PonA1’s cytoplasmic tail, if at all, this interaction occurs.  
 
My work on PonA1 and RipA demonstrates that these proteins localize to certain subcellular sites, 
suggesting that specific mechanisms exist to spatially organize these proteins in mycobacteria. RipA 
localizes to the cell’s septum, where it cleaves the peptidoglycan that joins the nascent daughter cells [9].  
PonA1 localizes to both the cell pole and septum, where it interacts with RipA [10], indicating it functions 
in both cell septation and cell elongation. The specific mechanisms by which RipA and PonA1 are 
localized at the cell pole or septum remain unknown. Because septal peptidoglycan must first be 
synthesized before it can be hydrolyzed to birth nascent daughter cells, one hypothesis is that PonA1 
could facilitate RipA’s recruitment to the septum, possibly through physical interactions. While my work 
showed that the PonA1-RipA interaction is not required for viability, loss of this interaction did diminish 
normal cell separation (Figure 2.10), indicating that RipA’s activity at the septum was abnormal. Hence, 
PonA1 could play a role in properly recruiting or activating RipA at the cell septum.  
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RipA may also modulate the spatial organization of cell elongation through its specific enzymatic activity 
at the septum. The septum becomes the cell pole in the next cell cycle, and the physical state of the cell 
pole’s peptidoglycan influences new peptidoglycan synthesis at that site. New peptidoglycan synthesis 
requires the generation of crosslinks between the glycan strands. However, RipA’s enzymatic activity 
precludes further crosslinking (Figure 5.2). This inhibits new peptidoglycan synthesis at the very tip of the 
cell pole, leaving the tip static. This inert peptidoglycan could thereby “direct” cell elongation complexes to 
a region just below the tip for new cell wall synthesis [11]. Indeed, a recent study demonstrated that cell 
wall synthesis complexes and cell wall precursor incorporation occurred at this sub-polar region [6].   
 
 
Figure 5.2 RipA’s hydrolytic activity prevents further peptidoglycan crosslinking. RipA cleaves the 
bond between the second (D-Glu) and third (meso-DAP) amino acids of the peptide tail (colored circles) 
that descend from the glycan strands (colored squares and hexagons). RipA’s hydrolysis precludes any 
new transpeptidation reactions, which require a tetrapeptide (for 3–3 crosslinks) or a pentapeptide (for 4–
3 crosslinks) tail. 
 
 
Temporal control of cell wall synthesis 
RipA’s activity at the septum must also be governed in time. If RipA is activated too early, destruction of 
cell wall peptidoglycan could occur, leading to lysis and cell death. The mechanism of RipA’s activation 
remains unknown. It may be that the cell orchestrates RipA’s proteolysis at the septum once a signal for 
septum completion has been received. The nature of this signal and how it is propagated remains 
uncharacterized. However, it is feasible that a series of protein-protein interactions temporally modulates 
when RipA’s processing occurs. Many of the enzymes that function in the divisome are recruited in a 
certain order [12], suggesting that the timing of divisome formation is regulated and that specific patterns 
of protein localization to the divisome are important for proper activity. RipA’s activation at the septum 
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could also rely on specific protein-protein interactions, not only for its proper recruitment to and 
localization within the divisome, but also for its proteolysis. The factor responsible for proteolyzing RipA is 
unknown, as is the spatiotemporal regulation of RipA’s processing. Much remains to be discovered about 
how the cell controls RipA’s processing in both time and space. 
 
A major finding of my work was the temporal regulation of PonA1’s enzymatic activity. This is the first 
illustration that a post-translational modification impacts activity of a penicillin binding protein, the 
workhorses of cell wall synthesis in walled bacteria. Phosphorylation plays a key role in governing cell 
growth and division in mycobacteria, which have evolved a complex network of phosphorylated targets 
[11]. Indeed, all steps of the peptidoglycan synthesis pathway are regulated by phosphorylation (GlmU for 
precursor synthesis [13], MviN for precursor export [14], and PonA1 for polymerization [Chapter 3]). 
Phosphorylation also regulates the synthesis of the other major cell wall macromolecules as well as the 
formation of cell growth and division complexes [11]. Why have mycobacteria evolved to so heavily use 
phosphorylation? It is perhaps because phosphorylation can quickly alter protein conformation or activity 
[14] . Quick responses facilitate malleability in the face of environmental stresses, and such plasticity may 
have aided the adaptation of Mtb [15] to the variable environment of the human host [11]. Alternatively, 
mycobacteria may have evolved a widespread phosphorylation network [16] as a method to regulate the 
timing of cell division. Several studies suggest that mycobacterial cell division is regulated more by time 
than by cell size [8,17], as is common in other bacteria [18]. The phosphorylation of many cell growth and 
division proteins could relay the information to commence cell elongation or division.  
 
PonA1 may additionally modulate the timing of cell wall biogenesis through its dual role in septation and 
elongation. Mycobacteria face the complex problem of growing from the site of former cell division. How 
does the cell transition the division site, occupied by the large divisome, into a site productive for cell 
elongation, which requires a separate protein machine? Does the divisome dissolve? Is its composition 
altered or localized to a sub-polar space? PonA1’s activity in both the divisome and elongation complex 
hints it could play a role in the cell’s segue from division to elongation in the same subcellular space. 
Further experiments are required to test this model. Timelapse imaging of fluorescently tagged PonA1 in 
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cells treated with small molecule inhibitors of specific cell elongation and division proteins may begin to 
address these questions. However, technological advancement is required as fluorescent tagging of cell 
wall associated proteins is technically challenging in mycobacteria, and current cell biological reagents 
are geared more towards E. coli.  
 
Temporal regulation of 4–3 and 3–3 crosslinking must also occur during cell wall synthesis. Although 
several works postulated that 3–3 crosslinking enzymes facilitate the transition into stationary phase 
[19,20], a comprehensive study of mycobacterial PG from multiple growth stages showed that 3–3 
crosslinking is equally prevalent in vegetative and stationary phase growth [21]. These data suggest that 
3–3 crosslinking enzymes are active during vegetative growth and are likely critical for normal cell 
elongation. Indeed, a recent study demonstrated that lack of the 3–3 transpeptidases LdtA and LdtB 
resulted in shorter cells [22]. I also observed decreased length in addition to increased cell width in cells 
that lack LdtB (Chapter 4). These data suggest that 3–3 crosslinking enzymes are active during 
vegetative growth and are important in maintaining normal cell shape. How does the cell determine 
whether a 4–3 or 3–3 enzyme crosslinks the nascent PG? Do these enzymes act sequentially? Several 
pieces of evidence suggest that 3–3 transpeptidases use a tetrapeptide substrate for their crosslinking 
reaction [23,24], which means another enzyme must first cleave the ultimate amino acid from 
pentapeptide tail of nascent peptidoglycan [25]. What are the temporal dynamics of those proteins in cell 
wall synthesis? Furthermore, it remains unclear whether previously 4–3 crosslinked peptide tails can later 
be used in a 3–3 transpeptidation reaction.  
 
However, my work showed that the function of PonA1 and PonA2 is correlated with LdtB during growth, 
which indicates that 4–3 and 3–3 crosslinking are temporally and/or spatially connected. Do these 
enzymes physically interact? Are their respective crosslinking activities coordinated? Much remains to be 
understood about the spatiotemporal interplay between 4–3 and 3–3 crosslinking enzymes and how the 
cell governs their activity. 
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Section 5.3 Future Directions 
My work has uncovered several common themes for how cell wall biogenesis is governed in 
mycobacteria – many which exist at the protein level of control. However, many questions remain for how 
the cell specifically defines sites and times of growth. 
 
Interaction Partners of PonA1 
As a major bifunctional peptidoglycan synthase that promotes cell elongation, PonA1 likely has interacting 
partners in the elongation complex in addition to its known partner in the divisome (RipA). Because of the 
dearth of information about the composition of the elongation complex, identifying PonA1 partners would 
greatly expand our understanding of how cell elongation is controlled in mycobacteria. These experiments 
would answer fundamental questions such as whether Wag31 interacts directly with PonA1, even 
transiently. The identified genetic interaction between PonA1 or PonA2 and LdtB may be a result of 
physical interaction. Identifying PonA1’s protein-protein interactions could determine whether 3–3 
transpeptidases exist in the classical elongation complex. Further experiments could address whether 
PonA1’s protein-protein interactions impact its retention in or the stability of the elongation complex.  
 
Additionally, it remains unknown whether PonA1’s phosphorylation mediates interactions with other 
factors. Pull down experiments with wildtype or phosphorylation mutants would test the importance of 
PonA1’s phosphorylation for any protein-protein interactions. Our model of PonA1’s phosphorylation 
regulating its TG activity needs experimental evidence. Analysis of peptidoglycan from cells that produce 
differently phosphorylated PonA1 protein could demonstrate whether the length of glycan chains, and 
hence PonA1’s TG activity, is impacted by its phosphorylation status.  
 
Investigation of 3–3 Transpeptidases  
Why have mycobacteria evolved to crosslink their peptidoglycan mainly with 3–3 bonds? Is there an 
advantage to 3–3 peptide crosslinks? Do they lend greater stability to the cell wall or more antibiotic 
tolerance? These transpeptidases are of biological interest because of the unusual prevalence of 3–3 
crosslinks in mycobacterial peptidoglycan, but also because classic beta-lactam antibiotics, such as 
 ! 166 
penicillin, do not inhibit these enzymes. Further work on these enzymes could be fruitful for 
chemotherapeutic development in Mtb (Chapter 4). 
 
Because Mtb encodes five of these enzymes (Appendix 1), much work is required to understand the 
biological roles of the individual proteins. One study suggested that ldtB was the most highly transcribed 
[20] , and presumably the most active, and failed to find enzymatic activity for three of the other 3–3 
transpeptidases, a finding which was recently challenged [23]. Furthermore, the majority of studies on 
these proteins focused on in vitro protein structure, biochemical activity, or drug inhibition [19,23,26-30]. 
Few works have investigated the activity or regulation of these enzymes in the cell or in the host 
[20,22,31]. Therefore, there is room for examining the individual importance of these proteins during 
growth and cell wall biogenesis. Directed knockouts, cell biological assays (population growth, cell shape, 
cell wall labeling [6,8,17], protein localization), biochemical analysis of isolated sacculi, and macrophage 
or mouse infections constitute straightforward first steps to determine the relative importance of each of 
Mtb’s L,D-transpeptidases to growth and cell wall synthesis in culture and during infection.  
 
Because of the frequency of 3–3 crosslinks in mycobacterial peptidoglycan, I hypothesized that these 
enzymes may exist in the traditional elongation complex or in distinct complexes that are also active at 
sites of growth [11]. Protein interaction studies have the potential to resolve whether these enzymes 
interact with known members of the cell wall biogenesis machinery, and localization of fluorescently 
tagged L,D-transpeptidases would spatially resolve these enzymes’ activity. My work demonstrated that 
loss of LdtB impacted cell width and cell length (also reported in another study [22]). Timelapse 
microscopy of cell-surface- or cell-wall- labeled Δldtb cells would determine whether the observed cell 
shape changes are due to alterations in cell elongation and/or in cell septation. Both processes impact 
cell length, and it is feasible that alterations in cell septation impact cell width. These experiments could 
define whether LdtB is more active in either process or whether it functions in peptidoglycan metabolism 
throughout the cell cycle.  
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Major Unanswered Questions on the Spatiotemporal Control of Mycobacterial Cell Growth and 
Division  
Several major questions remain unanswered in the field of mycobacterial cell growth and division. Studies 
investigating these questions would substantially expand our understanding of prokaryotic cell division, as 
mycobacteria have evolved to control their growth and division in different ways than many currently 
studied organisms. Additionally, resolving these questions has the potential to further our knowledge of 
how Mtb remains such a successful pathogen.  
 
How are the various layers of the cell wall synthesized in concert? How do all of these enzymes function 
together? Many factors involved in cell wall biogenesis are not essential for growth of Mtb in culture, 
which eases investigation of their activity during cell wall biogenesis. Genetic interrogation of these 
enzymes is relatively facile in Mtb. Transposon mutagenesis is efficient, and it is feasible to obtain highly 
complex libraries of transposon-disrupted loci [32], which could be manually ordered to facilitate 
downstream studies of individual factors. Additionally, several labs, including the Rubin lab, are currently 
constructing a whole-genome mutant collection wherein each locus is deleted or, for essential genes, 
conditionally expressed. Such resources will promote the study of how Mtb specifically organizes its cell 
wall synthesis. Additionally, the development of chemical probes for the arabinogalactan and mycolic acid 
layers would distinguish mutants in peptidoglycan, arabinogalactan, and mycolic acid synthesis 
(peptidoglycan probes exist [33] but optimization and probes targeting other PG moieties would be 
useful). These additional probes would greatly advance our understanding of AG and MA cell wall 
incorporation and the coordinated synthesis of the cell envelope. 
 
One major question in mycobacterial cell biology is how the division site is selected1. Mycobacteria have 
no known homologues to the systems widely present in other bacteria that regulate selection of the 
division site (Chapter 1). A combination of genetic and visual screens could identify factors that modulate 
division site selection in mycobacteria. Because the factors that govern division site selection may be 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Some of the ideas presented in this paragraph stem from conversations with Dr. Cara Boutte, a postdoc 
in the Rubin lab.!
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essential, an overexpression library could be used to search for mutants in cell division (a whole genome 
library, with some exceptions, exists). Alternatively, division site regulators may not be essential, and a 
whole genome transposon mutagenesis screen could query which genes impact division site localization. 
These libraries would need to be visually screened for cell division mutants. Mutant populations of interest 
could first be enriched for different cell sizes via filtering (unlike M. tuberculosis, M. smegmatis is quite 
long; single cells are on average 5 µm. Mutants in cell division may fail to divide and hence become 
longer; alternatively, mutants may become shorter if division is activated earlier than normal. Filtering with 
a 5µm filter could enrich for both classes of mutants). Alternatively, cell sorting (using a microfluidic based 
platform [34]  or a cell sorter [35,36]) could also enrich for differentially sized cells. Any mutants with 
widely different cell size compared to wildtype could be further investigated to determine whether the 
division site is aberrantly formed or matured. Determination of division site localization and stability can 
be assessed with timelapse microscopy of fluorescently-tagged FtsZ [37], the major cell division protein, 
in the mutant cells. 
 
Another significant unanswered question in the field is whether the apparent asymmetric growth and 
division of mycobacterial cells (Chapter 1) is important during infection. Timelapse microscopy of single 
cells during growth in macrophages is a first step to illuminating whether certain lineages of daughter cells 
survive better during growth in macrophages or in different host-like conditions. For example, do new pole 
daughter cells fare worse in host-like conditions? The seminal study on this work examined the survival of 
daughter cells in one condition – antibiotic stress – and many unanswered questions remain about 
whether asymmetric growth and division impacts the fitness of single cells in other stresses. A recent 
study examined the partitioning of irreversibly oxidized proteins during mycobacterial cell division and 
found asymmetric partitioning of the protein aggregates; the progeny with a greater proportion of the 
aggregates had diminished fitness during antibiotic stress [38]. These findings support the hypothesis that 
asymmetric growth and division, with its impacts on cell wall composition and protein content for each 
daughter cell, could impact the fitness of individual cells. Changes in individual cell fitness could have 
direct consequences on their survival in the human host. These hypotheses need to be tested in models 
that more closely resemble human infection. Ultimately, mutants that exhibit an altered symmetry of 
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growth and division should be analyzed for their ability to robustly survive in macrophage, mouse, or non-
human primate models. Do global changes to the spatiotemporal pattern of Mtb growth impact its survival 
in the host? Such findings would illuminate whether Mtb’s unusual mode of growth contributes to its 
extraordinary success as a human pathogen and aid the development of novel chemo- or immuno-
therapeutics. 
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Appendix 1. Mycobacterial cell wall synthesis enzymes. 
 
Enzyme Gene Function 
Lipid II Synthesis   
MurA rv1315 adds enoyl pyruvate to UDP—NAG 
MurB rv0482 reduces enoyl pyruvate to generate UDP—NAM 
MurC rv2152 adds L-Ala to UDP—NAM 
MurD rv2155 adds D-Glu to UDP—NAM—L-Ala 
MurE rv2158 adds DAP to UDP—NAM—L-Ala—D-Glu 
MurF rv2157 adds D-Ala—D-Ala to UDP—NAM—L-Ala—D-Glu—
DAP to form UDP—NAM—pentapeptide 
Ddl rv2981 D-Ala—D-Ala ligase 
Alr rv3423 alanine racemase 
MurX rv2156 generates Lipid I by appending UDP—NAM—
pentapeptide to decaprenol phosphate (DP) 
NamH rv3818 glycolates NAM moieties 
MurG rv2153 generates Lipid II by adding NAG to Lipid I 
MviN (MurJ) rv3910 putative lipid II flippase 
FhaA rv0020 modulates MviN functionality 
   
Peptidoglycan Synthesis   
PonA1  rv0050 transglycosylation and 4→3 transpeptidation of PG 
PonA2  rv3682 transglycosylation and 4→3 transpeptidation of PG 
PBPA  rv0016 4→3 transpeptidation of PG 
PBPB rv2163 4→3 transpeptidation of PG 
LdtA (LdtMt1)  rv0116 3→3 transpeptidation of PG 
LdtB (LdtMt2) rv2518 3→3 transpeptidation of PG 
LdtC (LdtMt5) rv0483 3→3 transpeptidation of PG 
LdtD (LdtMt3) rv1433 3→3 transpeptidation of PG 
LdtE (LdtMt4) rv0192 3→3 transpeptidation of PG 
possible penicillin binding 
lipoprotein  
rv2864 putative 4→3 transpeptidation of PG 
putative homologue of E. coli 
PBP4 
rv3627 putative 4→3 endopeptidase 
DacB1 rv3330 4→3 carboxypeptidase 
DacB2 rv2911 4→3 carboxypeptidase 
   
Arabinogalactan Synthesis   
RmlA rv0334 transfers dTDP to glucose (Glu) 
RmlB rv3464 dehydrates dTDP-Glu to dTDP-4-keto-6-deoxy-D-
Glu 
RmlC rv3465 epimerizes dTDP-4-keto-6-deoxy-D-glucose to 
dTDP-4-keto-rhamnose 
RmlD rv3266 generates dTDP-rhamnose from dTDP-4-keto-
rhamnose 
WecA rv1302 transfers NAGp from UDP—NAG to DP 
WbbL rv3265 adds dTDP-rhamnose to DP—NAGp to form the 
linker unit of AG synthesis 
Glf rv3809 isomerizes UDP—Galp to form UDP—Galf  
GlfT1 rv3782 transfers initial Galf to DP—NAGp—Rha 
GlfT2 rv3808 transfers Galf residues to DP—NAGp—Rha—Galf 
RfbE rv3781 putative ABC transporter (with RfbD) that 
translocates lipid-linked galactan chains across the 
plasma membrane 
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RfbD rv3783 putative ABC transporter (with RfbE) that 
translocates lipid-linked galactan chains across the 
plasma membrane 
UbiA rv3806 transfers 5-phosphoribose 1-diphosphate (pRpp) to 
DP to form DP-5-phosphoribose (DPPR) 
Rv3807 rv3807?* dephosphorylates DPPR to form DP-5-ribose (DPR) 
DprE1 rv3790 oxidizes DPR to form DP-2-keto-erythro-pentose 
(DPX) 
DprE2 rv3791 reduces DPX to form DP-Araf (DPA) 
AftA rv3792 transfers first Araf group to DP—NAGp—Rha—
Galf30 
EmbA rv3794 transfers Araf groups to DP—NAGp—Rha—
Galf30—Araf 
EmbB rv3795 transfers Araf groups to DP—NAGp—Rha—
Galf30—Araf 
AftB rv3805 transfers final Araf to DP—NAGp—Rha—Galf30—
Araf64 
AftD rv0236 generates the branched 1,3-Araf motif 
Rv1459 rv1459 generates the branched 1,3-Araf motif 
AftC rv2673 generates the branched 1,3-Araf motif 
   
Mycolic Acid Synthesis   
Fas rv2524 synthesizes C20-C26 fatty acid precursors from 
acetyl-CoA and malonyl-CoA 
FabD rv2243 transfers malonyl residue to acyl carrier protein 
(ACP) 
AcpM rv2244 facilitates fatty acid elongation by carrying growing 
acyl chains between enzymes of the Fas system 
FabH rv0533 condenses malonyl-ACP to produce β-ketoacyl-
ACP 
MabA (FabG1) rv1483 reduces β-ketoacyl-ACP to β-hydroxyacyl-ACP 
HadAB rv0635/ 
rv0636 
dehydrates β-hydroxyacyl-ACP to form 2-trans-
enoyl-ACP 
HadBC rv0636/ 
rv0637 
dehydrates β-hydroxyacyl-ACP to form 2-trans-
enoyl-ACP 
InhA rv1484 reduces 2-trans-enoyl-ACP for final chain 
elongation 
KasA rv2245 initial extension of β-ketoacyl chain to C40 by 
condensing with malonyl-ACP 
KasB rv2246 extends β-ketoacyl chain to C54 by condensing with 
malonyl-ACP 
EchA10*/EchA11* rv1142/ 
rv1141 
isomerizes 2-trans-enoyl-ACP to generate cis 
unsaturated precursors 
DesA2/DesA3 rv1094/ 
rv3229 
Desaturates the 2-trans-enoyl-ACP to generate 
unsaturated precursors 
MmaA2 rv0644 generates a cyclopropane ring into the distal chain; 
also cyclopropanates MmaA4’s product at the 
proximal cis site 
PcaA rv0470 generates a cyclopropane ring into the proximal 
chain 
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*Biochemical function of these enzymes have not been verified in the processes indicated. 
* Unsaturation could occur through two distinct mechanisms (see Barry et al, Infect Disord Drug 
Targets, 2007). !
 
 
 
 
 
 
 
 
 
 
MmaA4 rv0642 alters the distal cis unsaturation to an alcohol and 
adds a methyl group to generate cis-oxygenated 
precursors 
MmaA1 rv0654 alters the proximal cis unsaturation to an allylic 
methyl branch with trans saturation to generate 
trans-oxygenated meroacid precursors 
MmaA3 rv0643 transfers methyl group to secondary alcohols of 
MmaA4 and MmaA1’s products to generate cis- 
and trans-methoxy-meroacids 
CmaA2 rv0503 introduces trans cyclopropanation at proximal site 
of MmaA1’s product 
Rv0161* rv0161 oxidizes MmaA4’s hydroxy-meroacid in the first 
step of keto-meroacid precursor generation 
AdhE1*/Rv3057* rv0162/ 
rv3057 
reduces the oxidized product of Rv0161* to 
generate keto-meroacid precursors 
AccD4 rv3799 carboxylates the meromycolate precursor  
AccD5 rv3280 carboxylates the product of AccD4 to generate a 
precursor for Pks13 condensation 
FadD32 rv3801 acyl-adenylates the α-branch Fas precursor and 
loads it onto Pks13 
Pks13 rv3800 synthesizes mature α-mycolates from AccD5 and 
FadD32 products 
CmrA rv2509 reduces β-ketoacyl from Pks13 condensation for 
ligation to AG 
Rv3802* rv3802 putatively transfers mature mycolates to 
mannopyranosyl-1-phosphoheptaprenol (PL) to 
form myc-PL 
Rv1288*/Rv0519* 
 
rv1288/ 
rv0519/ 
putatively transfers myc-PL to trehalose 6-
phosphate forming TMM-phosphate for extracellular 
transport  
OtsB1* rv2006 putatively dephosphorylates TMM-6-P for 
extracellular transport 
Mmpl3 rv0206 putative transporter for TMM export 
FbpA/FbpB/FbpC/FbpD 
(Ag85 complex) 
rv3804/ 
rv1886/ 
rv0129/ 
rv3803 
transfers mycolic acid from TMM to arabinogalactan 
to mycolate the cell wall 
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Overview  
These data are the supplementary information for the manuscript under review that comprises Chapter 3.  
 
 
Attributions  
I performed the experiments and analyzed the data in S1, S2, S4, S5, S6, S7 (A,B,C), S8, S9, S10, and 
S11. I made all the strains for the experiments except for the E. coli overexpression vectors for wildtype 
and TG- PonA1, which were made by Michael Chao. Cara Boutte made the E. coli strains for the 
phospho-transfer experiments done in S7D. Christina Baer and Cara Boutte purified the Mtb kinases for 
the phosphorylation experiments. Amy Barczak performed the lipidomic analysis and analyzed the data in 
S3. Xavier Meniche performed the mass spec and analyzed the data in S7D. Jemila Caplan Kester made 
the microfluidic devices I used for experiments in S8. Hesper Rego helped set up the experiment in her 
CellASIC microfluidic device that is displayed in S5. 
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S1 Figure. Changes to PonA1 function modestly impacts Mtb morphology.  
(A) Cells that no longer express PonA1 or that express PonA1 catalytic or regulatory mutants exhibit no 
gross morphological changes. Scale bar, 2 µm. (B) Population doubling is not severely impacted by loss 
of PonA1 when cells are grown in standard laboratory conditions. (C) Expression of catalytic mutants of 
PonA1 does not significantly impact population doubling rates, suggesting that the defect observed during 
infection is not due to changes in growth rate. (D) Similarly, changes to PonA1’s regulatory activity do not 
significantly change population doubling rates.  
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S2 Figure. Normal cell growth requires a fully functional PonA1.  
(A) A panel of PonA1 mutants was constructed to investigate the cellular role of PonA1. Catalytic 
mutations in the TG or TP domain replace the active site serine with an alanine to abolish enzymatic 
activity (red X). The phosphorylation mutations either remove the phosphorylation site (yellow bar) by 
replacing the phosphorylated threonine with an alanine (lack of yellow bar) or attempt to mimic the 
phosphorylation with a threonine to aspartic acid muation (dark red bar). The truncation mutations were 
deletion of the majority of the cytoplasmic tail (Msm PonA195-827) or of the TP domain (Msm PonA11-360). 
(B) Expression of PonA1TP--FLAG complements bacterial growth, although population doubling rates are 
slightly dampened. (C) During exponential growth, the TP- cells have an average doubling time of 4.21 
hours, whereas isogenic wildtype doubles on average every 3.40 hours (p-value < 0.0001 by the unpaired 
two-tailed t-test). (D) The PonA1TP--FLAG isoform is stable, suggesting the phenotype of short cell length 
is due to lack of PonA1’s PG crosslinking. (E) Expression of an allele that encodes only PonA1’s TG 
domain (PonA11-360-FLAG) complements bacterial survival, although it dampens population doubling 
rates. (F) During exponential growth, PonA11-360 cells double on average every 4.23 hours, whereas 
isogenic wildtype doubled every 3.45 hours in this experiment (p-value < 0.0001 by the unpaired two-
tailed t-test). (G) The PonA11-360-FLAG protein is stable, suggesting the cell shape changes observed are 
due to changes in PonA1 function because of the truncated allele and not due to an unstable protein 
isoform.  
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S2 Figure (Continued) 
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S3 Figure. Mass spectrometric quantitation of pthiocerol dimycocerosate (PDIM) for strains used 
for mouse infections.  Total cell wall lipids from M. tuberculosis in mid-log phase growth were extracted 
with chloroform:methanol and quantitated using established liquid chromatography-mass spectrometry 
protocols [43].  Individual PDIM A and PDIM B species were identified based on characteristic retention 
times and highly accurate mass matching (NH4+ adducts). 
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S4 Figure. Overproduction of PonA1 mutants changes Msm cell shape.  
(A) Cells that overexpress different catalytic variants of PonA1 exhibit cell shape changes, including 
ectopic polar growth, bulging poles, and altered cell length. Cells were imaged six hours of induction. 
Scale bar, 2 µm. (B) Quantitation of cell length of cells in (A). A TG- allele of PonA1 negatively impacts 
cell length more than other catalytic variants, perhaps because these cells also produce the highest 
frequency of ectopic poles. Cells that do not exhibit an ectopic pole are shorter than wildtype, however, 
which may suggest a role for balanced PG synthesis in productive activity of the elongation complex 
(control: 237 cells; wildtype: 226 cells; TG-: 244 cells; TP-: 163 cells; TG-TP-: 234 cells; representative 
data. Significance was assessed by the Kolmogorov-Smirnov test. PonA1wt compared to PonA1TG- 
approximate p-value < 0.0001; PonA1wt compared to PonA1TP- approximate p-value < 0.0001; PonA1wt 
compared to PonA1TG-TP- approximate p-value < 0.0001). (C) Overexpression of PonA1 leads to ectopic 
poles usually at one pole; rare cells are observed with both poles having formed ectopic poles. However, 
these cells usually exhibit multiple septa (white arrows), indicating these cells are not truly uni-cellular and 
are not an accurate reflection of ‘symmetrically’ active growth poles. (D) Endogenous PonA1 tagged with 
RFP on the chromosome localizes to the cell pole and mid-cell in M. smegmatis.  
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S4 Figure (Continued) 
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S5 Figure. PonA1 is an early polar localizing factor that drives polar growth.  
(A) Msm cells that encode an overexpression vector for the TG- allele of PonA1-RFP were grown ± 
inducer to overproduce PonA1TG--RFP for four hours. The cells were then imaged for 17 hours ± inducer 
in the CellASIC microfluidic system to visualize cell growth. Cells that overexpress PonA1TG--RFP exhibit 
slow population growth as previously observed. PonA1 localizes to the pole prior to budding of the ectopic 
pole (follow cell with white arrow), suggesting that PonA1 is an early localizing factor at the growth tip and 
drives growth of the pole or ectopic pole upon PonA1 overproduction. Scale bar, 2 µm. (B) PonA1TG--RFP 
cells grown without inducer exhibit normal morphology in the CellASIC microfluidic system and grow 
robustly. Scale bar, 2 µm. 
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S6 Figure. Mycobacterial PonA1 encodes a phosphorylated cytoplasmic domain.  
(A) We used an H37Rv PonA1 (rv0050) construct with a start site 426 nucleotides upstream of the 
annotated start. This start site generates a protein with a predicted transmembrane pass, as expected for 
PBPs, and captures the translational start site. Alignment of the start site for Msm PonA1 (MSMEG_6900) 
with the Mtb genes shifts the start site by 126 nucleotides upstream. (B) The -426 Mtb PonA1 and -126 
Msm PonA1 protein align well with the CDC1551 sequence for PonA (proteins were aligned with ClustalO 
on the EBI server). These proteins contain a phosphorylated threonine (H37Rv PonA1 T34A; Msm PonA1 
T50A, yellow box). (C) Truncation of PonA1’s cytoplasmic tail or alteration of its phosphorylation site do 
not alter protein stability, suggesting the observed phenotypes are not due to aberrant protein production 
or folding. 
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S7 Figure. M. tuberculosis PonA1 complements M. smegmatis survival.  
(A) Msm cells that express Mtb -426 PonA1 show no morphological differences. Scale bar, 2 µm. (B) The 
Msm cells that only express Mtb -426 PonA1 also double at rates identical to isogenic wildtype, 
suggesting that -426 PonA1 fully complements growth of Msm that lacks endogenous PonA1. (C) The 
Mtb PonA1 allele is produced at similar levels to Msm PonA1 (the nonspecific band demonstrates lane 2 
has less protein loaded). (D) Mass spectrometric analysis confirms that PknB phosphorylates Mtb MBP-
PonA1cyto (with the -426 start site) in vitro. 
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S8 Figure. PonA1 phosphorylation regulates single cell elongation rates.  
(A) Msm cells that express phosphorylation mutants (T50A and T50D) or a truncation of the cytoplasmic 
tail of PonA1 (Δcyto) exhibit similar population doubling rates to isogenic wildtype or wildtype Msm. (B) To 
investigate the impact of PonA1’s phosphorylation on cell elongation and division, cells were stained with 
a green fluorescent dye that binds to the cell surface. After staining, single cells were imaged in custom 
microfluidic devices, and new cell wall elongation and division events were measured. (C) The increase in 
single cell elongation rate of cells that express PonA1T50A correlates with an increased length of single 
cells at division, as expected. (PonA1wt compared with PonA1T50A approximate p-value < 0.0001 by the 
Kolmogorov-Smirnov test.  PonA1wt compared with PonA1Δcyto approximate p-value < 0.0001 by the 
Kolmogorov-Smirnov test).  (D) Expression of T50A or Δcyto PonA1 do not impact single cell generation 
times. This suggests that the observed increased cell length is due to faster single cell elongation rates 
alone and is not impacted by altered septation timing. Significance was assessed by the Kolmogorov-
Smirnov test, and neither mutant population was statistically different than PonA1wt. (E) Cell elongation 
still occurs predominantly from the old pole in the absence of PonA1’s phosphorylation or cytoplasmic tail. 
(PonA1wt compared with PonA1T50A approximate p-value < 0.0001 by the Kolmogorov-Smirnov test.  
PonA1wt compared with PonA1Δcyto approximate p-value < 0.0001 by the Kolmogorov-Smirnov test). (F) 
The new pole exhibits mild increased elongation in cells that express T50A or Δcyto PonA1 compared to 
wildtype. (PonA1wt compared with PonA1T50A approximate p-value = 0.0036 by the Kolmogorov-Smirnov 
test.  PonA1wt compared with PonA1Δcyto approximate p-value = 0.0261 by the Kolmogorov-Smirnov test). 
Together with (E), these data suggest that loss of PonA1’s phosphorylation does not impact subcellular 
distribution of elongation complexes or PonA1’s localization within the elongation complex itself, since the 
majority of cell elongation still occurs at the old pole.  
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S8 Figure (Continued) 
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S9 Figure. Inactivating PonA1’s phosphorylation site and TP active site together impacts cell 
growth.  
(A) Cells that express a T50A,TP- allele of PonA1 exhibit slower population doubling time as compared to 
the single point mutants or isogenic wildtype, suggesting that PonA1’s phosphorylation may regulate TG 
activity to promote normal cell elongation and division. (B) T50A cells double on average every 3.52 
hours, TP- cells double every 4.21 hours (p-value < 0.0001 by the unpaired t-test compared to isogenic 
wildtype), and T50A,TP- cells double every 4.92 hours (p-value < 0.0001 by the unpaired t-test compared 
to isogenic wildtype; p-value = 0.0008 compared to TP- cells; p-value < 0.0001 by the unpaired t-test 
compared to T50A cells), whereas isogenic wildtype doubles every 3.40 hours. (C) The T50A,TP- allele is 
translated into a stable protein. 
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S10 Figure. Antibiotic tolerance shifts when PonA1’s activity changes.  
(A) The impact of rifampicin on M. tuberculosis cell fitness of PonA1 catalytic and regulatory mutants was 
measured by assessing growth by OD600 after six days ± drug treatment. (Statistical significance was 
assessed by one-way analysis of variance with Bonferroni’s multiple comparison test, and multiplicity 
adjusted p-values are reported. PonA1wt compared to PonA1TG- p-value < 0.0001; PonA1wt compared to 
PonA1TG-TP- p-value = 0.0295; PonA1wt compared to PonA1T34D p-value < 0.0001). (B) Changes in M. 
smegmatis cell fitness in the presence of TP domain inhibitors was evaluated by measuring population 
growth by OD600 after treatment with meropenem. (C) The minimum inhibitory concentration (MIC) of the 
TG inhibitor moenomycin was determined for both Msm and Mtb.  
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S11 Figure. Normal PonA1 activity is required for cell fitness during stress.  
(A) Fitness of Msm cells that lack PonA1’s TP activity (black outlined circles) during incubation with SDS 
was compared to isogenic wildtype cells (gray squares). Population growth was measured by OD600. (B) 
Fitness of Msm cells that lack PonA1’s phosphorylation site (black outlined circles) during incubation with 
SDS was compared to isogenic wildtype cells (gray squares). Population growth was measured by OD600. 
(C) Fitness of Msm cells during incubation with D-Met, L-Met or no treatment was measured by OD600. (D) 
Fitness of Msm TP- PonA1 cells during incubation with D-Met, L-Met or no treatment was measured by 
OD600. (E) Cells that express a TP- PonA1 grown until deep stationary phase (cultured for four days) were 
visualized via light microscopy. 
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Appendix 3. Mycobacterium smegmatis PonA1 suppressor screen. 
 
 
 
Overview 
These data comprise results from a screen I performed searching for suppressors of ponA1 essentiality in 
M. smegmatis.  
 
Attributions  
I performed the suppressor screen and isolated the genomic DNA from the strains. Dr. Thomas Ioerger at 
Texas A&M University performed the whole genome sequencing and alignment to the M. smegmatis 
genome. 
 
 
Rationale 
ponA1 is required for the growth of M. smegmatis but not for the growth of M. tuberculosis. We undertook 
a suppressor screen to determine whether we could identify a mutation that would relieve the requirement 
for ponA1 in M. smegmatis. This screen could potentially identify an important interaction that would 
illuminate PonA1 biology. 
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S12 Figure. A frameshift mutation in lpqU suppresses the essentiality of ponA1 in M. smegmatis. 
(A) Alignment of whole genome sequencing reads to the M. smegmatis genome. The ΔponA1 
L5::ponA1wt strain (red) has many reads that map to the ponA1 locus (black dashed box). The ΔponA1 
L5::tetR M. smegmatis strain (blue) has no reads that map to the ponA1 locus. (B) Whole genome 
sequencing reveals genetic mutations unique to a strain of M. smegmatis lacking ponA1 and confirms 
that ponA1 is deleted from the genome. The experimental strains differ from the wildtype M. smegmatis 
genome used for whole genome sequencing by several single nucleotide polymorphisms (SNPs) in 
MSMEG_0510 and MSMEG_4862. The most unique SNP in the suppressor strain (blue) was identified in 
LpqU. (C) Partial sequence of lpqU in the wildtype complement strain (red) and the ponA1 suppressor 
strain (blue). The single nucleotide deletion in lpqU (signified as “– ”) occurs approximately at the 18th 
amino acid, resulting in a frameshift and a likely truncated gene product. (D) BLASTp results from the M. 
tuberculosis LpqU homologue (rv1022). LpqU exhibits high homology to a lytic transglycosylase.  
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S12 Figure (Continued) 
 
(A) 
 
 
(B) 
Strain Locus Name Genetic Changes 
ΔponA1 L5::ponA1wt MSMEG_0510 Tagatose-1,6-bisP aldolase +g 
 MSMEG_4862 FabG ortholog +c 
 MSMEG_6900 PonA1 S644S, V753V 
ΔponA1 L5::tetR MSMEG_0510 Tagatose-1,6-bisP aldolase +g 
 MSMEG_4862 FabG ortholog +c 
 MSMEG_5416 LpqU -g 
 MSMEG_6538 FabG ortholog T84A (74%) 
 MSMEG_6900 PonA1 deletion of entire ORF 
 
 
(C)  
ATGGCTTCCAGCTGCTCGTGGCAGCTCGGCACGCCGATCCCGGAAGGTGTGCCGCCCCGGCCGGT
GATCCGGTCCCCGCGATCGACACCTA 
 
ATGGCTTCCAGCTGCTCGTGGCAGCTCGGCACGCCGATCCCGGAAGGTGTGCCG–CCCGGCCGGT 
GATCCGGTCCCCGCGATCGACACCTA 
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S12 Figure (Continued) 
 
(D)
 
 
 
 
 
 
Methods 
 
The ΔponA1 L5::ponA1wt strain (KanR) was transformed with an L5 integrating vector that encoded the 
tetR negative control gene. A positive control transformation with an L5 vector that encoded ponA1 was 
performed simultaneously. Of the surviving 7 colonies on the tetR transformation plate, one tested 
negative for the majority of the ponA1 locus by PCR. Genomic DNA was purified from both the putative 
suppressor strain and the ΔponA1 L5::ponA1wt strain and analyzed via whole genome sequencing. 
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Appendix 4. PonA1 mediates low-level rifampicin resistance in Mycobacterium 
tuberculosis.  
 
 
 
 
Overview  
These data were published in the manuscript titled Genomic analysis identifies targets of convergent 
positive selection in drug-resistant Mycobacterium tuberculosis by Maha R Farhat*, B Jesse Shapiro*, 
Karen J Kieser, Razvan Sultana, Karen R Jacobson, Thomas C Victor, Robin M Warren, Elizabeth M 
Streicher, Alistair Calver, Alex Sloutsky, Devinder Kaur, Jamie E Posey, Bonnie Plikaytis, Marco R 
Oggioni, Jennifer L Gardy, James C Johnston, Mabel Rodrigues, Patrick K C Tang, Midori Kato-Maeda, 
Mark L Borowsky, Bhavana Muddukrishna, Barry N Kreiswirth, Natalia Kurepina, James Galagan, 
Sebastien Gagneux, Bruce Birren, Eric J Rubin, Eric S Lander, Pardis C Sabeti, and Megan Murray in 
Nature Genetics in September 2013.  
 
*authors contributed equally 
 
 
Attributions  
Maha Farhat and B. Jesse Shapiro performed the whole genome sequencing and data analysis of the M. 
tuberculosis clinical strains that identified the SNPs in ponA1 associated with drug resistance. I generated 
the M. tuberculosis mutant strains and performed the drug susceptibility assays. 
 
 
 
 
 
 
 
 
 ! 196 
 
 
 
S13 Figure. Clinically identified single nucleotide polymorphisms in ponA1 mediate low-level 
tolerance to rifampicin in M. tuberculosis. 
(A) Bacterial survival (percent of untreated control OD600 absorbance) under increasing concentrations 
of rifampicin for ∆ponA1 (ponA1 deletion mutant), ∆::wildtype (ponA1 deletion mutant complemented with 
the wildtype ponA1 gene), ∆::G1521T (ponA1 deletion mutant complemented with ponA1 carrying the 
c.1521G>T allele) and ∆::C549G (ponA1 deletion mutant complemented with ponA1 carrying the c.549>G 
allele). (B) Bacterial survival as in A) of strains cultured in the presence of 0.00125 µg/ml rifampicin. Two-
sided t tests were used to evaluate significance. The difference in survival between the ∆::wildtype and 
∆::G1521T strains was significant (**), with a p-value of 0.006. Error bars, s.d. Four replicate experiments 
were performed with similar results; representative data are shown. 
 
 
Methods 
M. tuberculosis strain generation 
Rv0050, encoding ponA1, was replaced with a hygromycin resistance cassette using mycobacterial 
recombineering. The PonA1::HygR replacement was confirmed by PCR and whole genome sequencing. 
PonA1 SNP alleles C549G and G1521T were generated by site directed mutagenesis and sequence 
confirmed. Taking into account ponA1’s misannotated start site (see Chapter 3), the mutations were 
generated at nucleotide positions of -426. The C549G SNP is the identified C123G SNP; the G1521T 
SNP is the identified G1095T SNP. PonA1 wildtype or SNP alleles were cloned under the control of a 
constitutive promoter and integrated in the M. tuberculosis genome as single copies at the L5 phage 
integration site.  
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Drug susceptibility assays 
All strains were grown in Middlebrook 7H9 medium supplemented with 0.25% glycerol, 10% oleic acid–
albumin-dextrose-catalase, and 0.05% Tween-80. For MIC calculations, the strains ΔponA1, ΔponA1 
L5::ponA1wildtype, ΔponA1 L5::ponA1C549G, and ΔponA1 L5::ponA1G1521T were grown until mid-log phase 
(0.5 – 0.8 OD600) and then diluted to a calculated starting OD600 of 0.006 and grown ± drug for 6 days at 
37°C with shaking. All conditions were done in duplicate. Percent survival is calculated by normalizing the 
OD600 measurements of each strain to its respective untreated control. 
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Appendix 5. PonA1 is critical for normal tolerance to transpeptidase inhibitors. 
 
 
 
Overview  
These data will be published in a manuscript titled Structure of the transpeptidase domain of penicillin-
binding protein PonA1 from antibiotic resistant strain of Mycobacterium Tuberculosis by E.V. Filippova, 
K.J. Kieser, C.H. Luan, Z. Wawrzak, O. Kiryukhina, E.J. Rubin, and W.F. Anderson. The manuscript will 
be submitted soon. 
 
Attributions  
I generated the mutant M. tuberculosis and M. smegmatis strains. I performed the antibiotic susceptibility 
assays and analyzed the data.  
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S14 Figure. PonA1 is important for normal tolerance to transpeptidation inhibitors in M. 
tuberculosis and M. smegmatis. 
(A) Loss of PonA1’s transpeptidase activity renders M. tuberculosis cells more susceptible to carbenicillin 
and meropenem (green bars). Transglycosylase, TG; transpeptidase, TP. Two-tailed t-test assessed 
significance (*, p-value <0.05; **, p-value <0.01). (B) Loss of PonA1’s transpeptidase activity renders M. 
smegmatis cells more susceptible to treatment of penicillinV and meropenem. Squares, wildtype PonA1. 
Black-outlined circles, TP- PonA1 (S468A,S469A). 
 
 
 
Methods 
M. tuberculosis antibiotic susceptibility assays  
Log phase M. tuberculosis H37Rv strains were back-diluted to a calculated OD600 of 0.01 and grown in 
7H9 + OADC complete medium ± drug for six days in 24 well plates. Cells were grown at 37°C with 
shaking. Each strain was cultured in triplicate. Control wells contained no drug. Optical density of each 
A!
B!
M. tuberculosis!
A)  Log phase M. tuberculosis H37Rv strains were back-diluted to a calculated OD600 of 
0.01 and grown in 7H9 + OADC complete medium ± drug for six days in 24 well plates. 
Cells were grown at 37°C with shaking. Each strain was cultured in triplicate. Control 
wells contained no drug. Opti al den ity of each well measured after six days. Triplicate 
wells tr ated with drug were averaged and then normalized to the av rage of triplica e 
untreat d wells to calculate the percent survival in the pres nce of drug. Carbenicllin (1 
μg/ml) was co-treated with clavulanate (0.5 μg/ml). Meropenem was used at 0.15625 μg/
ml.#
B)  Log phase M. smegmatis mc2155 strains were back-diluted to a calculated OD600 of 
0.01 and grown in 7H9 + ADC complete medium ± drug for 48 hours in 96 well plates. 
Cells were grown at 37°C with shaking. Control wells contained no drug. Optical density 
of each well measured every 30 minutes. All data was plotted without normalization to 
untreated control strains. Cells were treated with penicillinV at 1 μg/ml, 0.5 μg/ml, 0.25 
μg/ml in the presence of 5 μg/ml clavulanate (cultured in triplicate) or meropenem at 2.5 
μg/ml, 1.25 μg/ml, and 0.625 μg/ml (cultured in duplicate). Squares, wildtype PonA1. 
Black-outlined circles, TP- PonA1 (S468A,S469A).#
M. smegmatis!
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well measured after six days. Triplicate wells treated with drug were averaged and then normalized to the 
average of triplicate untreated wells to calculate the percent survival in the presence of drug. Carbenicllin 
(1 µg/ml) was co-treated with clavulanate (0.5 µg/ml). Meropenem was used at 0.15625 µg/ml.  
 
M. smegmatis antibiotic susceptibility assays 
Log phase M. smegmatis mc2155 strains were back-diluted to a calculated OD600 of 0.01 and grown in 
7H9 + ADC complete medium ± drug for 48 hours in 96 well plates. Cells were grown at 37°C with 
shaking. Control wells contained no drug. Optical density of each well measured every 30 minutes. All 
data was plotted without normalization to untreated control strains. Cells were treated with penicillinV at 1 
µg/ml, 0.5 µg/ml, 0.25 µg/ml in the presence of 5 µg/ml clavulanate (cultured in triplicate) or meropenem 
at 2.5 µg/ml, 1.25 µg/ml, and 0.625 µg/ml (cultured in duplicate). 
 
